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ABSTRACT
Uterine leiomyomas, often called fibroids, are highly common tumors arising from smooth
muscle cells of the myometrium. Whereas cancers have the ability to metastasize,
leiomyomas are benign tumors that grow only locally. Nevertheless, leiomyomas frequently
cause a variety of health complications, including abdominal pain, abnormal menstrual
bleeding, and impaired fertility. Leiomyomas are the leading indication for hysterectomy
worldwide, and pose a significant socio-economic impact. Despite their major public health
impact, this disease attracts relatively little research.
Epidemiological and molecular studies have indicated that, in the etiology of leiomyomas,
genetic factors play a central role. Early cytogenetic studies revealed that approximately
half of all leiomyomas display non-random chromosomal abnormalities such as high
mobility group AT-hook 2 (HMGA2) gene translocations. Furthermore, family-based
linkage studies revealed that germline mutations in the fumarate hydratase (FH) gene result
in high penetrance susceptibility to uterine leiomyomas. Sporadic leiomyomas, however,
rarely harbor FH mutations and the majority lack chromosomal abnormalities, suggesting
that some driver genes remain undiscovered.
Recent advances in sequencing technologies have made it possible to examine tumor
genomes on a previously unprecedented scale. The aim of this thesis was to characterize the
molecular underpinnings of uterine leiomyomas by the use of genome-wide methods such
as massively parallel sequencing technology and gene expression microarrays. Using exome
sequencing, we discovered that 71% of leiomyomas display localized mutations in the
mediator complex subunit 12 (MED12) gene, making it their most commonly mutated gene.
Furthermore, with whole-genome sequencing, we discovered that a subset of leiomyomas
display highly complex chromosomal rearrangements, ones previously undetectable by
conventional cytogenetic techniques. These rearrangements closely resembled
chromothripsis, a phenomenon in which one or a few chromosomes are shattered into
multiple pieces and randomly stitched together in a single event. We also found these events
to have occurred multiple times, and some had resulted in genetic changes with a selective
value, such as collagen type IV alpha 5 chain and collagen type IV alpha 6 chain (COL4A5-
COL4A6) deletions.
Patients affected by leiomyomas frequently harbor multiple distinct tumor nodules.
Whereas the majority of studies have proposed that each leiomyoma arises independently,
we found some leiomyomas to display identical chromosomal abnormalities, suggesting a
common clonal origin. Whole-genome sequencing of clonally related leiomyomas revealed
intratumor genetic heterogeneity suggestive of a branching model of tumor growth.
ABSTRACT
9
Furthermore, we also discovered DEP domain containing 5 (DEPDC5)  as a novel tumor
suppressor gene, acting as a secondary driver gene in a subset of leiomyomas.
Our integrative analyses demonstrated that specific genetic defects were the major
determinants of expression changes in leiomyomas. Our observations indicate that at least
four molecular subtypes exist: leiomyomas harboring a MED12 hotspot mutation, HMGA2
overexpression, FH inactivation, or COL4A5-COL4A6 deletion. We also detected subtype-
specific expression differences in key tumorigenic pathways, including Wnt/β-catenin,
Prolactin, IGF-1, and NRF2 signaling.
Using genome-wide methods in this thesis work, we have discovered several novel
molecular defects that underlie leiomyoma etiology. These studies emphasize the
importance of stratification in leiomyoma research and offer a set of candidate biomarkers
that may facilitate the molecular classification of uterine leiomyomas. Millions of women
suffer from uterine leiomyomas, and the ability to classify each lesion should pave the way
towards personalized treatments.
REVIEW OF THE LITERATURE
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REVIEW OF THE LITERATURE
1. Tumor biology
The  human  body  consists  of  trillions  of  cells  that  grow,  divide,  and  die  in  an  organized
manner.  A tumor,  or  a  neoplasm,  is  an  abnormal  mass  of  cells  that  serves  no  biological
purpose. Solid tumors, such as colon and breast neoplasms, can either be benign or
malignant (cancer), whereas hematological malignancies such as leukemia are malignant
neoplasms that do not produce a cell “mass”. Benign tumors grow only locally, whereas
malignant tumors have the ability to invade or spread to distant organs, a phenomenon
known as metastasis. Metastases are the major cause of death from cancer,1 making most
benign tumors relatively harmless. Nevertheless, some benign tumor types, ones such as
leiomyomas or prolactinomas, cause clinical complications by creating pressure upon
adjacent organs or secreting abnormally high levels of hormones.2,  3 Furthermore, some
cancers arise from benign precursor lesions with varying malignant potential, often referred
to as premalignant lesions.4
Cancer development (carcinogenesis) is a multistep process in which neoplastic cells
gradually acquire new abilities in order to proliferate excessively, survive, and eventually
spread.5 Most cancers take several decades to develop, and aging is the greatest risk factor.6
Cancer is not a single disease, but rather a general term referring to a heterogeneous group
of disorders characterized by ten shared traits known as “the hallmarks of cancer” (Box 1).7
The ability to invade and metastasize is the only hallmark that never applies to benign
tumors.7
Several environmental factors, known as carcinogens, are directly involved in causing
cancer. Two of the most widely acknowledged carcinogens include ultraviolet light8 and
tobacco smoke9. Tobacco smoking results in the death of 1 in 10 adults worldwide10 and is
the leading preventable cancer cause, but obesity is rapidly overtaking tobacco.11 Infectious
agents such as Helicobacter pylori12 and human papilloma virus (HPV)13 have also proven
to cause cancer in humans.
It is overly simplistic to think of single causes of cancer, and a variety of both external as
well as internal factors influence cancer risk. Indeed, while tumor formation is clearly
influenced by environmental and lifestyle factors, internal factors such as inheritance are
highly important as well.14 Furthermore, a recent controversial study indicates that a
significant proportion of cancers arise due to bad luck resulting from random, uncontrollable
genetic errors rather than from hereditary or environmental factors.15
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Box 1. The hallmarks of cancer
I. Sustaining proliferative signaling: The ability to continue to proliferate without a
normally controlled signaling input.
II. Evading growth suppressors: The ability to evade growth suppressors that normally
limit cell proliferation.
III. Resisting cell death: The ability to evade programmed cell death (=apoptosis) by
circumventing critical apoptotic pathways.
IV. Enabling replicative immortality: The ability to maintain telomere length in order to
evade cell death by telomere shortening.
V. Inducing angiogenesis: The ability to form new blood vessels that invade and nourishes
the tumor with oxygen and other critical nutrients.
VI. Reprogramming cellular metabolism: The ability to adjust energy production in order
to satisfy the increased rate of cell proliferation.
VII. Avoiding immune destruction: The ability to evade cell destruction by lymphocytes
and macrophages.
VIII. Activating invasion and metastasis: The ability to escape from the primary growth site
and attach to distant locations.
IX. Genome instability and mutation: The ability to generate genetic diversity in order to
foster tumorigenesis and adapt to changing conditions.
X. Tumor-promoting inflammation: The ability to induce tumor-promoting
inflammation that supplies the tumor microenvironment with factors that aid in tumor
growth.
Modified from Cell, 144, Hanahan and Weinberg, Hallmarks of Cancer: The Next Generation (2011),
reprinted with the permission of Elsevier.
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It is widely accepted that most, if not all, tumors arise due to genetic defects. Cancer is
therefore called “a disease of the genome”. Indeed, the first step in tumorigenesis – known
as tumor initiation – is triggered by genetic mutations.16 Mutations can arise from physical
or  chemical  agents  known as  mutagens,  or  spontaneously  due  to  random errors  in  DNA
replication, repair, or recombination. Tumor initiation is followed by tumor promotion in
which  existing  tumors  are  stimulated  to  grow.16 Common tumor promoters include
hormones, particularly estrogens. These contribute to tumorigenesis by stimulating cell
proliferation rather than inducing mutations. A single mutation is rarely sufficient for the
development of a full-blown tumor, and additional genetic or non-genetic factors are
required for the stepwise progression into a more malignant state. This last phase of
tumorigenesis is known as tumor progression.16
Tumor masses are typically composed of both phenotypically and genetically distinct cell
populations.  Two models  have  aimed at  explaining  this  tumor  heterogeneity.  The  clonal
evolution model states that mutated cells are selected and expanded based on their individual
abilities.17 Neoplastic cells that are selectively advantageous will generate more daughter
cells than their competitor cells do and consequently become the more dominant cell
population. This process is called clonal selection and is analogous to Darwinian natural
selection, because neoplastic cells compete with each other for their survival.17 Clonal
selection continues to foster tumorigenesis in the process in which tumors become
increasingly malignant.
The cancer stem cell model states that only specific cells with stem cell characteristics are
responsible for the initiation and overgrowth of a tumor.18 These cancer stem cells have an
ability to self-renew and differentiate into different cell types.18 The clonal evolution and
the cancer stem cell models are not necessarily mutually exclusive, because the cancer stem
cells may themselves undergo clonal evolution.18 A recent study showed a strong correlation
between the lifetime number of tissue-specific stem cell divisions and tissue-specific cancer
risk, suggesting that a significant proportion of cancers arise due to random mutations in
cancer-initiating stem cells.15
A tumor mass does not consist only of mutated tumor cells, but also the surrounding cellular
environment in which the tumor grows. This tumor microenvironment is comprised of blood
vessels, inflammatory cells, immune cells, connective tissue fibroblasts, and extracellular
matrix (ECM) components.19 Stromal cells can interact with the mutated tumor cells and
thereby promote neoplastic transformation, support tumor growth and invasion, protect the
tumor from host immunity, and foster therapeutic resistance.19 The  stromal  cells  of  the
tumor microenvironment are generally genetically normal, but may occasionally harbor a
unique set of mutations,20 suggesting  that  stromal  cells  could  co-evolve  with  their
neighboring neoplastic counterparts. The tumor microenvironment contributes in part to
intratumor heterogeneity.19
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1.1 Tumor genetics
A mutation refers to any change in a DNA sequence, and such a change can be harmful,
neutral, or beneficial for the development of an organism.21 Mutations that are inherited are
known as germline mutations, whereas mutations that occur after conception are known as
somatic mutations.21 Mutation is an important process that creates genetic variation among
species. Genetic variations that are common within a population (frequency ≥1%) are
known as polymorphisms, with alternative forms of the same genes known as alleles.21
Mutations can be roughly divided into nucleotide-level (small-scale) or chromosome-level
(large-scale) mutations due to differences in their size, in how they arise, and in how they
are detected. Nucleotide-level mutations typically affect one or a few nucleotides and
include substitutions, insertions, and deletions (Figure 1A). Insertions and deletions smaller
than 50 nucleotides are collectively termed microindels. Mutations that affect only a single
nucleotide are termed point mutations or single nucleotide variants (SNVs). Single
nucleotide  polymorphisms  (SNPs)  refer  to  point  mutations  that  are  common  within  a
population and are the most common type of human genetic variation.22 Sanger sequencing
is the most widely used method for detecting nucleotide-level mutations.
Most eukaryotic genes are composed of exons and introns, reflecting the gene’s protein-
coding and non-coding sections. Proximal promoters, distal enhancers, silencers, and
insulators are important non-coding sequences that control gene expression. Exons are
surrounded by splice-site sequences that, during mRNA processing, instruct the removal of
introns.23 Exons are composed of codons: sequences of three nucleotides that encode for a
specific  amino  acid  or  a  stop  signal  during  protein  synthesis.  Mutations  that  affect  the
protein-coding sequence are classified into silent (synonymous) mutations encoding for the
same amino acid; missense (nonsynonymous) mutations encoding for a different amino
acid; and nonsense mutations encoding for a stop codon that truncates the protein (Figure
1A).  Frameshift  mutations  are  indels  of  a  small  number  that  is  not  divisible  by  three,
typically altering the reading frame of a gene and resulting in a truncated protein product.
Splice-site mutations may result in exon skipping, in activation of cryptic splice sites, in
creation of pseudo-exons within introns, or in intron retention (Figure 1A).23
Chromosome-level mutations, also called chromosomal abnormalities, include structural
rearrangements such as amplifications: the copying of regions; deletions: the loss of regions;
inversions: the reversal of regions; translocations: the interchange of regions between
nonhomologous chromosomes; and insertions: the transfer of fragments from one region
into another (Figure 1B). Complex chromosomal rearrangements involve more than two
chromosomes or more than two DNA double-strand breakpoints.24 An abnormal number of
chromosomes is called aneuploidy, whereas a whole chromosome loss is called monosomy
and a whole chromosome gain is called trisomy. Unlike nucleotide-level mutations, some
chromosomal abnormalities are detectable microscopically by cytogenetic techniques such
as G-banding or fluorescence in situ hybridization. Germline deletions or amplifications
larger than 50 nucleotides are collectively termed copy-number variations (CNVs), whereas
their somatic counterparts are termed somatic copy-number alterations (SCNAs).
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Figure 1. Types of mutations. Mutations can be classified into either nucleotide- or chromosome-level
mutations due to differences in their size, in how they arise, and in how they are detected. A) Nucleotide-
level mutations include substitutions, insertions, and deletions of one or a few nucleotides. Mutations
located within the protein-coding sequences of genes are further divided into silent, missense, nonsense,
or frameshift mutations, each reflecting differences in their encoded protein product. Splice-site
mutations may also affect the protein-coding sequence of a gene, resulting in partial or complete intron
retention or exon skipping. B) Chromosome-level mutations include amplifications, deletions,
inversions, translocations, and insertions.
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1.1.1 Genomic instability
Tumor  genomes  often  exhibit  a  high  rate  of  somatic  mutations  known  as  genomic
instability.25 The number of mutations often correlates with age,26 suggesting that
accumulation of spontaneous mutations or long-term exposure to specific mutagens may
explain the high number of mutations frequently seen in tumors. Indeed, smokers’ lung
cancer genomes have approximately 10 times as many mutations as non-smokers’.27
Prolonged exposure to radiation can also result in a high rate of DNA double-strand
breaks.28 Tumors  rarely  display  genomic  instability  on  both  the  small  and  large  scale,
indicating that distinct mutational processes generate different types of mutations.25
Chromosomal instability (CIN) is the most common type of genomic instability in tumors,
and refers to a high rate of chromosome-level mutations.25 CIN is subdivided into structural
CIN referring to a high rate of rearrangements and numerical CIN referring to aneuploidy.29
Although the underlying causes of CIN are still mostly unclear, at least five mechanisms
are known to generate chromosomal rearrangements: non-homologous end joining,
homologous recombination, microhomology-mediated replication-dependent
recombination, long interspersed element 1 (LINE-1)-mediated retrotransposition, and
telomere healing.30 Indeed, mutations in BRCA2 or genes encoding for the Fanconi anemia
core complex result in structural CIN though defective repair of interstrand crosslinks and
impaired homologous recombination.31 Telomere shortening is another mechanism leading
to structural CIN through repeated breakage-fusion-bridge cycles of unprotected sister
chromatid ends.32 Conversely, numerical CIN appears to result from weakened spindle-
checkpoint signaling, excessive centrosomes, defects in chromatid cohesion, abnormal
kinetochore-microtubule attachments, or increased spindle-microtubule dynamics.33
Nucleotide instability (NIN) refers to a high level of nucleotide-level mutations.
Microsatellite instability is a type of NIN characterized by insertions or deletions of a small
number of nucleotide repeats located within short repetitive sequences known as
microsatellites.34 Defects in the mismatch repair system give rise to this kind of instability,
such as mutations in the DNA-repair gene mutL homolog 1 (MLH1).25 Mutations in the
proofreading domains of DNA polymerases POLE and POLD1 was recently associated with
an extremely high rate of NIN, known as the hypermutator phenotype.35
Recent advances in sequencing technologies have made it possible to examine tumor
genomes on a previously unprecedented scale.36 This has led to the identification and
characterization of several novel mutational signatures, ones displaying different
combinations of mutation types.37 Different types of mutational processes are likely to cause
these distinct signatures. One of these signatures is termed Kataegis, which refers to a high
rate of nucleotide-level mutations – mostly C>T transitions – that co-localize around
chromosomal rearrangements.38 These technologies have also uncovered chromosome-
level mutations that have radically changed the view of how some chromosomal
rearrangements arise. Indeed, some of these novel patterns challenge the conventional
theory that cancer development is a gradual process of multiple cell divisions during which
independent mutations accumulate.
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1.1.1.1 Chromothripsis
In  2011,  Stephens  et  al.  described  a  novel  form  of  CIN  known  as  chromothripsis.39
Chromothripsis is a phenomenon in which a single “catastrophic” event results in up to
thousands of clustered rearrangements. Statistical modeling of complex rearrangements
detected in cancer genomes led to the hypothesis that these were generated in a single event
of local shattering followed by random reassembly.39 The term chromothripsis is derived
from the two Greek words: chromos for chromosome and thripsis for shattered into pieces.39
Rearrangements generated by chromothripsis have a few notable features. First, the double-
strand breaks are confined to a single chromosome or to local regions over a few
chromosomes. Second, the chromosomal fragments are randomly rearranged in all possible
orientations. Third, some fragments are not incorporated into the newly formed
chromosomes, thus resulting in two alternating copy-number states. Initially, the concept of
chromothripsis attracted criticism, because no direct experimental evidence was available
to support its existence.40 Complex chromosomal rearrangements have occasionally been
misinterpreted as chromothripsis, and so its hallmark features have recently been clarified
in order to accurately infer chromothripsis from massively parallel sequencing data.41
Although first described in chronic lymphocytic leukemia, chromothripsis has since been
established in a wide array of human cancers.42 Some of these chromothripsis events have
generated oncogenic fusion genes, disrupted tumor suppressor genes, or amplified
oncogenes within double-minute chromosomes.42 Interestingly, chromothripsis events can
also occur in the germline of healthy individuals or can cause congenital disorders.43 A
recent study described a remarkable case in which a chromothripsis event spontaneously
cured a patient of the immunodeficiency WHIM (warts, hypogammaglobulinemia,
infections and myelokathexis) syndrome.44 The chromothripsis event removed the defective
gene (CXCR4) causing this syndrome, resulting in repopulation of the bone marrow by cells
carrying this event.44
Following the initial discovery of chromothripsis, massively parallel sequencing technology
have revealed a few similar “one-off” events, including chromoanasynthesis and
chromoplexy. Chromoplexy is a phenomenon in which multiple adjacent double-strand
breaks result in a complex chain of rearrangements across multiple chromosomes.45
Chromoplexy differs from chromothripsis since it involves less breakpoints, more
chromosomes, and it generally lacks alternating copy-number states.45 Although the
mechanism behind chromoplexy is still unknown, the breakpoints in chromoplexy are
typically clustered within actively transcribed DNA and open chromatin.45 Conversely,
chromoanasynthesis results from serial, microhomology-mediated template switching
during DNA replication.46 Unlike chromothripsis, chromoanasynthesis is characterized by
small-scale amplifications and retention of heterozygosity.46 A common term proposed to
describe all of these one-off events, independent of their underlying mechanisms, is
chromoanagenesis.47 The initial trigger of these events is still unknown, and the mechanism
by which chromothripsis occurs was largely unclear until recently. Chromothripsis appears
to be caused by missegregation of chromosomes during cell division into physically isolated
micronuclei, inside of which the shattering and reassembly takes place.48
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1.1.2 Driver and passenger mutations
Although tumor genomes may carry up to thousands of mutations, carcinogenesis directly
involves only an estimated two to eight changes. Mutations that confer a selective growth
advantage are known as “driver mutations”, whereas mutations with no advantageous effect
are known as “passenger mutations”.49 One of the central challenges in cancer research is
to distinguish between these two. Another common challenge is to identify the “target
genes” of large-scale chromosomal abnormalities – ones typically affecting numerous genes
simultaneously. The key driver genes are typically mutated in a significantly higher
proportion of tumors than would be expected by chance, making it possible to confidently
identify some drivers from sequencing data alone. However, most cancer types display only
a few “mountains” and numerous “hills”, reflecting highly recurrently and less recurrently
mutated genes.49 The frequency does not always indicate drivers in the case of hills, because
the mutational background rates between individual tumor genomes and regions may vary
considerably. One effective way to recognize driver genes is to consider their mutational
patterns. Indeed, all driver genes follow two main types of mutational patterns: gain-of-
function mutations of oncogenes or loss-of-function mutations of tumor suppressor genes.
1.1.2.1 Oncogenes
A proto-oncogene is a gene that has the potential to drive tumorigenesis when activated by
a mutation or expressed at exceptionally high levels.49 When a proto-oncogene gains this
ability, it is called an oncogene. Proto-oncogenes typically encode for proteins that normally
function as growth factors, growth factor receptors, signal transducers, transcription factors,
or chromatin remodelers.50 In 1982, the very first human oncogene that is activated by
somatic mutations was discovered, HRAS.51
Oncogenes are characteristically activated by gain-of-function mutations, such as point
mutations, translocations, or amplifications.50 Mutated oncogenes are dominant, because
their activation requires only one single mutated copy. Missense mutations – the most
common type of oncogenic mutation – typically alter or enhance a very specific activity of
the encoded protein. These mutations are often located within specific regions known as
mutational “hotspots”. Although the majority of these hotspots lie in exons, recent studies
indicate that oncogenic mutations occur in non-coding sequences as well. Indeed, missense
mutations in the promoter of telomerase reverse transcriptase (TERT) – resulting in
increased expression of telomerase – were recently discovered as the most common type of
non-coding mutation in human cancers.52 Chromosomal amplifications can also activate
oncogenes by causing an increased gene dosage. Translocations can create oncogenic fusion
proteins with a completely new function or a combined function of the two fusion partners.
Translocations can also activate an oncogene by juxtaposing a proto-oncogene next to a
regulatory element such as a highly active promoter or enhancer. Mutations in the three
prime untranslated region (3’UTR) can activate an oncogene by disrupting the interaction
between mRNAs and microRNAs.53 MicroRNAs are small non-coding RNA molecules that
negatively regulate the translation of proteins by binding to complementary sequences
located at the 3’ end of untranslated transcripts. In addition to these different types of
mutations, retroviruses can insert an already activated oncogene into a host genome.54
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1.1.2.2 Tumor suppressor genes
A tumor suppressor gene protects a cell against tumorigenesis.49 The most commonly
mutated tumor suppressor gene in human cancers is tumor protein p53 (TP53).55 This gene
has numerous important functions in preventing tumorigenesis and is therefore known as
“the guardian of the genome”.55 Tumor suppressor genes are generally classified into
gatekeeper and caretaker genes.56 Gatekeeper genes encode for proteins that directly limit
cell division or stimulate apoptosis.56 Loss of these genes results in uncontrolled cell growth.
Caretaker genes, also known as stability genes, encode for proteins involved in maintenance
of genomic stability.56 Loss of these genes indirectly contributes to tumorigenesis by
causing an increased mutation rate.56 Mutations in caretaker genes themselves are therefore
neither selectively advantageous nor required for tumorigenesis.56 Consequently, caretaker
gene mutations are rare in sporadic tumors and more often are the underlying cause of
hereditary cancers.56 Landscaper genes represent a third and less-common type of tumor
suppressor.57 The  loss  of  these  contributes  to  tumorigenesis  by  altering  the  stromal
microenvironment to support the growth of neoplastic cells.57
According to Knudson’s two-hit hypothesis, a selective growth advantage occurs only when
both alleles of a tumor suppressor gene are inactivated (Figure 2).58 Tumor suppressor genes
are therefore recessive. However, exceptions include dominant negative mutations in which
a mutant protein interferes with the action of the corresponding wild-type protein.58 Another
exception is haploinsufficiency, in which the loss of a single copy results in a gene dosage
that is low enough to drive tumorigenesis.58
Tumor suppressor genes are typically inactivated by loss-of-function mutations, including
nonsense or frameshift mutations.49 Chromosomal rearrangements may also inactivate a
tumor suppressor gene by disrupting the gene itself or separating it from essential regulatory
elements.49 The  deletion  of  a  gene  and  of  its  surrounding  regions  is  known  as  loss  of
heterozygosity (LOH). The deleted region may also be replaced by a copy from the other
homologous chromosome, resulting in no net change in copy number. This phenomenon is
known as copy-neutral loss of heterozygosity (CN-LOH).59
Figure 2. Knudson’s two-hit model of tumorigenesis. According to Knudson’s two-hit hypothesis, loss
of both alleles of a tumor suppressor gene is a requirement for tumorigenesis. A) Tumor suppressor genes
are often inactivated by a loss-of-function mutation in conjunction with a larger chromosomal deletion.
B) In hereditary cancers, the “first-hit” is inherited in all cells of the body, leading to an earlier onset of
multiple primary cancers.
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1.1.3 Inherited tumor susceptibility
Tumor development is highly influenced by environmental and lifestyle factors, and the
majority of tumors are sporadic. An estimated 5 to 10% of cancers are said to be hereditary,
most of which result from germline mutations with high penetrance.14 Penetrance refers to
the proportion of individuals who carry a mutation that will give rise to a specific disease
or trait. A hereditary cancer syndrome is a genetic disorder characterized by early onset of
multiple primary tumors in several  family members.  The majority of the over 200 tumor
syndromes described are inherited in an autosomal dominant manner with incomplete
penetrance.14 These syndromes characteristically result from germline mutations in tumor
suppressor genes that conform to Knudson’s two-hit model of tumorigenesis (Figure 2B).
Family-based linkage studies have been highly successful in identifying such faulty genes,
including MLH1 in Lynch syndrome,60 RB transcriptional corepressor 1 (RB1) in hereditary
retinoblastoma,61 and neurofibromin 1 (NF1) in neurofibromatosis type I.62 However, the
use of linkage studies is typically limited to highly penetrant syndromes (Figure 3).
During the previous decade, research focus has shifted from Mendelian (single-gene)
models towards polygenic models of tumor susceptibility (Figure 3). The “common disease-
common variant” model proposes that many common cancers arise due to a combined effect
of multiple common low-penetrance variants.63 Genome-wide association studies (GWAS)
– in which thousands of individuals are investigated for associations between
polymorphisms and disease phenotypes – have been successful in identifying such
variants.64 Understanding the molecular mechanisms behind such variants remains
challenging because they are usually located in non-coding regions and are thus unlikely to
be directly causal. Exceptions include a variant (rs6983267) located within an enhancer that
directly regulates the activity of the proto-oncogene MYC.65 The variants identified through
GWAS and linkage studies explain only a small proportion of the entire estimated
heritability of common cancers. This has led researchers to seek this “missing heritability”.64
Approximately 15 to 20% of common cancers are considered “familial”, which is defined
as familial clustering of cancers.14 In contrast to hereditary cancers, these cases follow no
apparent inheritance pattern. The genetic background behind such cancer cases remains
largely unexplained, and much of the latest research seek to understand them. Many of these
cancers may arise due to rare variants with intermediate penetrance conferring a moderate
cancer risk (Figure 3). Novel technologies combined with new strategies may have the
potential to identify and characterize such complex patterns of inheritance.
Common risk variants may also be detectable by a novel approach known as admixture
mapping.66 With admixture mapping it is possible to detect disease-causing variants that
differ in frequency between two historically separate populations.66 This method is ideally
performed in a population descended from two ancestral groups, each of which have been
geographically isolated for tens of thousands of years: for example, African Americans with
West African and European ancestry.66
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Figure 3. The relationship between penetrance and risk allele frequency. Linkage studies have been
highly successful in identifying rare variants underlying Mendelian disorders. In contrast, genome-wide
association studies have been successful in identifying common variants contributing to the risk for many
common cancers. Familial aggregation studies indicate that a substantial fraction of the entire estimated
heritability remains to be uncovered. This missing heritability may be explained by relatively rare
variants with intermediate penetrance. Massively parallel sequencing combined with new strategies may
have the potential to identify and characterize such complex patterns of inheritance.
1.1.4 Tumor epigenetics
Epigenetics is the study of cellular and physiological traits that are heritable by daughter
cells and not caused by alterations to the DNA sequence.67 Use of the term “epigenetics” to
describe modifications that are not heritable remains controversial.68 Several external and
internal factors influence epigenetics, including age, the environment, and disease.69
Epigenetic modifications, or “tags”, include chemical alterations to the DNA strand or to
proteins  bound to  it.  These  modifications  may alter  the  chromatin  structure  of  DNA and
thereby alter gene expression. Epigenetics play a central role in nearly all cellular processes,
including embryonic development and differentiation of pluripotent stem cells.67
Furthermore, women carry two copies of the X chromosome, one of which is epigenetically
silenced in each cell of the body. Epigenetics explains, in part, how cells carrying identical
DNA differentiate into different tissues. In contrast to mutations, epigenetic alterations are
reversible, and their status frequently differs from cell to cell. Only a few studies have been
able to provide evidence for epigenetic tags that are transmittable to offspring.70 The
mechanisms by which these changes are transmitted are unclear, since the majority of
epigenetic tags are erased after fertilization through a process called reprogramming.71
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DNA methylation and histone modification are two universally accepted types of epigenetic
mechanism. DNA methylation is a chemical process in which specific enzymes add methyl
groups to DNA, predominantly at CpG sites where a cytosine is followed by a guanine.72
DNA methylation can regulate the transcription of genes by preventing or allowing the
binding of the basal transcriptional machinery or transcription factors to DNA.72 Eukaryotic
DNA is wrapped around special proteins called histones that form a large structure called
the nucleosome. Histones play a role in maintaining chromatin structure, thereby regulating
the transcription of genes.67
Epigenetic modifications may drive tumorigenesis, since tumors often exhibit a variety of
abnormal epigenetic patterns not present in the normal tissue from which they arise.73
Furthermore, hypomethylation can activate oncogenes, whereas hypermethylation can
silence tumor suppressor genes.73 Two different models aim to explain the mechanism by
which methylation influences tumorigenesis. The stochastic model proposes that selectively
advantageous changes occur by chance, whereas the instructive model proposes that DNA
methylation is maintained by trans-acting mutations.74 The role of epigenetic alterations in
tumorigenesis is largely unclear, and epigenetics is currently one of the most rapidly
expanding fields in cancer-related research.
2. Genome-wide methods for studying tumorigenesis
The field of molecular biology has undergone rapid changes during recent decades.
Research has shifted from an analysis of a handful of molecules to simultaneous analysis of
thousands of measurements on a genome-wide scale. Molecular biology has therefore
become a data-intensive field requiring new considerations for experimental design, data
analysis, and data visualization. Two of the most widely used high-throughput methods for
studying molecular biology are microarrays and massively parallel sequencing.36, 75 These
technologies have revolutionized the study of human diseases, especially in the field of
cancer. Indeed, cancers have historically been classified by their primary site of origin or
by their histology, but these technologies have led to the identification and classification of
molecular subtypes of cancers.
2.1 DNA microarray technology
DNA microarrays, also called gene-chips, were first introduced in 1995 as a tool for
studying the expression of thousands of genes simultaneously.75 This method was quickly
adopted for other purposes as well, including detection of copy-number variations or SNP
genotyping. Commercial- and custom-made microarrays are nowadays available from a
variety of manufacturers, including Illumina, Affymetrix, and Agilent.75 This technology is
based on the hybridization of fluorescent-labeled molecules of interest to complementary
probes that are attached on a surface consisting of silicon, nylon, or glass.75 Microarrays can
nowadays have up to millions of probes, consisting of oligonucleotides, cDNA, or cRNA.75
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After hybridization, the fluorescent dye is excited with a laser, and the array images are
quantified into numeric values.75 One drawback of this method is that it does not allow for
the identification of rearrangements such as translocations or inversions. Although
microarrays are increasingly being replaced by massively parallel sequencing technology,
the use of this technology remains particularly useful in gene expression profiling studies.
2.2 Massively parallel sequencing technology
Massively parallel sequencing, also known as next generation sequencing, refers to a novel
sequencing approach in which millions to billions of DNA or RNA fragments are sequenced
simultaneously.36 Since its commercial launch in 2005, massively parallel sequencing has
become widely available from several companies, including Illumina, Complete Genomics,
Life Technologies, Roche 454, and Helicos BioSciences.76 This technology has made it
possible to generate high-resolution sequencing data in less time and at lower cost.76 In
comparison, the sequencing of the human genome, known as the Human Genome Project,
was declared complete in April 2003 and ended up costing approximately $2.7 billion dollar
by an approach known as shotgun sequencing.77 These technologies have proven powerful
for studying complex genetic diseases such as cancer.
Targeted sequencing is a method that combines targeted capture with massively parallel
sequencing in order to explore regions of interest, typically exons.76 Whole-exome
sequencing refers to the sequencing of all known protein-coding regions of a genome, which
constitutes approximately 1% of the human genome.76 Whole-genome sequencing provides
full coverage of the entire genome and allows for detection of chromosomal abnormalities
with high precision.76 This method is, however, costly for large sample sizes. This is
particularly true for analysis of cancer genomes, since identification of somatic mutations
requires sequencing of both tumor and normal tissues from the same patient.
Although this technology was initially used to study DNA, it  has since been adopted for
other purposes as well, such as investigating the transcriptome (RNA sequencing), the
methylome (bisulfite sequencing), and interactions between DNA and transcription factors
(chromatin immunoprecipitation sequencing).36 Today, the cost of massively parallel
sequencing is steadily decreasing and quickly overtaking Sanger sequencing as the gold
standard sequencing technique. Since the sequencing of the first whole-cancer genome in
2008, this technology has led to the discovery of numerous cancer causing genes in a
relatively short time.78
2.2.1 Sample processing and sequencing
All currently available sequencing platforms require preprocessing of DNA into a library
that is suitable for sequencing. Although a wide variety of preparation protocols exists, each
of them includes the fragmentation of DNA into an appropriate size followed by adapter
ligation.36 This is typically followed by PCR amplification in which sufficient quantities of
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DNA are generated for the sequencing.36 Illumina sequencing is currently the platform most
widely used, and has a workflow that continues with immobilization of fragments onto a
glass slide known as a flow cell, where each DNA molecule is sequenced in parallel.36 This
sequencing involves cycles of repeated addition of all four nucleotides, each labeled with a
different dye.36 Paired-end  sequencing  refers  to  the  sequencing  of  both  ends  of  a  DNA
fragment, thus generating higher quality and more easily alignable sequencing data.36
2.2.2 Data analysis
One current drawback from these technologies is that they generate relatively short reads,
making genome assembly, alignment, and variant calling a difficult challenge that requires
the development of novel bioinformatic tools and algorithms. Another drawback is that it
produces gigabytes of data that are computationally intensive to analyze.
The first major step in the data analysis is alignment of the sequencing reads to a reference
genome. This process is particularly time consuming and requires a significant amount of
computing resources. Since a large part of the human genome consists repetitive regions,
aligning short reads is a difficult challenge. Reads carrying large indels are also difficult to
align and the PCR amplification step often results in overrepresentation of some DNA
fragments. Duplicate read removal and local indel realignment are therefore often
performed to refine alignments prior to variant calling.79 Bowtie, Burrows-Wheeler Aligner
(BWA), and Novoalign are some of the most widely used short read aligners.80
Once aligned, variant calling requires multiple different methods, each restricted to
detecting a variant of a particular size. Indeed, substitutions, microindels, chromosomal
rearrangements, and CNVs/SCNAs are typically detectable by different methods. Current
methods for detecting substitutions show high sensitivity and specificity and include
methods such as MuTect, VarScan 2, and Strelka.81 On the other hand, detection of
microindels and rearrangements are still problematic in both their sensitivity and specificity,
requiring complex scoring and filtering strategies in order to achieve reliable calls. GATK
Unified Genotyper, VarScan 2, SAMtools, and GTAK HaplotypeCaller include some of the
most widely used tools for detecting microindels,82 whereas BreakDancer, Pindel, Delly,
and novoBreak83 include some of the most widely used tools for detecting chromosomal
rearrangements. Varscan 2, HMMCOPY, ExomeCNV, and ABSOLUTE are popular for
detecting CNVs/SCNAs.84 Variant calling is highly dependent on the sequencing depth
coverage, and an average sequencing depth of 30x to 50x is often recommended for
sequencing tumor samples.85
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3. Uterine leiomyomas
3.1 Clinical features and prevalence
Leiomyomas are benign smooth muscle tumors of mesenchymal origin that can arise from
any tissue containing smooth muscle cells, but most frequently occurs in the uterus, small
bowel,  or  esophagus.  Uterine  leiomyomas  originate  from  the  muscle  cells  of  the
myometrium layer, and are classified into intramural, submucosal, and subserosal,
according to their anatomic position within the uterus (Figure 4).2 The ancient Greek
physician Hippocrates had already recognized the existence of these uterine masses, and
referred to these as “uterine stones”.86 The term “leiomyoma” will hereafter refer to uterine
leiomyomas unless stated otherwise.
Figure 4. Anatomical classification of leiomyomas according to their position within the uterus.
Leiomyomas most commonly grow within the smooth muscle layer of the uterine wall (intramural). They
may occasionally grow towards the uterine cavity (submucosal) or towards the abdominal cavity
(subserosal). Submucosal or subserosal leiomyomas may also grow on an elongated stalk (pedunculated).
Leiomyomas can be single or multiple, and the spectrum of symptoms depends largely on their size,
number, and location.
Leiomyomas are round, firm, sharply circumscribed and white-grayish neoplasms with a
limited vascularization network. They are typically surrounded by a pseudocapsule that
separates the neoplastic tissue from the myometrium.87 These tumors are histologically
composed of intersecting bundles of smooth muscle cells that resemble the normal
myometrium. Leiomyomas are commonly called fibroids, owing to their distinctive features
of fibrosis (excessive fibrous connective tissue).88 Indeed, a particular hallmark of
leiomyomas is the overproduction of extracellular matrix components, primarily consisting
of collagens, fibronectins, and proteoglycans.88 A major reason for their overgrowth is
accumulation of this disorganized extracellular matrix that is exceptionally stable.88
Leiomyomas  may  grow  as  a  single  nodule  or  in  clusters,  averaging  eight  nodules  per
affected uterus.89 Although they may grow to as large as 30 cm in diameter, the growth rate
of leiomyomas is relatively slow, with an average increase of 9% in volume over a 6-month
period.90 However,  they  display  significant  variability  in  growth  rate,  with  some  lesions
even regressing spontaneously.90 Furthermore, despite having the same hormonal
environment, leiomyomas within the same uterus often have different growth rates.90
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Uterine leiomyomas are the most common neoplasms found in women of childbearing age.
These tumors are typically detected during women’s middle or late reproductive years, and
they usually shrink after menopause. Approximately 70 to 80% of women will develop a
leiomyoma  by  the  age  of  50,  but  the  majority  will  be  asymptomatic  with  the  tumors
remaining undiagnosed.91 Nevertheless, approximately 25% of women with leiomyomas
will present with symptoms,89 making  them  one  of  the  most  common  tumors  afflicting
women. Symptoms include pressure upon adjacent organs, abnormal menstrual bleeding
and impaired fertility (Table 1).2, 92 Most symptoms are reflective of leiomyoma size and
location, but some symptoms may result from unknown biochemical alterations mediated
by the tumor.
Table 1. Clinical presentation of uterine leiomyomas
Asymptomatic
Abnormal uterine bleeding
 Heavy or prolonged menstrual bleeding (menorrhagia)
 Painful menstruation (dysmenorrhea)
 Anemia
Pressure on the bladder
 Frequent urination
 Difficulty or inability to urinate
 Hydronephrosis
Pressure on the rectum
 Constipation
 Tenesmus
Obstetric complications
 Premature labor
 Spontaneous miscarriage
 Infertility
Pain symptoms
 Pelvic discomfort or pain
 Painful intercourse (dyspareunia)
 Lower back pain
Increased waist size
Ascites
Polycythemia
Data in part derived from Reproductive Sciences, 19, Sabry M. et al., Medical Treatment of Uterine
Leiomyoma (2012).
Because of their high morbidity, leiomyomas are the foremost indication for hysterectomy
worldwide. Approximately 600,000 hysterectomies are performed yearly in the United
States, making it the second most common surgical procedure for women after Caesarean
section.93 By the age of 60, more than one-third of all women will have had a hysterectomy,
with 40% of these due to complications of leiomyomas.93 The social and economic impact
of this disease is therefore very high, in the United States costing an estimated 6 to 34 billion
dollars per year.94
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3.2 Pathological classification of uterine smooth muscle tumors
Smooth muscle tumors of the uterus consist of a heterogeneous group of mesenchymal
tumors ranging from benign leiomyomas to high-grade malignant leiomyosarcomas.
Several rare leiomyoma-like lesions should be distinguished from “conventional”
leiomyomas, as they display unusual histopathology or distinct growth patterns. These
leiomyoma variants account for approximately 10% of all leiomyomas (Table 2).95
Table 2. Classification of uterine smooth muscle tumors by the World Health Organization
Benign Morphological features
Conventional leiomyoma Bundles of smooth muscle cells with high extracellular content
Lipoleiomyoma Admixture of mature adipocytes and smooth muscle cells separated by thin fibrous tissue
Epithelioid leiomyoma Round to polygonal epithelial-like smooth muscle cells arranged in clusters or cords
Angioleiomyoma
(Vascular Leiomyoma) Presence of thick-walled vascular vessels
Myxoid leiomyoma Presence of myxoid material between smooth muscle bundles
Hydropic leiomyoma Presence of conspicuous zonal watery edema
Apoplectic leiomyoma Presence of hemorrhage and edema within nodules of hypercellular smooth muscle cells
Unusual growth pattern
Parasitic leiomyoma A leiomyoma detached from the uterus and attached to peritoneal surfaces from which itderives its blood supply
Disseminated peritoneal
leiomyomatosis Smooth muscle nodules scattered over the peritoneal surfaces
Intravenous leiomyomatosis Abnormal smooth muscle growth within vascular spaces from intrauterine venules to theright heart
Benign metastasizing leiomyoma Smooth muscle tumors located at distant organs in women with a prior history of uterinesurgery
Diffuse uterine leiomyomatosis Almost complete replacement of the myometrium by innumerable poorly defined, confluenttumor nodules
Dissecting leiomyoma
(Cotyledonoid leiomyoma) Extrauterine bulbous growth continuous with a dissecting myometrial component
Intermediate
Mitotically active leiomyoma High mitotic index (>10 mitotic figures per 10 high-power fields), but lacking tumor cellnecrosis and nuclear atypia
Cellular leiomyoma Increased cellularity, but lacking tumor cell necrosis, nuclear atypia, and high mitotic index
Leiomyoma with bizarre nuclei
(Atypical/Symplastic leiomyoma)
Presence of bizarre multinucleated smooth muscle cells (nuclear atypia), but lacking tumor
cell necrosis and high mitotic index
Smooth muscle tumors of uncertain
malignant potential (STUMP)
High mitotic index, increased nuclear atypia, and tumor cell necrosis, but not enough to meet
the criteria of a leiomyosarcoma
Malignant
Leiomyosarcoma Presence of tumor cell necrosis, high mitotic index, nuclear atypia, and increased cellularity
Data in part derived from Kurman R.J. et al., WHO Classification of Tumours of Female Reproductive
Organs. Fourth Edition (2014).
Smooth muscle tumors resembling uterine leiomyomas at the gross and histologic level, but
present at unusual locations include disseminated peritoneal leiomyomatosis, intravenous
leiomyomatosis, and benign metastasizing leiomyomas (Table 2).96 The etiology of these
conditions remains controversial, as they have been associated with a history of uterine
surgery for leiomyomas.96 Diffuse uterine leiomyomatosis is another usual growth pattern,
one in which the uterus is symmetrically enlarged due to a complete replacement of the
myometrium by innumerable poorly defined, confluent tumor nodules.97 The existence of
these quasi-malignant behaviors suggests that some leiomyoma cells have the potential to
spread and attach to distant locations. Nevertheless, it is important to note that these variants
are classified as clinically benign rather than premalignant.
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The  majority  of  uterine  smooth  muscle  tumors  are  readily  classified  as  either  benign  or
malignant based upon their gross and histologic features. Malignant leiomyosarcomas are
characterized by tumor cell necrosis, high mitotic activity, nuclear atypia, and increased
cellularity.98 Considerable debate still exists as to whether leiomyomas and
leiomyosarcomas are part of the same disease continuum. Leiomyosarcomas are extremely
rare and account for only 0.1% of uterine smooth muscle tumors, suggesting that
leiomyosarcomas arise de novo.99 The existence of leiomyoma variants displaying some,
but not all, features of malignancy suggests, however, that leiomyosarcomas may develop
from leiomyomas.98 Furthermore, leiomyosarcomas may occasionally display areas that are
histologically benign, supporting the view of a malignant transformation.100 The distinction
between leiomyosarcomas and some histologically intermediate variants tends to be
challenging; smooth muscle tumors that cannot be diagnosed as either benign or malignant
are sometimes classified as smooth muscle tumors of uncertain malignant potential
(STUMP).98 While it is conceivable that some leiomyomas may become malignant, what is
still  unclear  is  why  the  vast  majority  of  these  very  common  tumors  have  such  a  low
malignant potential.
Although  the  uterus  is  the  most  common  site  of  origin  for  both  leiomyomas  and
leiomyosarcomas, both of these tumor types can arise from any tissue that contains smooth
muscle cells. Uncommon sites of origin include the vulva, ovaries, bladder, urethra,
abdominal cavities, kidneys, and skin.101 Such extrauterine smooth muscle tumors are very
rare, and present a greater diagnostic challenge.
3.3 Diagnosis and clinical management
Uterine leiomyomas are often diagnosed incidentally during routine pelvic examination, and
confirmed by ultrasound.102 Magnetic resonance imaging provides a more accurate, but also
costly method for their detection and localizion.102 In general, leiomyomas are treated only
if they cause symptoms, and the treatment choice depends on patient age, general health,
symptoms, reproductive desires, and leiomyoma size and location.103 Leiomyomas can be
treated surgically, medically, or with minimally invasive techniques.103
Hysterectomy, the surgical removal of the uterus, is currently the most common intervention
for leiomyomas.103 Myomectomy, the surgical removal of leiomyomas leaving the uterus
intact, is the primary treatment choice for women who wish to preserve their fertility.103
After myomectomy, up to 25% of women will experience recurrence, and 10% will require
additional surgeries.104 The general belief is that these recurrences represent newly
developed leiomyomas rather than the same leiomyomas that grow back.
Open power morcellation refers to the dissection of large tissues into smaller pieces with an
electric morcellator.105 Although an efficient tool, this device has recently become a subject
of controversy. Morcellation may accidentally spread tumor tissue around the peritoneal
cavity or surgical ports. This may lead to postoperative growth of tumors at distant locations,
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sometimes referred to as “morcellomas”.106 Furthermore, morcellation may spread
unsuspected leiomyosarcomas, leading to worsened disease outcomes. An estimated 1/500
to 1/1000 hysterectomy specimens of a presumed leiomyoma will ultimately be confirmed
as leiomyosarcoma.107 The  U.S.  Food  and  Drug  Administration  have  therefore  issued  a
warning against the use of morcellators.108 However, this tool is more cost-effective than its
alternatives, with an estimated cost of 11 million dollars to prevent one unintentional case
of disseminated leiomyosarcoma.109
At present, medical management of leiomyomas is very limited and mainly serves to
temporarily relieve symptoms or to reduce the size of leiomyomas prior to surgery. The
most common medications include non-steroidal anti-inflammatory drugs, oral
contraceptive pills, selective progesterone receptor modulators, and gonadotropin-releasing
hormone agonists.92 Gonadotropin-releasing hormone agonists act on the pituitary gland to
reduce the level of estrogen produced by the ovary, leading to a reduction in leiomyoma
size by half within a 3-month period.92 Nevertheless, leiomyomas typically regrow once
treatment is stopped, and long-term use causes severe side effects associated with low
estrogen. A better understanding of the molecular underpinnings may allow for
identification of novel therapeutic targets that could effectively treat leiomyomas long-term.
3.4 Risk factors
Since leiomyomas are so common, it is reasonable to assume that many leiomyomas may
share a common risk factor. Epidemiological and experimental studies have identified
several  potential  risk  factors  for  leiomyomas  (Table  3),  most  of  which  are  not  yet  fully
understood and require further validation. Not only do these studies indicate that
leiomyomas develop under unfavorable environmental conditions, but that inheritance is
highly important as well.
Table 3. Risk factors for uterine leiomyomas
Risk Risk factor References Risk Risk factor References
Increased African American ethnicity 90, 91, 110 Decreased Menopause 111, 112
Positive family history 113-117 Increasing parity 118
Early age of menarche 119 Fruit and vegetable intake 120, 121
Age (reproductive years) 91, 122 Dairy intake 123
Nulliparity 124 Green tea extract 125
Hormone replacement therapy 112 Depot medroxyprogesterone acetate 126
Thyroid disease 127 Tobacco smoking 128
Hypertension 124, 129 Physical activity 130
Polycystic ovary syndrome 131
Vitamin D deficiency 132 Contradictory Oral contraceptives 128, 133
Obesity 112, 134 Pelvic inflammatory disease 135, 136
Psychological stress 137 Chlamydia 135, 136
Red meat intake 120 Diabetes 124, 138
Alcohol intake 139, 140
Caffeine intake 139
Radiation exposure 141
Diethylstilbestrol 142
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3.5 Etiology and pathogenesis
The etiology and pathogenesis of leiomyomas are still largely elusive, and several
hypotheses have attempted to explain their cause and nature. Interestingly, several of the
risk factors for leiomyomas can be linked to ovarian steroid hormones (estrogen and
progesterone). Indeed, ovarian steroid hormones are clearly essential, since leiomyomas are
rare before puberty and typically regress after menopause.111 Epidemiological, clinical, and
experimental data have established that leiomyoma growth is dependent on both estrogen
and progesterone.143 However, the reason behind this dependency is still unknown, and both
of these hormones are considered tumor promoters rather than tumor initiators. Some
researchers have hypothesized that leiomyomas mimic a pregnant myometrial cell type that
is hypersensitive to ovarian steroid hormones.144 Indeed, leiomyomas and parturient
myometrium share numerous characteristics, including expression of pregnancy-related
genes and increased production of extracellular matrix components.144
Although the hypothesis that leiomyomas are linked to inflammation dates back to 1932,145
more recent studies have postulated that uterine injury could trigger the formation of
leiomyomas through abnormal activation of growth factors involved in wound healing and
inflammation.146 Indeed,  leiomyomas  and  keloid  scars  are  both  more  common  among
African Americans, and both of these lesions display excessive extracellular matrix
deposition.147
Other studies have proposed that viral infections may trigger the transformation of
leiomyomas because transgenic mice expressing simian virus 40 (SV40) large T antigen –
under the control of a smooth muscle promoter – develop uterine smooth muscle tumors
that are estradiol dependent.148 Furthermore, transgenic mice expressing polyomavirus large
T  (PyLT)  antigen  –  under  the  control  of  the  mouse  mammary  tumor  virus  promoter  –
develop uterine leiomyomas as well.149
Although leiomyomas were not historically considered a genetic disease like cancer, the
prevailing theory is that their development is triggered by genetic mutations. The neoplastic
transformation of a single normal myometrial cell into a fully developed leiomyoma is likely
to be a multistep process involving a complex interplay between environmental factors,
ovarian steroid hormones, local growth factors, and genetic mutations.
3.6 Genetics
Epidemiological, cytogenetic, and molecular studies support a central role for genetics in
the predisposition, etiology, and pathogenesis of leiomyomas.115, 117, 150 However, the
identity of external or internal factors that initiate this process remains unknown. Uterine
leiomyomas have been associated with a variety of genetic changes, suggesting that
leiomyomas are not a single-gene disease.
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3.6.1 Genetic predisposition
Familial aggregation, twin, and racial prevalence studies provided the initial evidence for
an important role of genetic factors in leiomyoma development. Familial aggregation of
leiomyomas  was  already  reported  in  1938,  showing  that  leiomyomas  are  four  times  as
frequent in first-degree relatives of affected probands as among first-degree relatives of
unaffected probands.113 Leiomyomas are also twice as common in women with two or more
affected family members.115 Twin studies have revealed heritability estimates of 0.26 in
Finns,117 0.69 in the British,116 and 0.79 in Russians.114 Compared  with  dizygotic  twins,
monozygotic twins are twice as likely to be concordant for hysterectomy and more likely to
be hospitalized for leiomyomas.117
Leiomyomas are three to nine times as prevalent in African-American women as in
Caucasian women.91 Furthermore,  African-American women tend to develop tumors at  a
younger age, experience more severe symptoms, develop larger and a greater number of
tumors, and are more likely to undergo hysterectomy for leiomyomas.90, 91, 122 In addition,
leiomyomas in black women tend to have higher growth rates and respond differently to
medical treatment.90 Since no environmental risk factor has yet explained this racial
disparity, inherited susceptibility likely plays a major part. In support of this hypothesis, a
recent admixture-mapping study of African-Americans found a positive correlation between
percentage of African ancestry and leiomyoma risk.151
3.6.2 Genetic disorders associated with leiomyomas
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare autosomal dominant
disorder characterized by a susceptibility to uterine and cutaneous leiomyomas, as well as
to renal cell cancer in a subset of families.152 Recent studies have proposed a slightly higher
risk for pheochromocytomas and paragangliomas as well.153, 154 This disorder was first
described in 1973 as Reed’s Syndrome,155 and has since been known under several other
names, including multiple cutaneous leiomyomas, and multiple cutaneous and uterine
leiomyomatosis, reflecting differences in their clinical presentations.152 Uterine leiomyomas
associated with this syndrome have a higher prevalence, earlier age of onset, and require
treatment more often than those that are sporadic.152 Moreover, they typically display
distinct histological features, including a large nucleus with a prominent eosinophilic
nucleolus surrounded by a clear halo.152 The cutaneous leiomyomas (piloleiomyomas) are
multiple, and arise from the tiny muscles attached to hair follicles.152 The associated renal
cell cancer is highly aggressive and usually of papillary type II histology.152
Uterine leiomyomas are also a less common manifestation of Cowden syndrome156 and
Schwannomatosis157 (Table 4). Furthermore, extrauterine leiomyomas have been associated
with Alport syndrome,158 Gorlin syndrome,159 and Tuberous sclerosis (Table 4).160 The
presentation of uterine leiomyomas in some of these syndromes may be coincidental, since
sporadic leiomyomas are so very common.
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Table 4. Human genetic disorders associated with uterine or extrauterine leiomyomas
Genetic disorder OMIM# Tumor spectrum Causative gene(s)
HLRCC 150800 Uterine leiomyoma, piloleiomyoma, renal cell cancer FH
Cowden syndrome 158350 Uterine leiomyoma, multiple hamartoma PTEN
Schwannomatosis 162091 Uterine leiomyoma, cutaneous schwannoma, meningioma SMARCB1
Alport syndrome 308940 Esophageal leiomyomatosis, vulvar leiomyoma COL4A5, COL4A6
Gorlin syndrome 109400 Ovarian leiomyoma, basal cell carcinoma PTCH1
Tuberous sclerosis 606690 Lymphangioleiomyomatosis, angiomyolipoma, rhabdomyoma TSC1, TSC2
OMIM: Online Mendelian Inheritance in Man
3.6.2.1 Inactivation of FH
In 2002, family-based linkage analysis revealed that the HLRCC syndrome is caused by
heterozygous germline mutations in the fumarate hydratase (FH) gene,161 all leading to an
absent, truncated, or nonfunctional protein. Indeed, FH represents a classical tumor
suppressor gene, since the cutaneous, uterine, and renal tumors all display somatic loss of
the wild-type allele, conforming to Knudson’s two-hit model of tumorigenesis.152
Subsequent studies have revealed that only 1% of sporadic leiomyomas display somatic loss
of both FH alleles.162, 163 Because only 20% of HLRCC families display renal cell cancer,152
additional genetic or environmental factors are likely to be necessary for their development.
Several hypotheses have aimed at explaining the mechanism of FH mutations  in
tumorigenesis. FH encodes for fumarase, a citric acid cycle enzyme that catalyzes the
conversion of fumarate to L-malate in the mitochondrial matrix.164 The citric acid cycle is
a central metabolic pathway that finalizes the oxidative degradation of carbohydrates, fatty
acids, and proteins into carbon dioxide and chemical energy.164 Loss of fumarase results in
reduced citric acid cycle function and accumulation of its substrate fumarate.164 The
majority of functional studies have assumed that fumarate acts as an oncometabolite that
drives tumorigenesis, owing to its apparent function as a competitive inhibitor of a class of
enzymes known as α-ketoglutarate-dependent dioxygenases.165 Indeed, fumarate can inhibit
prolyl 4-hydroxylases that normally degrade hypoxia-inducible factor 1-alpha (HIF-1-α).166
Accumulation of this transcription factor results in activation of target genes involved in
angiogenesis, glycolysis, cell survival, and metastasis.167 This phenomenon has been termed
“pseudohypoxia”,166 since HIF-1-α is normally active under low oxygen conditions.
Fumarate can also inhibit histone demethylases and the ten-eleven-translocation family of
5-methylcytosine hydroxylases,165 both of which are involved in epigenetic regulation.
Consequently, renal cell cancers and paragangliomas with FH mutations display genome-
wide hypermethylator patterns known as the hypermethylation phenotype or the CpG island
methylator phenotype.168, 169
Mutations in genes encoding for other citric acid cycle enzymes are also involved in
tumorigenesis.164 Indeed, germline mutations in subunits of succinate dehydrogenase (SDH)
predispose to paragangliomas, whereas somatic mutations in subunits of isocitrate
dehydrogenase (IDH) occur in glioma and acute myeloid leukemia.164 Loss-of-function
mutations in the SDHx genes (SDHA, SDHB, SDHC, or SDHD) result in accumulation of
their substrate succinate, which can also act as a competitive inhibitor of α-ketoglutarate-
dependent dioxygenases.165 Conversely, gain-of-function mutations in the IDHx genes
(IDH1 or IDH2) result in the conversion of abnormally high levels of 2-hydroxyglutarate
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from α-ketoglutarate,164 which in turn acts as another competitive inhibitor of α-
ketoglutarate-dependent dioxygenases. Indeed, both paragangliomas with SDHx mutations,
and gliomas with IDHx mutations exhibit pseudohypoxia and the hypermethylation
phenotype.168, 170, 171 What remains to be seen is whether leiomyomas that harbor FH
mutations also display hypermethylation patterns, and whether some leiomyomas are driven
by SDHx or IDHx mutations.
Recent studies have shown that intracellular fumarate can activate the transcription factor
Nuclear factor erythroid 2-related factor 2 (NFE2L2, also known as NRF2) through post-
translational modification of its negative regulator kelch like ECH associated protein 1
(KEAP1).172 Indeed, fumarate is able to succinate KEAP1, a chemical process in which
fumarate spontaneously reacts with cysteine sulfhydryl groups to form a stable chemical
modification known as S-(2-succino)-cysteine (2SC).172 NRF2 is a master regulator of the
antioxidant response pathway, and its activation can drive tumorigenesis.173 Finally,
fumarate may play a role in stimulating the repair of DNA double-strand breaks,174
suggesting that loss of FH could trigger an increase in free radical generation, leading to
genomic instability.
3.6.3 Common low-penetrance risk variants
A few population-based studies have recently investigated, on a genome-wide scale, the role
of common genetic variants in susceptibility to leiomyomas (Table 5). The first GWAS of
leiomyomas identified three genome-wide significant loci on chromosomes 10q24.33,
22q13.1, and 11p15.5 among Japanese women.175 A  subsequent  GWAS  was  unable  to
replicate these findings among European Americans, but instead found a novel significant
locus on chromosome 17q25.3.176 The same study included a genome-wide linkage scan
that identified two significant linkage peaks on chromosomes 10p11.21 and 3p21.31, and
five suggestive peaks on chromosomes 2q37.1, 5p13.3, 11p15.5, 12q14.1, and 17q25.3.
Expression of the candidate gene fatty acid synthase (FASN) – located within the 17q25.3
region – was shown by immunohistochemistry to be elevated by 3-fold in leiomyomas when
compared to the corresponding myometrial tissue.
Two genome-wide admixture-mapping studies have recently aimed at identifying
leiomyoma risk variants that differ between African and European Americans (Table 5).
The first such study found only suggestive associations on chromosomes 2q33.3, 4p16.1,
and 10q26.3.151 The second study was unable to replicate these suggestive associations, but
instead, after controlling for covariates, found a significant locus on chromosome 1q42.2.177
Models with no stratification revealed several significant associations, of which
chromosome 2q32.2 displayed the highest score.177
No susceptibility locus has repeatedly emerged from these four genome-wide scans,
suggesting that leiomyoma risk is dependent on multiple variants with small effects.
Furthermore, the variants from these studies explain only a small proportion of the estimated
heritability, suggesting that additional susceptibility loci remain to be uncovered.
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Several follow-up studies have attempted to replicate the findings from these four genome-
wide scans. One study replicated variants within 22q13.1 and 11p15.5 in European
Americans.178 Furthermore, the variants within 22q13.1 were associated with increased
leiomyoma size, whereas the variants within 11p15.5 were associated with the intramural
leiomyoma subtype. A follow-up study, one using variants (both suggestive and significant)
derived from the first admixture mapping study and the genome-wide linkage scan, reported
several  significant  risk  associations  within  genes  that  encodes  for  components  of  the
extracellular matrix.179 A second study by the same group identified a variant within 4p16.1
to be significantly associated with increased leiomyoma size.180 A third study by the same
group, one evaluating variants (both suggestive and significant) derived from the two
GWAS, replicated the variants within 22q13.1 as significantly associated with increased
leiomyoma size among European Americans.181 The same study reported a variant within
2q22.1 to be associated with increased tumor size, but not with increased leiomyoma risk.
Table 5. Common variant susceptibility loci for uterine leiomyomas
Chromosome Risk variant/locus Candidate gene(s) Study (Reference)
Significant 10q24.33 rs7913069 SLK, OBFC1 Cha, P.C. et al. 2011 (175)
associations 22q13.1 rs12484776 TNRC6B, ADSL Cha, P.C. et al. 2011 (175)
11p15.5 rs2280543 ODF3, BET1L, RIC8A, IRT3 Cha, P.C. et al. 2011 (175)
17q25.3 rs4247357 FASN, CCDC57, SLC16A3 Eggert, S.L. et al. 2012 (176)
1q42.2 rs7546784 PCNXL2 Zhang, K. et al. 2015 (177)
2q32.2 rs256552 PMS1 Zhang, K. et al. 2015 (177)
10 9,632,527–72,985,946 COL13A1 Eggert, S.L. et al. 2012 (176)
3 169,614–76,307,730 - Eggert, S.L. et al. 2012 (176)
Suggestive 4p16.1 rs9715724 SORCS2 Wise, L.A. et al. 2012 (151)
associations 10q26.3 rs7100028 - Wise, L.A. et al. 2012 (151)
2q33.3 rs7573626 - Wise, L.A. et al. 2012 (151)
2 179,605,032–239,157,621 COL6A3 Eggert, S.L. et al. 2012 (176)
5 2,956,307–7,419,893 - Eggert, S.L. et al. 2012 (176)
11 278,505–7,282,771 - Eggert, S.L. et al. 2012 (176)
12 38,583,007–76,110,787 HMGA2 Eggert, S.L. et al. 2012 (176)
17 64,478,082–78,138,144 FASN, CCDC57, SLC16A3 Eggert, S.L. et al. 2012 (176)
3.6.4 Somatic chromosomal abnormalities
The first description of cytogenetic abnormalities in leiomyomas dates back to the late
1980s.182, 183 Since then, numerous cytogenetic studies have established that approximately
40% of leiomyomas harbor cytogenetically detectable chromosomal abnormalities, some of
which are leiomyoma-specific and non-random (Table 6).150
Chromosomally abnormal leiomyomas tend to be larger, more cellular, and have a higher
mitotic index,150 indicating that chromosomal abnormalities play fundamental roles in
leiomyoma pathobiology. Furthermore, chromosomal abnormalities are generally less
common among submucosal leiomyomas,147 and the type of abnormality may affect
leiomyoma size, anatomic location, or histopathology.150 In contrast to leiomyomas,
malignant leiomyosarcomas have highly complex karyotypes.184
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Rearrangements of 12q15 and deletions of 7q22 represent the two most common type of
chromosomal abnormalities in leiomyomas.150 Other less-common abnormalities include
rearrangements of 6p21, 14q24, and 10q22.150 These cytogenetic observations have led to
early attempts to categorize leiomyomas into molecularly distinct subtypes. It is still
somewhat unclear whether these abnormalities represent primary or secondary changes,
since some of these are present only within a subpopulation of tumor cells. This leaves
approximately 60% of leiomyomas without any cytogenetically detectable chromosomal
abnormalities, suggesting that submicroscopic mutations underlie the remaining tumors.
Table 6. Overview of regions recurrently affected by chromosomal abnormalities in leiomyomas
Chromosome Type of abnormality Putative target gene(s)
12q15 Translocation/Inversion/Trisomy HMGA2
6p21 Translocation HMGA1
14q24 Translocation RAD51B
7q22 Deletion/Inversion/Translocation CUX1, PCOLCE
10q22 Translocation/Deletion KAT6B
1q43 Deletion FH
1p36 Translocation/Deletion AJAP1, NPHP4
3q Deletion -
22q Deletion/Monosomy -
19q Deletion -
3.6.4.1 Chromosome 12q15 rearrangements and HMGA2
Cytogenetic studies have revealed that approximately 10% of leiomyomas harbor
rearrangements of chromosome 12q15,185 typically in the form of a balanced translocation
or a paracentric inversion. These rearrangements appear to be initiating or early events, since
they can be seen as a sole chromosomal abnormality, or as the only consistent abnormality
among several subclones.186 Rearrangements of 12q15 are also recurrent in several other
benign mesenchymal tumors, including breast fibroadenomas, endometrial polyps, lipomas,
angiomyxomas, pulmonary chondroid hamartomas, salivary gland adenomas, and
prolactinomas.150 These rearrangements appear to be rare in extrauterine leiomyomas,
because only a single vulvar leiomyoma187 and a single paratesticular leiomyoma188 have
emerged as harboring this rearrangement. However, 12q15 rearrangements do occur in
leiomyoma variants displaying unusual growth patterns, including intravenous
leiomyomatosis189 and disseminated peritoneal leiomyomatosis190. Considered together,
these observations indicate that a driver gene lies within this region.
High mobility group AT-hook 2 (HMGA2) is nowadays widely accepted as the target gene
of mesenchymal tumors carrying 12q15 rearrangements.191 In fact, HMGA2 was the very
first human driver gene discovered to be mutated in benign tumors.192 Positional cloning
revealed that the breakpoints in leiomyomas are typically located upstream of HMGA2,
leading to its increased expression.191 Furthermore, these rearrangements preferentially
target 14q24 as a balanced translocation partner.191 Surprisingly, the other mesenchymal
tumors usually target other regions and display breakpoints that are intragenic of HMGA2,
resulting in fusion transcripts containing the first three exons of HMGA2 and ectopic
sequences of other genes.191 Only  a  few  leiomyomas  have  been  found  to  harbor  such
fusions; these have involved RAD51B, COX6C, ALDH2, CCNB1IP1, or RTVL-H as fusion
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partners of HMGA2.185 However, most researchers agree that the fusion partners are not
directly involved in tumorigenesis. Indeed, every fusion transcript lack the 3’UTR of
HMGA2 that contains multiple binding sites for the let-7 family of microRNAs, a family
that negatively regulates the activity of HMGA2.193 Furthermore, transgenic mice
expressing either truncated or wild type forms of HMGA2 develop benign tumors, although
their tumor spectrum is slightly different: the former develop mainly lipomas, whereas the
latter develop prolactinomas as well.194 Of note, increased expression of HMGA2 has been
associated with an aggressive behavior in a variety of malignant neoplasias.191 However,
this overexpression is rarely accompanied by 12q15 rearrangements, with the notable
exception of some hematological malignancies.195-197
HMGA2 encodes for a nuclear transcription factor characterized by three DNA-binding
domains known as “AT-hooks”.194 HMGA2 can indirectly regulate the expression of genes
by binding to the minor groove of AT-rich DNA sequences, thereby inducing changes in
chromatin structure.194 HMGA2 is highly expressed during embryonic development and is
generally silenced in differentiated adult tissues.194 Some  adult  stem  cells  continue  to
express HMGA2, however.198 Leiomyomas with HMGA2 rearrangements tend to be larger
than chromosomally normal leiomyomas,199 suggesting that HMGA2 stimulates cell growth.
Indeed, Hmga2-null mice are born with reduced body size,200 and a few GWAS have
identified variants within the HMGA2 locus  to  be  associated  with  human  height.201
Furthermore, a specific TC dinucleotide repeat (TC227) located within the 5’UTR of
HMGA2 has been associated with small stature and an increased expression of HMGA2 in
leiomyomas.202 In addition, the Guinness World Book record holder for the tallest teenager
harbors a germline inversion involving the HMGA2 locus.203, 204
Several different hypotheses have attempted to explain the oncogenic action of HMGA2 in
human neoplasms, most of which are related to its ability to regulate gene expression. While
the exact role of HMGA2 in leiomyomas remains unclear, HMGA2 has the ability to induce
E2F1 activity, enhance expression of G1-S cell-cycle checkpoint genes, enhance AP1
activity, regulate myoblast proliferation, activate the mechanistic target of rapamycin
(mTOR) signaling pathway, inactivate p53-induced apoptosis, impair DNA-repair, enhance
expression of inflammatory proteins, and modulate epithelial-to-mesenchymal transition.191
3.6.4.2 Chromosome 6p21 rearrangements and HMGA1
Approximately 3% of leiomyomas harbor rearrangements of chromosome 6p21.185 These
rearrangements result in elevated levels of their target gene: high mobility group AT-hook 1
(HMGA1).205 Since HMGA1 and HMGA2 (HMGAx) are two closely related and highly
evolutionarily conserved genes,191 it is reasonable to assume that these genes have
overlapping functions in tumorigenesis. HMGA1 rearrangements appear to be common in
benign metastasizing leiomyomas,206 and in several other mesenchymal tumors as well,
including pulmonary chondroid hamartomas, lipomas, and endometrial polyps.150 Unlike
HMGA2 rearrangements, 6p21 rearrangements are never intragenic of HMGA1.
Rearrangements of HMGA1 may also, albeit rarely, target 14q24 in leiomyomas.205
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3.6.4.3 Chromosome 14q24 rearrangements and RAD51B
Approximately 9% of leiomyomas harbor rearrangements of chromosome 14q24.185 The
recurrent involvement of 14q24 in leiomyomas and other mesenchymal tumors suggests
that  a  driver  gene  is  located  within  this  region,  as  well.  Positional  cloning  of  the  14q24
region revealed that the breakpoints are randomly scattered within DNA repair protein
RAD51 homolog 2 (RAD51B).207 Whereas overexpression of HMGAx is  likely  to  be  the
primary pathogenic outcome, disruption of RAD51B may play a secondary role. Indeed,
RAD51B is important in DNA double-strand break repair by homologous recombination,
and haploinsufficiency of RAD51B causes chromosomal instability in human cell lines.208
Both ionizing and ultraviolet radiation can induce the expression of RAD51B,  causing  a
delay in the G1 phase of the cell cycle or apoptosis.209
Rare germline mutations in RAD51B and its closely related genes RAD51C and RAD51D
are associated with familial breast and ovarian cancers, whereas common variants within
the seventh and tenth intron of RAD51B are low risk factors for breast cancer.210
Furthermore, a recent study of chemoresistant ovarian cancers reported recurrent
chromosomal rearrangements that disrupted RAD51B.211 In addition, germline
translocations affecting the RAD51B locus predispose to familial thymomas.212 It  is  still
unclear whether RAD51B contributes to leiomyoma development only by providing
HMGAx with  an  effective  regulatory  element,  or  whether  loss  of RAD51B itself is also
selected for.
3.6.4.4 Chromosome 7q22 abnormalities
Approximately 7% of leiomyomas harbor deletions affecting the q-arm of chromosome 7.150
Deletions of 7q are also recurrent in lipomas, endometrial polyps, and some hematological
malignancies.150 The frequent involvement of 7q deletions in leiomyomas indicates the
presence of a tumor suppressor gene within this region. Defining the minimally deleted
region and finding a putative tumor suppressor gene has been challenging due to
inconsistent deletion maps and the gene-dense nature of the deleted regions.213-215 The key
pathogenic region has, however, been pinpointed to chromosome band 7q22.150 Indeed,
leiomyomas may occasionally harbor inversions or translocations affecting this specific
region.150 The foremost candidate is currently Cut like homeobox 1 (CUX1), but no second-
hit mutations have been found in the gene.216
Deletions  of  7q  may  co-exist  with HMGAx rearrangements, and are sometimes only
subclonally present,217 indicating that they are involved in tumor progression rather than
tumor initiation. Some studies have proposed that 7q deletions could have a negative effect
on tumor growth, since leiomyomas with 7q deletions in a mosaic state tend to be smaller
than those leiomyomas with a normal karyotype.217 In contrast to HMGA2 rearrangements,
7q deletions are highly unstable and frequently disappear in cell cultures, suggesting that 7q
deletions are not essential for the neoplastic transformation of leiomyomas.217 Although 7q
deletions are frequent in leiomyomas, all evidence points to a secondary or a passenger role
for these abnormalities.
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3.6.4.5 Chromosome 10q22 rearrangements and KAT6B
Approximately 2% of leiomyomas harbor rearrangements of chromosome 10q22,185 and
typically involve chromosome 17q21 as a translocation partner.218, 219 Positional cloning of
four leiomyomas harboring this specific translocation revealed recurrent breakpoints within
the third intron of lysine acetyltransferase 6B (KAT6B), located at 10q22.219 A recent study
reported a retroperitoneal leiomyoma to harbor this specific translocation as well.220 Using
RNA sequencing, they identified a fusion gene involving the first three exons of KAT6B and
the  last  five  exons  of KANSL1. KAT6B has also been reported to form fusion transcripts
with CREBBP (16p13) in acute myeloid leukemia,221 suggesting that KAT6B is the primary
driver gene rather than KANSL1.
KAT6B encodes for a histone acetyltransferase that is a component of the MOZ/MORF
protein complex, which play a role in epigenetic regulation.221 Of note, 10q22
rearrangements may also occur in leiomyosarcomas, and leiomyomas with 10q22
translocations tend to be histopathologically cellular,219, 222 suggesting that this genetic
defect may lead to higher malignant potential.
3.6.4.6 Rare chromosomal abnormalities and candidate genes
A variety of chromosomal abnormalities occurs at a much lower frequency in leiomyomas
(Table  6).  The  majority  of  these  tend  to  be  subclonal  changes  that  co-occur  with  the
previously discussed chromosomal abnormalities,150 suggesting that they are involved in
tumor progression rather than in tumor initiation. Although rare in conventional
leiomyomas, deletions of 1p, 22q, and 19q frequently co-occur with each other and are one
of the most common chromosomal abnormalities seen in benign metastasizing leiomyomas,
intravenous leiomyomatosis, and STUMPs.206, 223, 224 Moreover, cellular leiomyomas
frequently harbor 1p deletions, and these tumors appear to display gene expression patterns
similar to those seen in leiomyosarcomas.225
A small subset of leiomyomas display a balanced translocation involving chromosomes
1p36 and 2p24 as their only chromosomal abnormality,185 suggesting that this represents
another rare molecular pathway to leiomyoma formation. Positional cloning studies have
revealed that the breakpoints on chromosome 1p36 are located between adherens junctions
associated protein 1 (AJAP1) and nephrocystin 4 (NPHP4).226 Of note, one study reported
a retroperitoneal leiomyoma to harbor a balanced translocation that resulted in an in-frame
fusion gene involving EWSR1 (9q33) and PBX3 (22q12),227 suggesting that these genes may
also be involved in the development of uterine leiomyomas.
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3.7 Clonality
Clonality studies have revealed an identical pattern of X-chromosome inactivation among
several subclones of a leiomyoma,228-230 suggesting that each leiomyoma originates as a
monoclonal tumor. X-inactivation studies have also revealed a random pattern of X-
chromosome inactivation among multiple tumors from the same uterus, suggesting that each
leiomyoma arises independently.228-230 Furthermore, each tumor typically displays a unique
set of chromosomal abnormalities.150 Although most researchers agree that the majority of
leiomyomas arise as monoclonal tumors through discrete initiating triggers, a few studies
have encountered identical cytogenetic changes among multiple leiomyomas from the same
patient,231-234 indicating that some uterine lesions are clonally related. Furthermore,
pulmonary leiomyomas and concurrent uterine leiomyomas show an identical pattern of X-
chromosome inactivation,235 suggesting that benign metastasizing leiomyoma arises from
disseminated uterine lesions. Likewise, patients with disseminated peritoneal
leiomyomatosis tend to have multiple concurrent peritoneal nodules that display an identical
pattern of X-chromosome inactivation.236 One patient with intravenous leiomyomatosis
showed an identical pattern of X-chromosome inactivation among three retroperitoneal
leiomyomas and one intracaval leiomyoma.237 Surprisingly, patients with diffuse uterine
leiomyomatosis display a random pattern of X-chromosome inactivation among different
uterine sites,97 suggesting that this condition is caused by multiple independent lesions
fusing with each other and blending imperceptibly. Of note, criticism regarding the use of
X-inactivation assays for determining clonality has recently grown.238, 239
Leiomyomas are composed of several phenotypically dissimilar cell types, including
smooth muscle cells, vascular smooth muscle cells, and fibroblasts.240 Some  debate  still
exists as to whether leiomyomas arise from a mature smooth muscle cell (myocyte) or from
a myometrial stem cell. A growing body of evidence indicates that each leiomyoma
originates from a transformed somatic stem cell of the myometrium that differentiates into
all the various cell types of a mature leiomyoma.241 Indeed, recent studies show that
approximately 1% of the cells of a leiomyoma display stem cell-like properties, known as
the leiomyoma side population.241
3.8 Animal models
Animal models provide invaluable tools for investigating human genetic diseases.
Currently, no suitable animal model exists that closely replicates the molecular pathogenesis
of human uterine leiomyomas, but several animal models displaying leiomyoma-like lesions
have provided insight into the pathobiology and treatment of these tumors (Table 7).
The most widely investigated animal model is the Eker rat. These rats, first described by
Reidar Eker in 1954, spontaneously develop uterine leiomyomas and renal cell cancer at a
high frequency.242 Eker rats carry a heterozygous germline mutation in the tuberous
sclerosis 2 gene (Tsc2), resulting in the growth of both renal and uterine lesions.242 These
tumors display LOH at the Tsc2 locus, resulting in biallelic loss of the gene.242 In fact, the
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Eker rat was among the very first animal models that confirmed Knudson’s two-hit model
of tumorigenesis.243 These uterine tumors display increased expression of Hmga2,
suggesting that Tsc2 may regulate the activity of Hmga2.244 Germline mutations in the
human TSC2 leads to the tuberous sclerosis syndrome, characterized by a susceptibility to
a variety of neoplasms, including lymphangioleiomyomatosis and occasionally renal cell
cancer.245 These patients show no increased risk for uterine leiomyomas, however.
Several genetically engineered animal models develop leiomyoma-like lesions (Table 7).
Of note, although transgenic mice overexpressing HMGA2 do not develop leiomyomas,
these mice do develop other mesenchymal tumors that could be useful in studying the
mechanism of HMGA2 in uterine leiomyomas,194, 246 since the pathogenic mechanisms are
likely to overlap.
Leiomyomas have also been studied by means of xenotransplantation of human-derived
leiomyoma cells into severe combined immunodeficiency (SCID) mice (Table 7).
Moreover, xenotransplantation of human myometrial cells that have been transfected with
truncated forms of HMGA2 develop leiomyoma-like tissues similar to those of human
uterine leiomyomas.247
Spontaneous development of uterine leiomyomas is also common among several other
animal  species,  some  of  which  have  been  used  to  study  this  disease  (Table  7).  Female
German shepherd dogs with a germline loss-of-function mutation in the Birt-Hogg-Dubé
(Bhd) gene develop a variety of benign and malignant neoplasms, including uterine
leiomyomas and renal tumors.248 Germline mutations in the human homologue FLCN cause
the Birt-Hogg-Dubé syndrome, characterized by development of skin, lung, and kidney
tumors.249 These patients show no increased risk for uterine leiomyomas, however.
Approximately 8% of guinea pigs develop leiomyomas by the age of four,250 indicating that
these could serve as a feasible animal model of this disease.
Table 7. Overview of animal models in study of uterine leiomyomas
Animal model Method Requirements Reference
Rat (Eker) Selective breeding Germline Tsc2 mutation (242)
Mouse Genetic engineering Conditional knockout of Tsc2 (251)
Mouse Genetic engineering Conditional expression of human PRLHR (252)
Mouse Genetic engineering Conditional overexpression of β-catenin (253)
Mouse Genetic engineering Conditional expression of SV40 large T antigen (148)
Mouse Genetic engineering Conditional expression of PyLT antigen (149)
Mouse (SCID) Xenotransplantation Adenoviral transduction with COX2 & VEGFA (254)
Mouse (SCID) Xenotransplantation Estrogen supplementation (255)
Mouse (SCID) Xenotransplantation Ovariectomy, estrogen and progesterone supplementation, renal capsule (256)
Mouse (SCID) Xenotransplantation Estrogen and progesterone supplementation (257)
Mouse (SCID) Xenotransplantation Lentiviral transduction with SV40 T antigens, ovariectomy, hormonesupplementation, matrigel supplementation with EGF, bFGF, & insulin (258)
Mouse (SCID) Xenotransplantation Transfection of truncated HMGA2 in myometrial cells (247)
Rat (Wistar) Xenotransplantation Immunosuppressant drugs (mycophenolic acid), estrogen supplementation (259)
Mouse (CD-1) Drugs Prenatal exposure to diethylstilbestrol (142)
Guinea pig Spontaneous - (250)
German Shepherd Spontaneous Germline Bhd mutation (248)
Pot-bellied pig Spontaneous - (260)
Baltic gray seal Spontaneous - (261)
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3.9 Signaling pathways
Whereas genetic defects are likely to initiate leiomyoma formation, it is unclear how these
defects mediate neoplastic transformation. Our understanding of the molecular mechanisms
underlying leiomyoma development has been somewhat limited by the lack of suitable in
vitro cell cultures. Cultured leiomyoma cells tend to grow more poorly and senesce more
quickly than the normal myometrial cells do.262 Microarray studies have, however, provided
insights into the molecular signatures of leiomyomas, revealing hundreds of differentially
expressed genes between leiomyomas and normal myometrial tissue.203, 214, 263-268 Although
some of these genes are likely to act as effectors or promoters of leiomyoma growth, which
of these are critical for tumorigenesis remains unclear.
Although leiomyomas are clearly ovarian steroid-dependent tumors, the molecular
mechanisms by which these hormones promote leiomyoma growth remain undetermined.
Their mitogenic effects may be mediated through local production of growth factors,
cytokines, and chemokines.269 However, evidence for increased levels of estrogen or
progesterone receptors in leiomyomas are inconsistent,143 and genes related to estrogen or
progesterone signaling are not among the most significantly enriched genes in
leiomyomas.263 Furthermore, the presence or absence of steroid hormones does not seem to
alter significantly the global gene expression pattern of leiomyomas.203
Several growth factors and growth-factor receptors are differentially expressed in
leiomyomas.269 Growth factors generally act over short distances and typically promote
growth by binding to cell-surface receptors that activate signaling transduction cascades.
Growth factors shown to influence leiomyoma growth include insulin-like growth factor
(IGF), transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-
β), heparin binding epidermal growth factor (HB-EGF), acidic fibroblast growth factor
(aFGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and
vascular endothelial growth factor (VEGF).270 These appear to activate signaling pathways
such as PI3K/AKT/mTOR, EGFR/MAPK, or TGF-β/Smad.270
The PI3K/AKT/mTOR pathway is of particular interest, because a recent study showed that
the  inhibition  of  RE1  silencing  transcription  factor  (REST)  induces  upregulation  of
prolactin-releasing peptide receptor (PRLHR), leading to increased cell proliferation
through activation of this pathway.252 Using a transgenic mouse model, they demonstrated
that conditional overexpression of human PRLHR results  in  the  development  of  a  uterus
with phenotypic features similar to that of human leiomyomas, including myometrial
hyperplasia and excessive extracellular matrix deposition.252 A microarray  study  showed
that leiomyomas from humans and Eker rats share dysregulation of genes that are part of
the mTOR pathway.267 Furthermore, Tsc2 is a well-known negative regulator of the mTOR
pathway. Progestins (synthetic progesterones) promote leiomyoma cell survival through
activation of the AKT pathway,271 whereas inactivation of AKT (also known as Protein
kinase B) induces cellular senescence.272 Phosphatidylinositol-3 kinase (PI3K) and
mammalian target of rapamycin (mTOR) appear to be required for estradiol promotion of
G1 cell-cycle progression and leiomyoma cell proliferation.273
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The Wnt/β-catenin pathway is another pathway considered important in development of
leiomyomas. β-catenin is, under normal conditions, regulated by the tumor suppressor gene
APC and its loss results in stabilization of β-catenin, leading to nuclear localization of β-
catenin and activation of Wnt target genes.274 A mouse model that constitutively expresses
β-catenin in the uterine mesenchyme develops tumor nodules similar to those of human
uterine leiomyomas.253 These lesions show high levels of mTOR and its downstream target
phospho-S6-kinase.253 Conversely, selective removal of β-catenin from mesenchymal tissue
results in reduced uterine size and replacement of myometrial cells by adipocytes.275 A
recent study showed that cells surrounding the leiomyoma side population activate the
Wnt/β-catenin in a paracrine manner.276 Another recent study showed that inhibition of the
canonical Wnt pathway attenuates cell growth in primary leiomyoma cell cultures.277
Microarray studies have consistently shown that genes related to extracellular matrix are
predominantly differentially expressed in leiomyomas, suggesting their involvement in the
formation of a myofibroblast phenotype.266 Treatment  of  myometrial  cells  with  TGF-β
promotes the expression of genes encoding for extracellular matrix components, and
reduces the expression of genes that degrade extracellular matrix.278
Only a few studies have accounted for the genetic background of leiomyomas when
examining for differentially expressed genes and dysregulated pathways. Microarray studies
have revealed that genetic defects can have profound consequences on the global gene
expression profiles, since leiomyomas with FH, HMGA2, or 1p abnormalities show distinct
gene expression patterns.203, 264, 265 One study reported the SRF-FOS-JUNB pathway to be
downregulated in leiomyomas that are deficient for FH,279 whereas another study
highlighted a significant dysregulation of genes related to G1/S checkpoint regulation
among leiomyomas that harbored an HMGA2 translocation.203
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AIMS OF THE STUDY
1) To characterize the spectrum of somatic substitutions and microindels that drive uterine
leiomyoma development by exome sequencing
2) To characterize the spectrum of chromosomal abnormalities that drive uterine
leiomyoma development by whole-genome sequencing and SNP arrays
Discoveries from these studies clarified the subsequent aims:
3) To study the frequency and genomic architecture of clonally related leiomyomas by
genome-wide methods
4) To explore genome-wide transcriptional differences and similarities between
leiomyomas harboring distinct genetic drivers
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MATERIALS AND METHODS
1. Study material and ethical issues (I-IV)
The study material consisted of fresh-frozen uterine leiomyoma and corresponding
myometrial specimens from five separate collections and from two HLRCC patients (Table
8). All tissue specimens were collected during hysterectomies in Finland between 2001 and
2015. One of the collections (Series M) consisted of tissue specimens from anonymous
patients with the approval of the director of the health care unit. The other specimens were
obtained from patients who signed an informed consent upon entering the study. One of
these (Series My5000) consisted of a prospective set of leiomyomas that was carefully
collected in order to include all leiomyomas at least five mm in diameter. We performed a
thorough investigation on these patients’ medical records as well.
The  Ministry  of  Social  affairs  and  Health  in  Finland,  and  the  Ethics  Committee  for
gynecology and obstetrics, pediatrics and psychiatry of the Hospital Distinct of Helsinki and
Uusimaa, Finland approved all of the studies.
Table 8. Overview of sample series utilized in the studies
Series ID Leiomyomas Patients Hospital Time frame Informed consent
M 211 74 Helsinki University Central Hospital 2001-2002 No
B7 (HLRCC) 6 1 Helsinki University Central Hospital 2002 Yes
My 160 64 Helsinki University Central Hospital 2003-2008 Yes
N7 (HRLCC) 6 1 Turku University Hospital 2007 Yes
My1000 55 12 Helsinki University Central Hospital 2012 Yes
My5000 125 18 Helsinki University Central Hospital 2013 Yes
My6000 544 184 Helsinki University Central Hospital 2013-2015 Yes
2. Histopathological evaluation (I-IV)
Sections of fresh-frozen leiomyoma tissues were stained with hematoxylin and eosin
according to standard procedures. A pathologist evaluated the tumor slides for number of
mitotic figures per 10 high-power fields, degree of cellularity and nuclear atypia, and
presence of tumor cell necrosis. As expected, all tumors showed a very high tumor
percentage (>90%).
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3. DNA, RNA, and cDNA preparation (I-IV)
DNA  was  extracted  with  the  FastDNA  Kit  (MP  Biomedicals).  RNA  was  extracted  with
TRIzol Reagent (Invitrogen) or Tri Reagent RT (Molecular Research Center), and purified
by  the  RNeasy  MinElute  clean  up  kit  (Qiagen).  The  concentration  and  the  purity  of  the
extracted RNA were measured by the Agilent 2100 Bioanalyzer (Agilent). Extracted RNA
was converted to cDNA according to standard procedures.
4. Genome-wide methods (I-IV)
Several high-throughput methods were utilized to study leiomyomas on a genome-wide
scale (Table 9). The corresponding myometrium samples were included in all experiments.
Table 9. Overview of the number of tumors and the type of genome-wide tools used in each study
Whole-exome
sequencing
Whole-genome
sequencing
Expression
microarray SNP array RNA sequencing
Study Tumors Patients Tumors Patients Tumors Patients Tumors Patients Tumors Patients
I 18 17 - - 10 10 - - - -
II - - 38 30 38 30 - - - -
III - - 5 2 4 1 69 11 - -
VI - - 63 45 94 60 50 36 2 2
4.1 Whole-exome sequencing (I)
Genomic DNA libraries were prepared using NEBNext DNA Sample Prep Reagent Set 1
Kit (New England Biolabs). Whole-exome capture was carried out using Agilent SureSelect
Human All Exon Kit (Agilent). The libraries were paired-end sequenced using the Genome
Analyzer II (Illumina) at the Institute of Molecular Medicine Finland (FIMM). The length
of the reads was 80 to 82 nucleotides. The exome capture kit targeted approximately 38
megabase pairs (Mbps) of coding DNA.
Sequencing-read quality control was assessed using FastQC.280 One of the tumor samples
was re-sequenced due to its poor quality. Preprocessing and data analysis was carried out
using the NextGENe v2.1 software (Softgenetics). The adapter sequences were trimmed
with an in-house-developed script, and the sequencing reads were aligned against the hg19
reference genome. All tumor calls were filtered against the respective myometrium samples,
against an in-house control set of 156 exomes sequenced with the same platform, and against
polymorphisms reported in The Single Nucleotide Polymorphism database (dbSNP) build
132 and Ensembl release 59. The following criteria served to call a somatic mutation: a
coverage of at least 4, an allelic fraction of at least 0.2, and a NextGENe mutation score of
at least 6. We excluded silent mutations, but included mutations located at a maximum of
three base pairs upstream or downstream of exon boundaries.
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4.2. Whole-genome sequencing (II-IV)
Paired-end whole-genome sequencing was performed with either Complete Genomics (CG)
or Illumina massively parallel sequencing technology. One tumor-normal pair (MY64 m1)
was sequenced with both platforms. Genomic DNA libraries were prepared and sequenced
according to their respective sequencing service protocols. The Illumina samples had a
median sequencing coverage of at least 30, and consisted of reads that were 100 bps in
length. The CG samples had a sequencing coverage of at least 40.
4.2.1 Detection of somatic substitutions and microindels (II-IV)
No data pre-processing was necessary with the CG samples, since their service provided us
with substitution and microindel calls. Illumina-aligned (ELAND) samples were realigned
with  GATK  IndelRealigner,  duplicate  reads  were  filtered  out  with  Picard  Tools,  and
substitutions and microindels were detected with VarScan 2.281 Variations detected in the
tumors were filtered against the corresponding myometrium samples, against 93 Finnish
individuals from the 1000 Genomes Project (phase 1 release v2), against 157 in-house
exome or whole-genome controls, and against polymorphism reported in the dbSNP Build
132. The following criteria served to call a somatic mutation: a coverage of at least 6, and
an allelic fraction of at least 0.2. The minimum quality score (phred) was 29 for Illumina
and 94 for CG samples. Somatic mutations located within protein-coding genes were
annotated with Ensembl version 69.
Some modifications were made to the whole-genome-sequencing pipeline in Studies III and
IV. All Illumina whole-genome sequencing samples (including all of the Illumina samples
from Study II) were aligned against the 1000 Genomes phase 2 human reference sequence
assembly hs37d5 using BWA (v0.6.2) with parameters -n 0.06 (maximum edit distance) and
-q 5 (read trimming).282 Microindels were detected by GATK SomaticIndelDetector with
default parameters. Substitutions were called by MuTect 1.1.4 with default parameters.283
Variations detected in the tumors were filtered against germline variants present in a whole-
genome sequencing dataset of 139 Finnish controls. The following criteria served to call a
somatic mutation: a coverage of at least 4, and a quality score of at least 20. Somatic
mutations located within protein-coding genes were annotated with Ensembl version 71.
In Study III, four clonally related leiomyomas were processed further in order to gain more
informative data regarding any genetic similarities or differences between the four related
tumors. Here we also considered somatic substitutions located in non-coding regions, and
therefore maximized specificity by exploring only those regions of high mappability (1000
Genomes Phase 1 Strict Accessibility Mask). We randomly selected 10 myometrium whole-
genomes as additional controls; a somatic call was filtered out if any of these controls
contained a single read harboring exactly the same substitution. We also explored whether
any of the remaining mutations were present in any of the other tumors but not called by
MuTect.
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4.2.2 Detection of somatic copy-number alterations (II-IV)
Raw copy-number ratios were generated from Illumina tumor-normal pairs with VarScan
2,281 and segmented by DNAcopy with a minimum of 5 markers (min.width=5).284 For each
sample, the segments were subtracted against the average of all their segments. Segments
(including CG-provided segments) less than 0.3 were defined as a double deletion, 0.3 to
0.8 as a deletion, 1.2 to 1.7 as a duplication, and greater than 1.7 as a triplication. Segments
at a maximum of 2 kbps apart were merged, segments located within chromosomal gaps
(UCSC Gap track table) were excluded, and segments less than 100 kbps were filtered out.
Study IV included some modifications: raw copy-number ratios were generated, log2
transformed, corrected for GC-waves, smoothed, and segmented with Partek Genomic
Suite™ v. 6.5 (Partek Incorporated). Segments were called with the following parameters:
a minimum of 500 markers, a signal-to-noise of 0.5, and a segmentation p-value of 0.0001.
Segments with a log2-ratio less than –0.2 were assessed as deletions and greater than 0.2 as
amplifications. Segments located within noisy regions (such as telomeres) were assessed as
technical artifacts and manually filtered out.
4.2.3 Detection of chromosomal rearrangements (II-IV)
Chromosomal rearrangements were detected from Illumina-aligned data with BreakDancer
1.2.285 Tumor samples were run with the following parameters: a mapping quality of at least
65, and at least 4 supporting read pairs. Myometrium samples were run with the following
parameters: a mapping quality of at least 1, at least 1 supporting read pair, and an output
score of at least 1. All tumor calls (including the CG-provided rearrangements) were filtered
against the myometrium calls; a tumor call was filtered out if both of its breakpoints were
present in any of the myometrium samples within 1000 bp window. Calls reported as
deletions or amplifications were similarity filtered against the Database of Genomic
Variants.286 Tumor calls were also filtered out if any one of the two breakpoints were located
within a segmental duplication287 or a region of exceptionally high sequencing depth288.
Tumor calls were manually inspected with the Integrative Genomics Viewer, and filtered
out if it resided within a repetitive or poorly aligned region, or if a similar rearrangement
were observable in the paired myometrium sample but not called by BreakDancer.
4.2.3.1 Detection of interconnected chromosomal rearrangements
In order to detect interconnected rearrangements likely to have occurred simultaneously, we
designed a novel computational algorithm that considered the proximity and orientation of
rearrangement calls. An event graph – consisting of nodes and edges – was constructed for
each sample. Each double-strand break creates two nodes, representing the left (head) and
the right (tail) end of a double-strand break. If the two nodes are at most 1000 bps apart, and
if one of the nodes is in the head orientation, whereas the other is in the tail orientation then
the two nodes are connected by an edge. If a deletion is present between two nodes, then
the distance between the nodes is shortened by the length of the deletion.
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The next step was to identify components representing complex chromosomal
rearrangements. Components corresponds to the total amount of nodes that are linked to
each other by edges. Components that comprised four or more nodules were statistically
assessed with a permutation test. Components representing a balanced translocation were
manually excluded. The test statistic was the total number of breakpoint ends involved in
each component. The breakpoint data were permuted by randomly repositioning each
breakpoint end within the original chromosome. After 100,000 permutations, an empirical
p-value was computed as p = x/n,  where x is  the number of cases,  n is  the number of all
cases, and the random test statistic is higher than the observed value.
4.3. Gene expression microarrays (I-IV)
The gene expression samples in Study I were analyzed using Affymetrix GeneChip Human
Genome U133 Plus 2.0 arrays (Affymetrix), whereas the samples in Studies II and IV were
analyzed using Affymetrix GeneChip Human Exon 1.0 ST (Affymetrix). Hybridization and
quality control were performed at the Biomedicum Functional Genomics Unit (FuGU)
according to the instructions provided by Affymetrix.
All of the gene expression data analyses were performed with Partek Genomic Suite™ v.
6.5. In Study I, the gene expression data were normalized by the GC-RMA method (Gene
Chips Robust Multichip Analysis), and the probes were mapped using Brainarray Custom
CDF files (HGU133Plus2_Hs_ENSG,v.14.1.0). Unsupervised hierarchical clustering
analysis (Euclidian distance, average linkage) used the 10% most variable genes, defined
by the coefficient of variation. Differential expression analysis was carried out by a paired
t-test. False discovery rate control (FDR, Benjamini and Hochberg method) served to
correct for multiple testing.289 Genes with an FDR (q-value) less than 0.05 and a fold change
(FC) of 1.5 were considered significant. Pathway enrichment analysis was carried out with
Webgestalt  using  the  Kyoto  encyclopedia  of  genes  and  genomes  (KEGG)  pathways.290
Pathways with a q-value less than 0.05 were considered significant.
In Studies II to IV, the gene expression data were quantile-normalized by the RMA method
(Robust Multichip Average), and adjusted for probe sequence and for GC-content using
Partek. Probes were mapped with Brainarray Custom CDF files (HuEx10stv2_Hs_ENSG,
Version 16). Technical replicates were averaged, and Partek’s Batch effect removal
algorithm removed technical noise originating from the five different batches. Unsupervised
hierarchical clustering analysis (Cosine correlation) used the 1% most variable genes (n =
372), defined by the coefficient of variation.
A paired t-test served to identify genes differentially expressed in all leiomyomas as
compared to the corresponding myometrium samples. A one-way analysis of variance
(ANOVA) test identified genes differentially expressed between leiomyomas of different
genetic subtypes and the myometrium samples. Multiple test correction was carried out with
FDR.  Genes  with  a q-value  less  than  0.05  and  a  FC  of  2  were  considered  significant.
Pathway enrichment analysis was carried out using QIAGEN’S Ingenuity Pathway Analysis
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software. To identify the most uniquely expressed genes for four different leiomyoma
subtypes, a two-way ANOVA test (factors: individual and mutation status) was constructed
that compared each subtype against the rest of the leiomyoma and myometrium samples.
These genes have a subtype-specific expression level that differs from levels in both the
other leiomyoma and myometrium samples. Exon-level analysis of gene expression data
were performed with default parameters using Affymetrix-provided annotations (v35,
GRCh37/hg19). To identify genes most significantly downregulated by chromosome 7q22,
22q, and 1p deletions, three separate two-way ANOVA tests compared leiomyomas
harboring the abnormality in question against those myometrium and leiomyoma samples
that lacked the abnormality.
4.4 SNP arrays (III-IV)
All samples were analyzed using Illumina HumanOmni2.5-8 BeadChips (Illumina) arrays.
Sample preparation, hybridization, and quality control were performed at the Estonian
Genome Center, University of Tartu or at Illumina.
The SNP arrays were pre-processed with Genome Studio, and the data analysis performed
with  Partek  Genomic  Suite™  v.  6.5.  Raw  copy-number  ratios  were  constructed,  log2
transformed, and corrected for GC waves. Partek’s segmentation algorithm was performed
by two different sets of parameters. In the first set, we used stricter parameters: a minimum
of 50 markers, a signal-to-noise of 0.5, and a segmentation p-value of 0.0001. Segments
with a log2-ratio less than –0.2 were defined as deletions and greater than 0.2 as
amplifications. The second set was utilized to detect large subclonal SCNAs. Here we used
the  following  parameters:  a  minimum  of  1000  markers,  a  signal-to-noise  of  0.2,  and  a
segmentation p-value of 0.0001. Additional segments (not detectable with the first set of
parameters) with a log2-ratio less than –0.05 were defined as subclonal deletions and greater
than 0.05 as subclonal amplifications. Regions of CN-LOH were detected from genotype
calls using Partek’s LOH algorithm with parameters: max probability of 0.99, genomic
decay of 0, and genotype error of 0.001. A segment was defined as a CN-LOH event if LOH
was detectable but no change in copy-number. All regions of SCNAs and CN-LOH were
visually inspected (by log2-ratio and b-allele frequency plots), and segments assessed as
technical artifact were manually filtered out. Only regions larger than 20 kbps were reported,
and regions less than 200 kbp apart were merged.
4.5 RNA sequencing (IV)
RNA sequencing libraries were prepared from rRNA-depleted (RiboMinus Transcriptome
Isolation Kit, Life Technologies) samples with Illumina TruSeq RNA Sample Preparation
kit A (Illumina) according to the manufacturer’s instructions. Quality control was performed
with FastQC v0.10,280 and the data were aligned against the human reference genome hg19
by TopHat v1.4.1.291
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5. Sanger sequencing validation (I-IV)
Sanger sequencing served to validate genes recurrently affected by somatic substitutions or
microindels that were detectable by exome or whole-genome sequencing. To confirm that
the detected mutations were somatic, we performed Sanger sequencing with the
corresponding myometrial tissues as well. Chromosomal rearrangements of interest with
low-confidence calls were also subject to Sanger sequencing validation. Oligonucleotide
primers were designed with Primer3 using hg19 as the reference genome.292
DNA fragments were amplified with the AmpliTaq Gold DNA Polymerase (Applied
Biosystems)  and  purified  with  the  ExoSAP-IT PCR Purification  Kit  (USB Corporation).
The sequencing was performed with the BigDye Terminator v.3.1 Kit (Applied Biosystems)
on an ABI3730 Automatic DNA Sequencer (Applied Biosystems) at FIMM, or an ABI3100
Capillary Sequence Analyzer (Applied Biosystems) at the Sequencing Core Facility at the
Haartman Institute. DNA sequences were analyzed with the Mutation Surveyor
(Softgenetics). Sequencing graphs were also manually inspected for any mutations not
automatically detected by the software.
6. In silico prediction tools (I)
Alternative Splice Site Predictor (ASSP)293 and NetGene2294 served in predicting whether
intronic mutations affected splicing. Multiple sequence alignment analysis was performed
with Muscle295 for the following species: human (Q93074), mouse (A2AGH6), zebrafish
(Q2QCI8), fruit fly (Q9VW47) and baker’s yeast (P25648). Intronic sequence alignment
was performed with Multiz,296 and secondary structure prediction was performed with
PSIpred.297
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RESULTS
1. Exome sequencing reveals high frequency of MED12
mutations (I)
To characterize the spectrum of somatic substitutions and microindels that underlie
leiomyoma etiology, we exome sequenced 18 uterine leiomyomas and corresponding
myometrial  tissues  from  17  Finnish  patients.  This  revealed  ten  leiomyomas  harboring  a
mutation within exon 2 of mediator complex subunit 12 (MED12). MED12 was the only
recurrently mutated gene, and all of the mutations were verified with Sanger sequencing.
Sanger sequencing of 207 additional leiomyomas revealed MED12 exon 2 mutations in 159
out of 225 (70.7%) leiomyomas from 80 patients (Figure 5). The majority of mutations were
missense, and 110 of them affected codon 44 – leading to all six possible amino acid changes
– followed by 11 affecting codon 36, and 3 affecting codon 43. Ten leiomyomas harbored
an intronic T to A mutation located eight base pairs (bps) upstream of exon 2. This change
was predicted to create a premature splice acceptor site. cDNA sequencing confirmed that
this mutation resulted in a transcript that included the last six bases of intron 1. Several
microindels – ranging from 3 to 43 bps – were detected in 25 leiomyomas, all of which were
predicted to result in an in-frame transcript. In silico prediction tools revealed these
mutations to affect an evolutionarily conserved region of the gene.
To examine whether other parts of MED12 were mutated as well, we sequenced all 45 exons
in 10 leiomyomas harboring an exon 2 MED12 mutation, and in 20 leiomyomas lacking a
MED12 mutation, revealing no additional mutations. Since MED12 is located on the X
chromosome, one of the two alleles is epigenetically silenced. cDNA sequencing of 16
leiomyomas  with  a MED12 mutation revealed that the mutant allele was predominantly
expressed in all cases. We also examined whether these mutations correlate with clinical
features, revealing an inverse association between MED12 mutations and tumor size (two-
sided Wilcoxon rank sum test, p = 0.015).
Figure 5. The spectrum of MED12 mutations among 225 uterine leiomyomas.
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2. Clonally related leiomyomas are relatively common (II-III)
In Study II, we explored the genomic landscape of 38 uterine leiomyomas from 30 patients
by whole-genome sequencing. This sample set was selected to include 16 leiomyomas with
a MED12 mutation,  4  with  biallelic  loss  of FH, and 18 that lacked both of these driver
defects. Four of the patients had two or more leiomyomas that were whole-genome
sequenced.
An unexpected finding was that two tumor pairs from two patients (MY18 & M44)
displayed several identical chromosomal abnormalities. Based on the number of discordant
read-pairs of chromosomal rearrangements, and the average log2-ratio of deletions, we
inferred that some chromosomal abnormalities were clonally present in MY18 m3 and M44
m2, whereas the same abnormalities were only subclonally present in MY18 m2 and M44
m1. None of the abnormalities detected in MY18 m2 and MY18 m3 were present in the
third tumor (MY18 m1) from the same patient. Among the 30 patients included in the study,
four (MY18, M29, M38, & M68) had additional tumors displaying either the same or no
MED12 mutation with respect to any of the other tumors that were whole-genome
sequenced from the same patient. These tumors were analyzed further using Sanger
sequencing for point mutations found in the whole genomes. This revealed three additional
tumors (MY18 m4, MY18 m5, & MY18 m6) to be clonally related to MY18 m2 and MY18
m3, and one tumor (M38 m1) to be clonally related to M38 m5. We found altogether nine
clonally related leiomyomas, each of which lacked any mutations in MED12 or FH.
Using  SNP  arrays  and MED12 Sanger sequencing in Study III, we investigated the
frequency of clonally related leiomyomas in a prospective set of 103 leiomyomas collected
from 14 consecutive patients who underwent hysterectomy due to symptomatic lesions. One
of these patients (MY5006) was diagnosed as an HLRCC patient, since she harbored a
germline mutation in FH (c.583A>C, p.M195V). Leiomyomas with a different MED12
mutation were assumed to be independent, and only tumors with an identical MED12
mutation status were analyzed further with SNP arrays. A total of 69 tumors from 11 patients
were examined for shared and unique SCNAs and CN-LOH. We detected four of these
patients as having clonally related leiomyomas, including the HLRCC patient.
In 103 leiomyomas from 14 patients, we detected 13 (13%) clonally related leiomyomas in
4 (29%) patients. Each clonally related leiomyoma lacked a MED12 mutation (Fisher’s
exact test, p = 0.006). Out of the 42 leiomyomas with a MED12 mutation, only 19 displayed
SCNAs, none of which was identical between tumors from the same patient. Since the
remaining 23 tumors harbored no detectable SCNAs, these tumors could not be investigated
for a clonal relationship. A careful review of all the patients’ medical records revealed prior
myomectomy in two of the four patients (MY5005 & MY5006) with clonally related
tumors.  In  contrast,  prior  myomectomy  was  confirmed  in  only  one  of  the  ten  patient
(MY5013) that lacked clonally related leiomyomas. None of the clonally related
leiomyomas displayed unusual histopathology.
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2.1 Intratumor genetic heterogeneity and DEPDC5 mutations (III)
To gain insight into the genomic architecture of clonally related leiomyomas, we performed
whole-genome sequencing with four such lesions (MY21 m1-m4) from one patient. All four
tumors  were  confirmed  as  clonally  related,  since  they  harbored  identical  chromosomal
abnormalities on chromosomes 3, 12, 14, and 22. Furthermore, all four tumors shared 295
identical somatic substitutions. We interpreted tumor m4 to be the primary tumor consisting
of several genetically distinct subpopulations (Figure 6). Using SNP array data, we were
also able to infer intratumor genetic heterogeneity in two other sets of clonally related
leiomyomas from two other patients (MY5014 & MY5006). See Figure 11B-C for the
interpretation of the tumors from patient MY5006.
We unexpectedly detected a different truncating DEP domain containing 5 (DEPDC5)
mutation  in  each  of  the  four  clonally  related  leiomyomas.  Furthermore,  all  four  tumors
displayed an identical deletion on chromosome 22, resulting in a biallelic loss of DEPDC5.
We found no other gene to be recurrently mutated among these four tumors. All four tumors
displayed, however, an identical translocation between HMGA2 and RAD51B, resulting in
HMGA2 overexpression. We searched for DEPDC5 mutations in an in-house whole-
genome sequencing dataset of 65 leiomyomas, revealing one additional leiomyoma (M26
m1) to harbor a truncating DEPDC5 mutation. This sample also displayed a deletion of the
whole chromosome 22, and an HMGA2-RAD51B translocation. All five DEPDC5
mutations were validated with Sanger sequencing (Figure 10).
Figure 6. Genomic architecture of four clonally related leiomyomas from patient MY21. A) Two
sets of substitutions (Set 1 & Set 2) were present only in two out of the four clonally related tumors from
patient MY21. Set 1 (n = 75) was present in m3 and m4, whereas Set 2 (n = 20) was present in m1 and
m4. Since both of these sets were present in tumor m4 and at a much lower average allelic fraction, we
interpreted this lesion to consist of several genetically distinct subpopulations. B) A likely explanation
for this pattern is that tumors m3 and m1 (and probably m2) arose from a different subpopulation that
originated from tumor m4. Additionally, each tumor gradually acquired a unique set of mutations,
including a separate inactivating mutation in DEPDC5.
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3. Whole-genome sequencing reveals complex chromosomal
rearrangements (II)
Whole-genome sequencing of 38 uterine leiomyomas revealed a subset of leiomyomas as
displaying highly complex chromosomal rearrangements (CCRs) resembling
chromothripsis. Compatible with chromothripsis, these rearrangements were locally
clustered, involved one to four chromosomes, and displayed alternating copy-number states
between breakpoints (Figure 7A). A CCR was defined as a series of rearrangements
interconnected by a minimum of three double-strand breaks involving six DNA ends. Using
an in-house-developed computational algorithm to identify such cases among the 38
leiomyomas,  we  identified  17  as  harboring  one  or  more  CCRs.  CCRs were  significantly
more common among leiomyomas that lacked mutations in MED12 or FH mutations (two-
tailed Fisher’s exact test, p <0.001). Indeed, none of the four FH-deficient leiomyomas, and
only three of the 16 leiomyomas with a MED12 mutation displayed a CCR.
Interestingly, we detected a few leiomyomas as harboring multiple separate CCRs. For
example, we detected two spatially separate CCRs in two clonally related tumors (MY18
m2 & MY18 m3): one involving chromosomes 1, 2 and 20, the other involving
chromosomes 12 and 14. Although a third CCR – involving chromosome 5 – was also
detected in both tumors, this CCR was only subclonally present in MY18 m2, suggesting
that it occurred as a temporally separate event. Another sample (MY23 m4) displayed two
separate  CCRs,  one  of  which  involved  chromosome  2  and  one  copy  of  chromosome  7,
whereas the other involved chromosome 5 and the other copy of chromosome 7.
Furthermore, some CCRs resulted in driver changes with a selective value, such as
rearrangements between HMGA2 and RAD51B (Figure 7B).  Of note,  most CCRs did not
exhibit the high number of breakpoints typical for chromothripsis in the context of cancer.
Indeed, an arbitrary threshold of at least 20 intrachromosomal breakpoints has often defined
chromothripsis. Therefore, only five (MY10 m3, MY23 m4, MY46 m1, MY47 m1, &
MY64 m1) of the 17 leiomyomas with a CCR reflected typical examples of chromothripsis.
Sanger sequencing validation was performed with all of the rearrangements detected in three
selected leiomyomas (MY47 m1, MY64 m1, & MY18 m3), each of which harbored a high
number of breakpoints and one or more CCRs.
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Figure 7. Complex chromosomal rearrangements (CCRs) resembling chromothripsis in a subset
of leiomyomas. A) Chromothripsis is a phenomenon in which one or a few chromosomes are locally
shattered and randomly reassembled in a single event. This process often leads to highly complex
chromosomes and loss of DNA fragments. B) The circos plot above illustrates chromosomal
rearrangements (lines) and deleted regions (blue rectangles) detected in a leiomyoma (MY64 m1). A
chromothripsis event in this leiomyoma involved chromosomes 6, 8, 12, and 14. This event generated a
driver rearrangement involving HMGA2 and RAD51B. B is from The New England Journal of Medicine,
369, Mehine et al., Characterization of uterine leiomyomas by whole-genome sequencing (2013),
reprinted with the permission of Massachusetts Medical Society.
4. Chromosomal abnormalities create driver changes (II-IV)
As expected based on our exome-sequencing study, we identified no other genes besides
MED12 and FH to be recurrently mutated on nucleotide-level among the 38 leiomyomas
whole-genome sequenced in Study II. We therefore searched for chromosomal
rearrangements that could act as driver changes. In line with cytogenetic studies, the
HMGA2 locus  was  the  region  most  commonly  rearranged  (n  =  9).  All  of  these
rearrangements resulted in overexpression of HMGA2, confirming HMGA2 as the target
gene. The RAD51B locus was the second most rearranged region (n = 8), owing to the fact
that the majority of HMGA2 rearrangements involved this locus as a translocation partner.
Using deletion and breakpoint mapping of the RAD51B locus, we concluded that a putative
enhancer for HMGA2 must be located within chr14:68,217,257–68,760,115. Only two
samples (MY30 m1 & M38 m5) displayed an HMGA2 rearrangement that targeted another
region, both of which showed the weakest upregulation of HMGA2. One of these (MY30
m1) displayed additional breakpoints within the 3’UTR of HMGA2, providing an alternative
mechanism for HMGA2 overexpression. We identified one leiomyoma (M17 m1) as
harboring a deletion of the whole chromosome 14 and a localized deletion within RAD51B,
resulting in biallelic loss of RAD51B. This sample lacked the involvement of HMGA2.
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A chromosomal region containing collagen type IV alpha 5 chain (COL4A5) and collagen
type IV alpha 6 chain (COL4A6) was the third most commonly rearranged region. Three
samples displayed a characteristic chromosomal deletion – previously reported in
esophageal  leiomyomas  –  that  resulted  in  removal  of  the  5’  ends  of  both COL4A5 and
COL4A6, which are located head-to-head on opposite strands (Figure 8). We found MED12,
FH, HMGA2, and COL4A5-COL4A6 abnormalities to be mutually exclusive, suggesting
that these represent different molecular subtypes of leiomyomas. Leiomyomas lacking all
of these four abnormalities are henceforth termed quadruple-negative leiomyomas.
Since none of the other recurrent rearrangements resulted in any noticeable driver changes,
we explored for non-recurrent rearrangements around known driver genes. We identified
and validated one quadruple-negative leiomyoma (MY22 m1) to harbor a rearrangement
between HMGA1 and cardiac mesoderm enhancer-associated non-coding RNA (CARMN,
previously known as MIR143HG), resulting in overexpression of HMGA1. In one sample
(MY47 m1), we detected and validated a rearrangement located upstream of cyclin D1
(CCND1), resulting in the highest expression of this gene among all 38 leiomyomas
analyzed. In another sample (MY10 m3), we detected and validated a rearrangement that
simultaneously disrupted one copy of the tumor suppressor genes TP53 and NF1.
In addition to the whole-genome sequencing datasets included in Studies II and III, Study
IV involved 51 additional leiomyomas analyzed by whole-genome sequencing or SNP
arrays or both. A subset of these samples were selected for the study since they were known
(based on previous work) to lack a MED12 mutation, to display biallelic loss of FH, or to
harbor LOH at chromosome 22q. All of these samples were screened for rearrangements
and deletions located within or close to HMGA2, HMGA1, or COL4A5-COL4A6.
We detected 18 of these to harbor an HMGA2 rearrangement or HMGA2 overexpression, or
both, one of which (MY51 m3) harbored breakpoints within the 3’UTR of HMGA2 and
lacked the involvement of RAD51B. Two samples (M26 m1 & M31 m1) harbored an
HMGA2 rearrangement in which the breakpoints were located downstream of RAD51B.
Using SNP arrays, we identified one quadruple-negative leiomyoma (MY6010 m3) and one
leiomyoma of the MED12 subtype (MY5008 m3) as harboring a deletion located upstream
of HMGA1. We also detected one additional leiomyoma (M21 m1) as harboring a simple
COL4A5-COL4A6 deletion (Figure 8). Of note, one leiomyoma (M30 m1) of the HMGA2
subtype exhibited a rearrangement within the COL4A5 locus  that  did  not  result  in  the
characteristic COL4A5-COL4A6 deletion.
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Figure 8. COL4A5-COL4A6 abnormalities in two leiomyomas. A) We detected one leiomyoma (M21
m1) to harbor a simple deletion that resulted in the removal of the 5’ends of both COL4A5 and COL4A6,
located head-to-head on chromosome Xq22.3. B)  Another  sample  (MY23  m4)  displayed  a  similar
abnormality that was generated by a chromothripsis-like event. Dashed lines represent rearrangements
detected by whole-genome sequencing.
In addition to these recurrent abnormalities, we detected one leiomyoma (MY16 m1) of the
MED12 subtype to harbor a sole balanced translocation, t(6, 8)(q13;q12). The breakpoints
were located ∼2.3 kbp downstream of PLAG1 zinc finger (PLAG1) and ∼21.9 kbp
downstream of collagen type XII alpha 1 chain (COL12A1). Furthermore, two quadruple-
negative leiomyomas (M51 m1 & MY5007 m2) harbored a large-scale amplification
spanning PLAG1. We also identified one quadruple-negative leiomyoma (M18 m1) as
harboring a rearrangement with breakpoints in intron 1 of insulin like growth factor binding
protein 5 (IGFBP5)  and  intron  10  of platelet derived growth factor receptor beta
(PDGFRB). cDNA sequencing confirmed that this rearrangement resulted in an in-frame
fusion joining exon 1 of IGFBP5 to exon 11 PDGFRB.
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4.1 Commonly deleted regions on chromosomes 7, 22 and 1 (II-IV)
In  Studies  II  to  IV,  we  explored  commonly  deleted  regions  on  chromosome  7q.  SCNA
analysis revealed 14 leiomyomas harboring a deletion that spanned 7q22 (Figure 9A). We
identified CUX1 as the most commonly affected gene within this region. Sanger sequencing
validation revealed one sample (MY23 m4) to harbor two separate rearrangements, each
disrupting one copy of CUX1. We detected and validated another sample (M32 m8) to
harbor a subclonal translocation between chromosomes 7 and 22, one that disrupted CUX1.
Another leiomyoma (MY1 m1) displayed a 7q deletion and a second-hit 5 bps deletion in
zinc finger HIT-type containing 1 (ZNHIT1; Figure 9B). Two samples displayed targeted
chromosomal rearrangements affecting cullin 1 (CUL1) and enhancer of zeste 2 polycomb
repressive complex 2 subunit (EZH2), resulting in significant downregulation of CUL1 (FC
= –1.7). Deletions of 7q were the SCNA most commonly detected in Study III, and these
were present only in leiomyomas that harbored a MED12 mutation (Fisher’s exact test, p =
0.006). Four of these deletions were barely detectable (–0.2> log2-ratio >–0.1), suggesting
that they are secondary events relative to MED12 mutations. CUX1 was  located  in  the
minimally deleted region, and at the breakpoint end of one of the deletions (MY5013 m5).
Figure 9. Chromosomal abnormalities and nucleotide-level mutations detected on chromosome 7q.
A) We identified chr7:104,849,448–111,900,000 (green segment) as the minimally deleted region on 7q
and chr7:101,732,303–102,100,000 (red) as another commonly deleted region. Two samples (MY23 m4
& M32 m8) displayed rearrangements within this region, both of which had rearrangements that
disrupted CUX1, making it the gene most commonly affected on 7q. Furthermore, one of these (MY23
m4) displayed two separate rearrangements, each disrupting one copy of CUX1. Two samples (M17 m1
& MY64 m1) displayed targeted rearrangements disrupting CUL1 and EZH2, located on 7q32. One
sample  (MY1  m1)  harbored  a  7q  deletion  and  a  five  bp  deletion  in ZNHIT (c.156_160delCAAGA),
resulting in biallelic loss of the gene. B) Since the five bp deletion appeared to be subclonal, we examined
whether it was present in other parts of the tumor as well. We performed Sanger sequencing with nine
different parts of the tumor, marked A-I. Parts H and I are on opposite sides of the tumor, and J represents
the corresponding myometrium sample. The sequencing chromatograms show two distinct sequences in
all nine parts, with variable ratios for the wild-type and mutant sequence. The start of the mutant sequence
(lacking the reference nucleotides CAAGA) is marked with an arrow in each chromatogram.
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In  Study  IV,  we  also  searched  for  commonly  deleted  regions  of  recurrent  22q  and  1p
deletions. We detected 20 leiomyomas harboring a 22q deletion and one leiomyoma (MY23
m4) harboring chromosomal rearrangements within the most commonly deleted region
(Figure 10). One of the rearrangements was located ~14 kbp upstream of the putative target
gene DEPDC5. Interestingly, we detected another commonly deleted region on 22q. One
sample (M9 m3) displayed a rearrangement within this region plus a deletion of the whole
chromosome 22, resulting in biallelic loss of SWI/SNF related, matrix associated, actin
dependent regulator of chromatin, subfamily b, member 1 (SMARCB1). We found 18
leiomyomas harboring a 1p deletion and only one protein-coding gene was located within
the minimally deleted region: NPHP4 (Figure 11A).
Figure 10. Chromosomal abnormalities and nucleotide-level mutations detected on chromosome
22q. One patient harbored four clonally related leiomyomas (MY21 m1-m4), each of which displayed
an identical deletion on chromosome 22 and a different truncating mutation in DEPDC5, providing a
unique second-hit mutation in each of the four tumors. Further examination revealed one additional tumor
(M26 m1) to display biallelic loss of DEPDC5, through a truncating DEPDC5 mutation and a deletion
of the whole chromosome 22. In total, we detected 20 leiomyomas harboring a 22q deletion, and the
minimally deleted region chr22:27,111,559–33,871,686 contained DEPDC5. We identified one
additional leiomyoma (MY23 m4) to harbor chromosomal rearrangements within this region, one of
which was located ∼14 kbp upstream of DEPDC5. We identified chr22:24,087,031-24,200,000 as
another commonly deleted region, and one leiomyoma (M9 m3) displayed a rearrangement in within this
region in conjunction with a deletion of the whole chromosome 22, resulting in a biallelic loss of the
well-known tumor suppressor gene, SMARCB1.
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Figure 11. Deletions and amplifications affecting chromosome 1. A) In Study IV, we identified
chr1:5,753,010–5,953,574 as the minimally deleted region on chromosome 1p. This region contained
only one protein-coding gene: NPHP4 B) In Study III, we identified a chromosome 1q deletion in 14 of
15 leiomyomas from one patient (MY5006). This patient was diagnosed with the HLRCC syndrome,
because she was found to harbor a germline mutation in FH (c.583A>C, p.M195V). The remaining tumor
(m5) displayed an inactivating point mutation in FH (IVS4-11A>G; predicted damaging). Six of these
tumors displayed an identical CN-LOH event on chromosome 1q (green segments). C) One of the tumors
(m8) displayed an additional amplification on chromosome 1. This amplification cannot have occurred
prior to the CN-LOH event, since it was not present in the other five clonally related tumors. Nor can the
amplification be a subsequent event, since the b-allele frequencies within this amplified region are
heterozygous. Thus, the amplification must be present in a genetically distinct subpopulation not
harboring the CN-LOH event.
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5. Gene expression profiling reveals distinct expression profiles
(I-II, IV)
In Study I, we performed gene expression profiling using 10 leiomyomas, 8 of which
harbored a MED12 mutation.  This  initial  data  indicated  that  leiomyomas  with  a MED12
mutation display a global gene expression pattern differing from that of other leiomyomas.
In Studies II and IV, we confirmed this observation by examining 94 leiomyomas by
transcriptional profiling. Furthermore, we also found leiomyomas to cluster according to
the mutation status of HMGA2, FH, and COL4A5-COL4A6 (Figure 12).
Figure 12. Unsupervised hierarchical clustering analysis of 94 leiomyomas from 60 patients.
Hierarchical clustering analysis showed that most leiomyomas clustered together according to the
mutation status of MED12 (green), HMGA2 (blue), FH (red), and COL4A5-COL4A6 (purple). The
remaining 19 quadruple-negative leiomyomas showed transcriptional heterogeneity and grouped into
several different branches. Four of these clustered with leiomyomas of the HMGA2 subtype, two of which
harbored a genetic HMGA1 abnormality (orange). One leiomyoma (MY5008 m3) harbored an HMGA1
abnormality and a MED12 mutation, consequently clustering with leiomyomas of the MED12 subtype.
Another leiomyoma (MY16 m1) harbored a PLAG1 translocation and a MED12 mutation, consequently
clustering with leiomyomas of the MED12 subtype. Two quadruple-negative leiomyomas (MY5007 m2
& M51 m1; yellow) displayed large-scale amplifications that spanned PLAG1, one of which (MY5007
m2) clustered with leiomyomas of the HMGA2 subtype. Chromosomal abnormalities affecting 7q22,
22q, and 1p had no major impact on the clustering of samples. The sample set also included four sets of
clonally related leiomyomas, each of which clustered within its own set (X, Y, Z, & Q).
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5.1 Pathway enrichment analysis using differentially expressed genes (I, IV)
In Study I, we identified 924 genes (q <0.05; |FC| >1.5) to be differentially expressed
between  the  eight  leiomyomas  with  a MED12 mutation and eight corresponding
myometrium samples. Enrichment analysis using KEGG pathways revealed three
significantly altered pathways: focal adhesion, ECM-receptor interaction, and the Wnt
signaling pathway.
In Study IV, we compared 94 leiomyomas versus the corresponding 60 myometrium
samples, revealing 135 genes to be significantly differentially expressed (q <0.05; |FC| >2).
We found zinc finger matrin-type 3 (ZMAT3) as the most significant gene. Indeed, this gene
was upregulated in all leiomyomas, regardless of subtype (Figure 13A). We also compared
leiomyomas of different genetic subtypes against all 60 myometrium samples. This revealed
258, 265, 296, and 198 genes to be significantly differentially expressed (q <0.05; |FC| >2)
in leiomyomas of the MED12, HMGA2, FH and COL4A5-COL4A6 subtypes, respectively.
We did not perform a similar expression analysis with the quadruple-negative leiomyomas,
since they showed high transcriptional heterogeneity in the hierarchical clustering analysis.
We performed a separate pathway analysis with each set of differentially expressed genes
(Table 10). No pathway reached statistical significance for leiomyomas of the COL4A5-
COL4A6 subtype. We detected the Wnt/β-catenin pathway to be one of the most
significantly dysregulated pathways in the complete set of leiomyomas (Table 10).
Furthermore, the pathway analysis predicted this pathway as inhibited. Additionally, the
Wnt antagonist secreted frizzled related protein 1 (SFRP1) was significantly upregulated
(FC  =  2.1)  in  leiomyomas  of  the MED12 subtype, whereas the Wnt antagonist WNT
inhibitory factor 1 (WIF1) was significantly upregulated (FC = 4.7) in leiomyomas of the
HMGA2 subtype.
We identified prolactin signaling as another significantly dysregulated pathway (Table 10).
In addition, we identified prolactin (PRL) itself as one of the most highly upregulated (FC
= 3) genes in the complete set of leiomyomas. This gene was particularly highly upregulated
in leiomyomas of the HMGA2 (FC = 7.7) and COL4A5-COL4A6 (FC = 9.9) subtypes, but
also significantly upregulated (FC = 2.6) in leiomyomas of the MED12 subtype. We also
identified prolactin releasing hormone receptor (PRLHR)  as  one  of  the  most  highly
upregulated (FC = 2.9) genes in the complete set of leiomyomas. This gene was particularly
highly upregulated (FC = 8.8) in leiomyomas of the MED12 subtype, but also significantly
upregulated (FC = 2.6) in leiomyomas of the HMGA2 subtype.
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Table 10. The most significantly enriched pathways according to Ingenuity Pathway Analysis
All leiomyomas MED12 subtype HMGA2 subtype FH subtype
Ingenuity Canonical Pathway q-value z-score q-value z-score q-value z-score q-value z-score
Inhibition of matrix metalloproteases 8.3E-04 - 2.2E-04 - 1.8E-01 - 2.0E-01 -
Colorectal cancer metastasis signaling 1.4E-03 –0.3 1.1E-06 –0.5 3.1E-02 –0.3 3.5E-01 –1.6
RAR activation 1.5E-03 - 1.2E-02 - 8.3E-02 - 1.9E-01 -
Glucocorticoid receptor signaling 2.4E-03 - 1.1E-02 - 1.9E-02 - 6.3E-01 -
Wnt/β-catenin signaling 2.7E-03 –0.5 6.9E-04 –0.7 4.2E-02 –0.5 1.6E-01 –0.8
Endothelin-1 signaling 2.7E-03 –1.9 5.4E-02 –1.6 1.6E-02 –1.7 3.5E-01 –0.5
Prolactin signaling 2.7E-03 0.5 3.4E-03 0.8 1.6E-02 1.6 7.7E-01 -
Granulocyte adhesion and diapedesis 2.8E-03 - 9.6E-03 - 2.8E-01 - 7.4E-01 -
Agranulocyte adhesion and diapedesis 3.8E-03 - 4.6E-03 - 2.9E-01 - 5.8E-01 -
Bladder cancer signaling 4.3E-03 - 6.9E-03 - 4.2E-02 - 2.4E-01 -
IGF-1 signaling 6.5E-03 - 3.2E-02 - 5.4E-02 - 4.8E-01 -
Role of macrophages, fibroblasts, and
endothelial cells in rheumatoid
arthritis
7.4E-03 - 5.3E-05 - 5.4E-02 - 3.5E-01 -
HIF1α signaling 7.4E-03 - 3.4E-03 - 2.4E-01 - 5.1E-01 -
Growth hormone signaling 1.0E-02 - 1.2E-02 1.0 3.1E-02 1.0 3.5E-01 -
PI3K signaling in B lymphocytes 1.3E-02 –2.2 2.5E-03 –2.5 4.2E-02 –2.5 3.5E-01 –2.0
Neuropathic pain signaling in dorsal
horn neurons 2.8E-02 0.0 8.1E-02 0.0 1.6E-02 0.4 2.7E-01 0.0
IL-8 signaling 3.6E-02 –0.5 3.2E-02 –1.1 3.1E-02 0.0 - -
Hepatic fibrosis / hepatic stellate cell
activation 3.6E-02 - 9.8E-06 - 3.1E-02 - 1.7E-01 -
D-myo-inositol-5-phosphate
metabolism 5.3E-02 - 2.9E-01 - 3.1E-02 - 6.5E-01 -
Axonal guidance signaling 6.3E-02 - 2.5E-03 - 1.5E-01 - 2.4E-01 -
Glioma signaling 7.6E-02 - 1.7E-01 - 3.1E-02 1.6 - -
Complement system 7.9E-02 - 4.6E-02 - 3.1E-02 - 1.9E-01 -
NRF2-mediated oxidative stress
response 8.1E-02 - 1.2E-01 - 7.2E-02 - 2.3E-02 1.3
Glioblastoma multiforme signaling 1.4E-01 - 7.8E-02 1.3 3.1E-02 0.0 7.7E-01 -
Role of osteoblasts, osteoclasts, and
chondrocytes in rheumatoid arthritis 2.3E-01 - 3.4E-03 - 5.1E-01 - 3.5E-01 -
Pentose phosphate pathway - - - - - - 3.9E-02 -
A positive z-score indicates a predicted activation, and a negative z-score indicates a predicted
inactivation of the enriched pathway. A z-score could not be calculated for all enriched pathways.
5.2 Uniquely expressed genes in leiomyomas of different subtypes (II, IV)
To identify the most uniquely expressed protein-coding genes for each leiomyoma subtype,
we compared leiomyomas of each subtype against all of the other leiomyoma and
myometrium samples. These genes represent candidate biomarkers that could potentially
serve  to  distinguish  the  different  subtypes.  The  20  most  (q <0.05; |FC| >2) uniquely
expressed genes are presented in Table 11.
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Table 11. Top 20 most significantly differentially expressed genes in leiomyomas of the MED12,
HMGA2, FH, and COL4A5-COL4A6 subtypes
MED12 subtype HMGA2 subtype FH subtype COL4A5-COL4A6 subtype
Gene q-value FC Gene q-value FC Gene q-value FC Gene q-value FC
RAD51B 6.4E-22 3.8 HMGA2 5.0E-33 10.3 AKR1B10 4.1E-42 27.1 IRS4 3.4E-08 10.5
PLP1 3.5E-20 3.2 IGF2BP2 6.0E-28 4.4 TKT 6.7E-35 4.4 NSG1 8.8E-08 2.2
GARNL3 2.4E-19 2.3 CCND2 7.9E-18 2.5 PDK1 2.8E-24 3.6 MXRA8 4.9E-05 –2.5
KIAA1199 2.8E-18 5.7 IL11RA 7.7E-17 2.7 SLC7A11 4.8E-24 7.2 FBLN1 4.9E-05 –3.8
LAMP5 3.0E-18 5.1 C19orf38 1.3E-15 3.0 G6PD 9.9E-22 3.9 PCSK2 2.1E-04 3.3
MMP11 6.7E-18 5.5 PLAG1 3.1E-15 8.2 PIR 1.7E-21 3.2 DPYD 5.7E-04 –2.7
ADAM12 8.7E-17 8.8 GRPR 1.2E-13 8.3 GCLM 4.1E-21 3.7 SPATA6 7.2E-04 –2.0
POPDC2 9.7E-17 3.2 PAPPA2 7.4E-13 7.1 SRXN1 4.6E-18 2.4 CTNNA3 7.7E-04 2.5
CPA3 2.8E-15 –5.0 PLA2R1 7.4E-13 –4.3 ENTPD7 1.1E-17 4.1 TMEM55A 6.9E-03 2.1
THSD4 4.7E-15 2.5 TBX3 3.1E-12 –2.4 TNFRSF21 3.1E-16 10.3 PCDHB8 9.3E-03 2.4
CACNA1C 5.6E-15 2.1 CBLN4 3.7E-12 3.1 SLC6A6 8.7E-15 4.8 SCG2 1.4E-02 8.7
MMP16 8.0E-15 4.0 GPR20 1.6E-11 2.7 NQO1 6.4E-13 7.3 SLAIN1 1.6E-02 –2.1
CNTROB 1.6E-14 2.2 GPR22 4.6E-11 4.1 BNIP3 9.4E-13 3.0 PLAGL1 1.8E-02 –2.5
NHSL2 1.6E-14 2.0 QPRT 5.5E-11 2.0 RNF128 1.2E-12 2.4 PARM1 1.9E-02 –3.0
KCNAB3 1.9E-14 3.1 PAWR 8.7E-11 –2.7 MGAT5 2.5E-12 2.5 LIX1 2.0E-02 2.4
UNC5D 6.0E-14 2.8 MB21D2 1.1E-10 2.3 PGD 2.7E-11 3.0 RHOB 2.0E-02 –2.0
HPGDS 9.1E-14 –2.4 CCND1 2.5E-10 3.6 FAM46C 2.7E-11 4.4 TGFBR3 2.3E-02 –2.0
PCP4 1.2E-13 3.3 WIF1 3.3E-10 5.0 AEBP1 4.2E-11 –3.9 HIST1H4H 3.1E-02 2.1
WBSCR17 1.4E-13 2.2 EGFR 4.2E-10 –2.2 SESN3 2.4E-10 4.0 COL4A5 3.6E-02 –3.7
RUNDC1 1.4E-13 2.2 AVPR1A 4.7E-10 –4.3 ABCC3 5.6E-10 2.1 PCDHB2 3.7E-02 4.4
Figure 13. The most uniquely expressed gene in leiomyomas of different subtypes. A) ZMAT3 was
the most significantly differentially expressed gene in leiomyomas versus the myometrium tissue
(brown). B) RAD51B was the most uniquely expressed gene in leiomyomas of the MED12 subtype
(green). C) Exon-level analysis revealed that the overexpression of RAD51B in MED12 mutant
leiomyomas (red) versus the myometrium tissue (blue) originated predominantly from a non-coding
transcript (ENST00000492236). D) HMGA2 was the most uniquely expressed gene in leiomyomas of
the HMGA2 (blue) subtype. E) AKR1B10 was the most uniquely expressed gene in leiomyomas of the
FH (red) subtype. F) IRS4 was the most uniquely expressed gene in leiomyomas of the COL4A5-COL4A6
(purple) subtype.
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In Study II, we identified RAD51B as  the  most  uniquely  expressed  gene  (FC  =  3.8)  in
leiomyomas of the MED12 subtype, an observation that we confirmed in Study IV (Table
11; Figure 13B). However, exon-level analysis revealed that this upregulation corresponded
to a non-coding transcript of RAD51B (ENST00000492236; Figure 13C). We validated this
observation by RNA sequencing of two tumor-normal pairs (MY18 m1 & MY23 m1). Of
note, we detected a lower expression of this non-coding transcript in their corresponding
myometrium. Among the 20 most uniquely expressed genes in leiomyomas of the MED12
subtype, three encode for matrix metalloproteases (ADAM12, MMP16,  & MMP11). The
pathway enrichment analysis confirmed a significant dysregulation of matrix
metalloproteases (Table 10). Of note, leiomyomas of the MED12 subtype displayed a
significant upregulation (FC = 3.1) of insulin like growth factor 2 (IGF2).
We identified HMGA2 as the most uniquely expressed gene (FC = 10.2) in leiomyoma of
HMGA2 subtype (Table 11; Figure 13D). The second most significant gene (FC = 4.3) was
insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2),  a  gene  known  to  be
directly regulated by HMGA2.298 The proto-oncogene PLAG1 was the sixth most uniquely
expressed gene (FC = 8.2), suggesting that HMGA2 may regulate  this  gene  as  well.  The
three leiomyomas with a genetic HMGA1 abnormality also exhibited a significant
upregulation (FC = 5.6) of PLAG1. In fact, among the 34 leiomyomas harboring a MED12
mutation, only two showed upregulation of PLAG1 (FC  >2),  one  of  which  harbored  an
HMGA1 abnormality (MY5008 m3; FC = 2.5) and the other a PLAG1 translocation (MY16
m1; FC = 17.5). Further investigation showed upregulation of PLAG1 in two quadruple-
negative leiomyomas (MY5007 m2; FC = 11.1 & M51 m1; FC = 7.5), both of which
harbored a large-scale amplification on chromosome 8 that spanned PLAG1. All of the three
samples with a genetic PLAG1 abnormality showed expression patterns similar to those
seen in leiomyomas with an HMGA2 or HMGA1 abnormality. In fact, one of these samples
(MY5007 m2) clustered among leiomyomas of the HMGA2 subtype. Studies have shown
that PLAG1 directly regulates the expression of IGF2.299-301 We  detected  a  significant
upregulation of IGF2 in leiomyomas of HMGA2 (FC = 3) and MED12 (FC = 3.1) subtypes.
Differential expression analysis also revealed a significant upregulation (FC = 4.3) of IGF2
in the three leiomyomas with a genetic PLAG1 abnormality.
We identified aldo-keto reductase family 1 member B10 (AKR1B10) to be the most uniquely
expressed  gene  (FC  =  26.7)  in  leiomyomas  of  the FH subtype (Table 11; Figure 13E).
AKR1B10 was upregulated in all FH-deficient leiomyomas, and in none of the other
leiomyoma nor myometrium samples. NRF2 mediated oxidative stress response was the
most significantly dysregulated pathway (Table 10). Compatible with this observation,
among the 20 most uniquely expressed genes, eight are known targets of the transcription
factor NFR2 (AKR1B10, TKT, PIR, SLC7A11, NQO1, SRXN1, SLC6A6, & GCLM).302-305
The pentose phosphate pathway was the only other significant pathway. Indeed, among the
20 most uniquely expressed genes, three encode for key enzymes of this pathway (TKT,
PGD,  & G6PD). None of the other leiomyoma subtypes displayed a significant
dysregulation  of  these  two  pathways  (Table  10).  Of  note,  while  leiomyomas  of  the FH
subtype displayed a significant upregulation (FC = 4.8) of PLAG1, we found a significant
downregulation (FC = –2.5) of IGF2 in these lesions.
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Although COL4A5 and COL4A6 are  both  affected  by COL4A5-COL4A6 deletions, only
COL4A5 displayed a statistically significant downregulation (FC= –3.7) when compared to
the myometrium samples. We identified insulin receptor substrate 4 (IRS4) to be the most
uniquely expressed gene (FC=10.5) in leiomyomas of the COL4A5-COL4A6 subtype (Table
11; Figure 13F). Our statistical analysis also revealed a unique downregulation (FC = –2.5)
of the putative tumor suppressor PLAG1 like zinc finger 1 (PLAGL1), which is structurally
similar to PLAG1 (Table 11).
5.3 Downregulated genes by chromosome 7q22, 22q, and 1p deletions (IV)
Assuming that 7q22, 22q, and 1p deletions, each targets a driver gene that results in reduced
gene dosage, we searched for downregulated genes within these deletions by performing a
separate differential expression analysis that compared leiomyomas with each abnormality
in question against leiomyoma and myometrium samples lacking the abnormality. The 20
most significantly downregulated protein-coding genes (q <0.05) located within commonly
deleted regions are presented in Table 12.
Table 12. Top 10 genes downregulated genes by 7q22, 22q, and 1q deletions
7q22 deletion 22q deletion 1p deletion
Gene q-value FC # Gene q-value FC # Gene q-value FC #
LMTK2 1.9E-04 –1.3 8 FBXO7 1.1E-12 –1.4 19 UBE4B 6.6E-11 –1.5 16
COPS6 7.5E-04 –1.3 9 MTMR3 7.6E-12 –1.4 19 EXOSC10 5.7E-08 –1.3 16
CUX1 7.9E-04 –1.5 13 DEPDC5 5.6E-08 –1.3 19 DNAJC16 5.7E-08 –1.2 15
MLL5 2.0E-03 –1.4 11 RNF185 1.6E-07 –1.5 19 GNB1 8.1E-08 –1.3 15
TNPO3 2.0E-03 –1.3 8 EIF3D 2.0E-07 –1.3 18 PRDM2 9.9E-08 –1.3 15
ZNF800 4.6E-03 –1.2 7 DUSP18 4.0E-07 –1.4 19 FAM54B 1.4E-07 –1.4 15
PNPLA8 1.9E-02 –1.4 13 TTC28 7.5E-07 –1.4 19 VPS13D 1.4E-07 –1.5 16
ZNF394 2.0E-02 –1.3 9 EP300 8.3E-07 –1.3 15 RERE 2.5E-07 –1.5 17
CADPS2 2.0E-02 –2 8 MAPK1 1.2E-06 –1.3 16 KIF1B 6.0E-07 –1.5 16
PMPCB 2.1E-02 –1.4 11 MKL1 1.3E-06 –1.4 16 CLSTN1 9.8E-07 –1.5 16
# = total number of deletions that spanned the gene among a total of 94 leiomyomas.
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DISCUSSION
Uterine leiomyomas rank among the most common symptomatic human neoplasms, but
considering their major public health impact, their etiology is severely understudied. The
current classification of leiomyomas is largely based on histological features, with a
molecular classification sorely lacking. Decades of work utilizing classical cytogenetic
techniques have demonstrated that leiomyomas are a genetic disease characterized by
chromosomal abnormalities that are non-random and leiomyoma-specific. Approximately
60% lack chromosome-level abnormalities, suggesting that submicroscopic mutations
underlie the remaining tumors. Massively parallel sequencing technologies have made it
possible to examine tumor genomes on a previously unprecedented scale. Utilizing genome-
wide methods in this thesis work, we have made several breakthrough findings that provide
invaluable insights into the molecular basis of these very common tumors.
1. MED12: a key driver in leiomyomas
Exome sequencing of 18 uterine leiomyomas, followed by screening of an additional 207,
revealed localized mutations in the MED12 gene in 71% of these lesions. MED12 consists
of 45 exons, and all of the mutations detected were located in exon 2 or in the preceding
intron-exon boundary. We found this region to be highly evolutionary conserved; none of
the mutations was present in the corresponding myometrial tissue; all were predicted to
result in an in-frame protein product, and no tumor showed more than one MED12 mutation.
Considered together, these mutational patterns strongly indicate that mutated MED12 acts
an oncogene, and that these hotspot mutations represent gain-of-function mutations.
Furthermore, the affected tumors expressed mainly the mutated form of MED12,
demonstrating that the mutations reside on the active X chromosome. Exome sequencing
revealed no other recurrently mutated genes, highlighting MED12 as  a  key  driver  in  the
majority of leiomyomas.
Since our initial discovery, a number of subsequent studies have reported similar
frequencies of MED12 mutations among leiomyomas from various different populations, at
an overall frequency of 64% (Table 13). Small sample sizes and a tendency towards
selecting larger tumors may have underestimated the true frequency of MED12 mutations.
Furthermore, we recently discovered that mutations may infrequently (2%) reside at the end
of exon 1 as well,306 and the majority of studies have not accounted for this region in their
sequencing analyses. Indeed, in a prospectively collected, well-documented, and unselected
series of sporadic leiomyomas, we found the mutation frequency to be closer to 84%.307
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Table 13. Frequency of MED12 hotspot mutations in uterine leiomyomas from various populations
* Confidence intervals calculated by the asymptotic (Wald) method.
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1.1 MED12 hotspot mutations in leiomyoma variants, leiomyosarcomas, and
extrauterine leiomyomas
Multiple subsequent studies have screened for MED12 mutations in leiomyoma variants,
leiomyosarcomas, and extrauterine leiomyomas, demonstrating that MED12 mutations
occur at a significantly lower frequency in histological variants of leiomyomas (Table 14).
Indeed, cellular leiomyomas and leiomyomas with bizarre nuclei show a particularly low
frequency (Table 14). Their lower prevalence indicates that other factors than MED12
mutations are responsible for their unusual histology.
MED12 mutations  also  occur,  albeit  at  a  lower  frequency,  in  STUMPs  and  uterine
leiomyosarcomas, suggesting that these mutations are selectively advantageous in
malignant tumors as well. Alternatively, some leiomyomas harboring a MED12 mutation
may have undergone malignant transformation. The role of MED12 in malignancy remains
obscure, since the majority of leiomyosarcomas lack protein expression of MED12,
including those with a MED12 mutation.311, 314, 324 Furthermore, one study reported a
leiomyosarcoma to harbor a frame-shift mutation in MED12.314 Although MED12
mutations occur in metastatic lesions as well,317 one recent study described a patient in
which  the  primary  tumor  displayed  a MED12 mutation, whereas its two metastases did
not.330 Considered together, these observations suggest that MED12 mutations occur in the
early stages of leiomyosarcoma formation and that as the tumors progress towards
malignancy, their expression becomes unnecessary or is lost. It is tempting to speculate that
MED12 mutations have a negative effect on the malignant potential of leiomyomas, and that
their common occurrence may explain why leiomyomas rarely, if ever, progress. It would
also be reasonable to assume that other genetic defects are responsible for the aggressive
behavior of leiomyosarcomas. Indeed, exome sequencing recently revealed that uterine
leiomyosarcomas frequently harbor TP53 and ATRX, chromatin remodeler (ATRX)
mutations, some of which co-occurred with MED12 mutations.331 Furthermore, one study
examined for MED12 mutations in four leiomyosarcoma cell lines, but found none.317
Other studies have screened for MED12 mutations in smooth muscle tumors of various
anatomical sites (Table 14). These have revealed MED12 mutations  in  a  total  of  22
extrauterine leiomyomas and in only 1 extrauterine leiomyosarcoma (Table 14). Some
researchers have hypothesized that MED12 mutations occur only in tumors that originate
from tissues developing from the Müllerian duct.311 Although  a  few  leiomyomas  of  the
kidney, ovary, and cervix have been reported to display a MED12 mutation, these mutations
are significantly more common in leiomyomas at retroperitoneal and pelvic sites,317, 318
supporting the view that some of these actually originate from pedunculated leiomyomas
that have become detached from the uterus.101 Of note, MED12 mutations are not restricted
to humans, as similar type of mutations occur in canine vaginal leiomyomas.311
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Table 14. Frequency of MED12 hotspot mutations in leiomyoma variants, extrauterine
leiomyomas, and leiomyosarcomas
Phenotype Frequency Population Study (Reference)
Mitotically active leiomyoma 86% (6/7) Chinese Zhang, Q. et al. 2014 (320)
38% (10/26) Finnish Mäkinen, N. et al. 2013 (313)
Total 48% (16/33) - -
Leiomyoma with bizarre nuclei 25% (1/4) Japanese Matsubara, A. et al. 2013 (319)
17% (3/18) Finnish Mäkinen, N. et al. 2013 (313)
10% (4/42) Chinese Zhang, Q. et al. 2014 (320)
0% (0/5) French Pérot, G. et al. 2012 (324)
Total 12% (8/69) - -
Cellular leiomyoma 33% (2/6) Japanese Matsubara, A. et al. 2013 (319)
14% (3/22) Chinese Zhang, Q. et al. 2014 (320)
9% (6/67) Finnish Mäkinen, N. et al. 2013 (313)
Total 12% (11/95) - -
Lipoleiomyoma 0% (0/4) Japanese Matsubara, A. et al. 2013 (319)
Intravenous leiomyomatosis 0% (0/9) American Buza, N.et al. 2014 (224)
Extrauterine leiomyoma* 100% (7/7) German Rieker, R.J. et al. 2013 (308)
50% (1/2) German Markowski, D.N. et al. 2013 (311)
17% (10/58) American Schwetye, K.E. et al. 2014 (318)
16% (3/19) American Ravegnini, G. et al. 2013 (317)
5% (1/20) Dutch de Graaff, M.A. et al. 2013 (325)
0% (0/42) Finnish Kämpjarvi, K. et al. 2012 (332)
0% (0/51) Japanese Matsubara, A. et al. 2013 (319)
Total 11% (22/199) - -
STUMP 11% (2/18) Chinese Zhang, Q. et al. 2014 (320)
11% (1/9) French Pérot, G. et al. 2012 (324)
8% (1/12) American Schwetye, K.E. et al. 2014 (318)
Total 10% (4/39) - -
Uterine leiomyosarcomas** 30% (6/20) American Schwetye, K.E. et al. 2014 (318)
30% (3/13) American Ravegnini, G. et al. 2013 (317)
21% (4/19) Finnish Mäkinen, N. et al. 2016 (331)
20% (2/10) French Pérot, G. et al. 2012 (324)
17% (2/12) Japanese Matsubara, A. et al. 2013 (319)
14% (1/7) Dutch de Graaff, M.A. et al. 2013 (325)
11% (4/38) Chinese Zhang, Q. et al. 2014 (320)
9% (3/32) American Bertsch, E. et al. 2014 (314)
7% (3/41) Finnish Kämpjarvi, K. et al. 2012 (332)
7% (1/14) German Markowski, D.N. et al. 2013 (311)
4% (1/24) Chinese Wang, H. et al. 2015 (321)
0% (0/5) Korean Je, E.M. et al. 2012 (326)
Total 13% (30/235) - -
Extrauterine leiomyosarcoma 4% (1/25) American Schwetye, K.E. et al. 2014 (318)
0% (0/23) Dutch de Graaff, M.A. et al. 2013 (325)
0% (0/10) American Ravegnini, G. et al. 2013 (317)
0% (0/20) Japanese Matsubara, A. et al. 2013 (319)
0% (0/20) German Markowski, D.N. et al. 2013 (311)
0% (0/38) French Pérot, G. et al. 2012 (324)
Total 1% (1/136) - -
* Included are leiomyoma variants displaying unusual growth pattern of possible uterine origin.
** Included are extrauterine metastases of known uterine origin.
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1.2 MED12 hotspot mutations in other human neoplasms
Several screening studies have shown that MED12 mutations are rare or completely absent
in the majority of human neoplasms (Table 15). Furthermore, none of the major large-scale
cancer-sequencing efforts, such as The Cancer Genome Atlas (TCGA) project or the
International Cancer Genome Consortium (ICGC), has highlighted recurrent MED12
mutations. Exceptions include chronic lymphocytic leukemia and colorectal cancer, both of
which exhibit MED12 mutations at a significantly lower frequency than in leiomyomas.333,
334 Of note, the mutational spectrum of MED12 mutations in chronic lymphocytic leukemia
differs from that of leiomyomas, since the former display an unexpectedly high proportion
of exon 1 mutations.333
A recent exome-sequencing study described a high frequency of MED12 mutations in
fibroadenomas of the breast.335 Similarly as seen in uterine leiomyomas, MED12 was the
only recurrently mutated gene, and the tumors’ mutational spectrum was nearly identical,335
suggesting that both of these tumors types share the same etiology. Furthermore, both are
benign, ovarian steroid-dependent, and arise from smooth muscle cells. Fibroadenomas are
biphasic tumors composed of epithelial  and stromal components,  and the mutations were
exclusively present in the stromal cells.335 Several follow-up studies have validated the
occurrence of MED12 mutations in fibroadenomas, revealing a similar frequency as in
leiomyomas (Table 15). Of note, HMGA2 rearrangements occur in fibroadenomas as well,
suggesting that MED12 and HMGA2 have overlapping functions in tumorigenesis.150
Several subsequent studies have revealed a similar frequency of MED12 mutations in
phyllodes tumors of the breast (Table 15). These are rare fibroepithelial tumors that share
morphological features with fibroadenomas,336 suggesting a shared origin. However,
phyllodes tumors have a variable clinical behavior, and are classified as benign, borderline,
or malignant. MED12 mutations occur at a noticeable lower frequency in the malignant
cases.337 In contrast to the benign and borderline cases, malignant lesions harbor additional
mutations in classical driver genes such as TP53, RB1, and NF1.338 Furthermore, TERT
promoter mutations tend to co-occur with MED12 mutations in phyllodes tumors, regardless
of tumor grade.339 Interestingly, a recent study showed that leiomyosarcomas harbor ATRX
or DAXX mutations, resulting in alternative lengthening of telomeres.331 It is tempting to
speculate that that leiomyomas and fibroadenomas may progress to a more malignant state
as they acquire defects in telomerase activity. Although MED12 mutations are absent in
most human neoplasms, it remains to be seen whether some rarer neoplasms could carry
MED12 mutations.
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Table 15. Frequency of MED12 hotspot mutations in other human neoplasms
Neoplasm Frequency Population Study (Reference)
Fibroadenomas of the breast 85.7% (18/21) Singaporean Tan, J. et al. 2015 (336)
66.7% (6/9) Japanese Nagasawa, S. et al. 2015 (340)
65.4% (17/26) American Piscuoglio, S. et al. 2015 (341)
62.1% (36/58) Japanese Yoshida, M. et al. 2015 (342)
61.0% (61/100) American Piscuoglio, S. et al. 2016 (343)
59.2% (58/98) Singaporean Lim, W.K. et al. 2014 (335)
59.1% (13/22) German Pfarr, N. et al. 2015 (344)
50.0% (9/18) Taiwanese Lien, H. et al. 2016 (345)
46.6% (27/58) Japanese Mishima, C. et al. 2015 (346)
Total 59.8% (245/410) - -
Phyllodes tumors of the breast 80.4% (37/46) Japanese Yoshida, M. et al. 2015 (342)
74.1% (20/27) Japanese Mishima, C. et al. 2015 (346)
73.6% (39/53) Taiwanese Lien, H. et al. 2016 (347)
70.9% (56/79) Singaporean Tan, J. et al. 2015 (336)
66.7% (10/15) American Cani, A.K. et al. 2015 (338)
63.8% (30/47) American Piscuoglio, S. et al. 2015 (341)
62.5% (70/112) Singaporean Ng, C.C. et al. 2015 (348)
60.5% (46/76) American Piscuoglio, S. et al. 2016 (343)
46.0% (81/176) Korean Yoon, N. et al. 2016 (337)
45.5% (5/11) Japanese Nagasawa, S. et al. 2015 (340)
56.3% (9/16) German Pfarr, N. et al. 2015 (344)
Total 61.2% (403/658) - -
Chronic lymphocytic leukemia 5.2% (37/709) Finnish Kämpjarvi, K. et al. 2015 (333)
8.8% (10/114) French Guièze, R. et al. 2015 (349)
3.4% (3/88) American Wang, L. et al. 2011 (350)
1.9% (3/160) American Landau, D. et al. 2013 (351)
1.9% (2/105) Spanish Quesada, V. et al. 2012 (352)
1.8% (3/168) French Damm, F. et al. 2014 (353)
Total 4.3% (58/1344) - -
Colorectal cancer 0.5% (2/392) Finnish Kämpjarvi, K. et al. 2012 (332)
0.4% (1/224) American The Cancer Genome Atlas (334)
0.3% (1/389) Korean Je, E.M. et al. 2012 (326)
Total 0.4% (4/1005) - -
DISCUSSION
72
1.3 Other pathogenic MED12 mutations
Exome sequencing of prostate cancer, adrenocortical carcinomas, and renal cell cancer have
recently revealed recurrent mutations in other parts of MED12 (Table 16). MED12
mutations in prostate cancer are highly localized, affecting the leucine- and serine-rich (LS)
domain (Figure 14A).354 The mutations detected in adrenocortical carcinoma and renal cell
cancer are more scattered within the MED12 gene and predicted as damaging (Figure 14A).
Furthermore, the mutations in adrenocortical carcinomas tend to affect the Med12-PQL
domain, which is an interaction site for β-catenin (Figure 14B).355 Germline mutations –
typically affecting the LS domain – cause the hereditary syndromes Opitz-Kaveggia (also
known as FG syndrome), Lujan-Fryns, and Ohdo syndrome.356 These syndromes have
overlapping phenotypes, including mental retardation and dysmorphic features.356 None of
these syndromes has been associated with increased tumor risk, however.
Table 16. Other pathogenic MED12 mutations
Neoplasm/Syndrome Frequency Location Study/OMIM#
Prostate cancer 5.4% (6/111) Exon 26 Barbieri, C.E. et al. 2012 (354)
2.3% (4/171) Exon 26 TCGA, ICGC (357)
1.3% (1/80) Exon 26 Kämpjarvi, K. et al. 2016 (358)
0% (0/226) Exon 26 Stoehr, R. et al. 2013 (359)
Total 1.9% (11/588) Exon 26 -
Adrenocortical carcinoma 4.9% (6/122) Exons 34-35, 38-39 & 41 Assie, G. et al. 2014 (355)
Renal cell cancer 4.5% (3/67) Exons 19, 24 & 35 Arai, E. et al. 2014 (360)
Opitz-Kaveggia syndrome - Exon 21 305450 (356)
Lujan-Fryns syndrome - Exon 22 309520 (356)
Ohdo syndrome - Exons 22 & 37 300895 (356)
1.4 Possible mechanisms of tumorigenesis
MED12 encodes for a subunit of the multiprotein complex known as Mediator, which serves
as a bridge between transcription factors and the RNA polymerase II transcriptional
machinery.361 Mediator facilitates the transcription of almost all eukaryotic genes, and
functions as a context-dependent positive or negative regulator of transcription.361 The
human core Mediator, consisting of 26 subunits, is divided into three domains known as the
head, middle, and tail (Figure 14C). MED12 forms, together with MED13, Cyclin-C, and
CDK8 or CDK19, a fourth submodule known as the CDK8 module.361 MED12 connects
Cyclin-C-CDK8/19 to the core Mediator and serves as an essential regulator of the kinase
activity of the CDK8 module.361 Mediator exists in two major forms, one of which contains
the CDK8 module, whereas the other do not.361 The large form, “L mediator”, acts as a
transcriptional repressor, whereas the smaller form, “S mediator”, stimulates basal
transcription.361 Of  note, cyclin dependent kinase 8 (CDK8) acts an oncogene that is
amplified in over half of colorectal cancers.362
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We recently demonstrated that one consequence of MED12 mutations is weakened
interaction between MED12 and Cyclin-C-CDK8/19, resulting in decreased kinase activity
of the CDK8 module.363 In a subsequent study, we screened leiomyomas for mutations in
other components of the CDK8 module, but found none.364 The prostate cancer-linked
mutations did not show the same effect, but rather a weakened interaction between MED12
and other components of the Mediator.358 The manner by which these consequences
contribute to tumorigenesis remains unclear.
MED12 participates normally in various signaling pathways, including p53, Sonic
hedgehog, mTOR, estrogen, TGF-β, and Wnt/β-catenin.356 Indeed, MED12 can act as a
transcriptional activator of Wnt target genes through its interaction with β-catenin,356
suggesting that MED12 mutations may act through the Wnt/β-catenin signaling pathway.
We initially observed a significant dysregulation of genes related to Wnt signaling in
leiomyomas harboring a MED12 mutation. Several subsequent studies have examined for a
possible role of activated Wnt signaling in leiomyomas, yielding somewhat contradicting
results.268, 276, 277, 310, 324 The Wnt/β-catenin pathway appears to be activated in the
leiomyoma side population,276 and its inhibition attenuates leiomyoma cell growth.277 On
the other hand, the majority of leiomyomas, including those with a MED12 mutation, show
β-catenin localization into the membrane, indicative of low transactivation activity.324
Furthermore, our pathway analyses revealed a predicted inhibition of the Wnt/β-catenin
pathway in leiomyomas. Compatible with this prediction, we detected the Wnt antagonist
SFRP1 to be specifically upregulated in leiomyomas of the MED12 subtype and the Wnt
antagonist WIF1 to be specifically upregulated in leiomyomas of the HMGA2 subtype.365 It
should be noted that although SFRP1 is a well-known inhibitor of Wnt, one study postulated
that SFRP1 might demonstrate anti-apoptotic effects in leiomyomas.366 The role of MED12
mutations in Wnt signaling remains obscure, and at least three different types of Wnt
signaling pathways exist.
One study showed that knock-down of MED12 expression in the human leiomyoma cells
result in reduced levels of extracellular matrix genes, including fibronectin and collagen
type 1.367 Furthermore, integrated expression profiling of leiomyomas and fibroadenomas
carrying MED12 mutations has revealed a shared dysregulation of genes related to
extracellular matrix organization.335 These observations suggest that MED12 play  an
important role in regulating genes involved in extracellular remodeling. Compatible with
this hypothesis, we found “Inhibition of matrix metalloproteases” to be the most
significantly altered pathway in leiomyomas of the MED12 subtype. Matrix
metalloproteases are key proteins involved in extracellular matrix remodeling.368 Several of
these matrix metalloproteases, including ADAM metallopeptidase domain 12 (ADAM12),
were uniquely upregulated in leiomyomas of the MED12 subtype. A recent study showed
that knockdown of the long non-coding RNA Intergenic 10 results in downregulation of its
neighboring gene ADAM12 and inhibition of leiomyoma cell proliferation.369 Another study
showed that  inhibition  of  MED12 results  in  resistance  to  a  wide  variety  of  cancer  drugs
through activation of TGF-β receptor signaling via elevated TGF-βR2 protein expression.370
It is well known that leiomyomas display elevated levels of TGF-β receptors,269 suggesting
that MED12 mutations could play a role in modulating this pathway.
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A recent study showed that leiomyoma cell cultures carrying a MED12 mutation can barely
survive the first passages,371 making research into the molecular consequences of MED12
mutations difficult. Conversely, another study showed that conditional expression of the
most common MED12 mutation (c.131G>A) in a mouse model results in the development
of uterine lesions.372 Not only does this animal model confirm a driver role for MED12 in
tumorigenesis, but also provides researchers with an accurate tool to study the mechanism
of MED12 mutations in leiomyomas; interestingly, these murine tumors also show
chromosomal instability, including highly complex chromosomal abnormalities.372
Figure 14. Schematic of the human MED12 protein and the Mediator complex. A) The MED12
protein, consisting of 2177 amino acids, is divided into four domains based on its amino-acid content: L,
the leucine-rich domain; LS, the leucine- and serine-rich domain; PQL, the proline-, glutamine- and
leucine-rich domain; and OPA, opposite paired domain. The protein contains also three conserved
domains: Med12 (yellow), Med12-LCEWAV (red), and Med12-PQL (blue). Leiomyomas, breast
epithelial tumors, and chronic lymphocytic leukemia harbor highly localized mutations affecting the
early regions of MED12, whereas other pathogenic mutations are located towards the middle or end of
MED12. Germline mutations are underlined. B)  Predicted  3D  structure  of  the  MED12  protein
highlighting the three conserved domains. C) The human core Mediator, consisting of 26 subunits, has a
head, middle, and tail module. MED12 is part of a fourth submodule, known as the CDK8 kinase module.
B is  from Journal of Cellular Biochemistry, 117, Banaganapalli et al. A Computational Protein
Phenotype Prediction Approach to Analyze the Deleterious Mutations of Human MED12 Gene (2016),
reprinted with the permission of John Wiley and Sons.
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2. Clonality and intratumor genetic heterogeneity
Patients affected by uterine leiomyomas tend to have multiple separate nodules,89 each of
which is assumed to arise independently, as each shows a random pattern of X-inactivation.
Furthermore, each leiomyoma tends to harbor a unique set of mutations, including distinct
cytogenetic abnormalities and a different MED12 mutation. A few studies have, however,
reported separate leiomyomas with cytogenetic abnormalities that appear to be identical,231-
234 suggesting that not all leiomyomas arise independently. Using whole-genome
sequencing, we were able to detect numerous rearrangements clearly identical among
separate lesions from the same patient, signifying that some are in fact clonally related.
In order to investigate the frequency of clonally related leiomyomas, we examined for
identical chromosomal abnormalities among 103 leiomyomas from 14 consecutive patients
by  use  of  SNP  arrays.  We  detected  four  (29%)  patients  with  13  (13%)  clonally  related
leiomyomas, each of which lacked any MED12 mutations.  Since  the  majority  of
leiomyomas with a MED12 mutation displayed no chromosomal abnormalities, we cannot
exclude the possibility of some being clonally related, as well. While one cannot extrapolate
the exact frequency of this phenomenon from these studies, due to their small sample sizes,
these preliminary observations suggest that clonally related leiomyomas are relatively
common among leiomyomas that lack a MED12 mutation. This phenomenon may
occasionally explain the occurrence multiple leiomyomas within the same uterus.
2.1 Possible mechanisms of tumor spread
The very hallmark of cancers as compared to benign tumors is the ability to spread and form
secondary tumors. Leiomyomas are often viewed as a textbook example of a benign tumor
that does not undergo malignant transformation. However, it is now known that uterine
leiomyomas can spread due to uterine surgery, demonstrating that some leiomyoma cells
have the ability to attach and grow at distant locations. Indeed, pedunculated leiomyomas
may become detached from the uterus and attach to peritoneal surfaces. In Study III, we
investigated the surgical history of patients with clonally related leiomyomas and found
prior myomectomy in only two out of five patients with clonally related leiomyomas.
Since no mutations have proven to directly cause metastasis, some researchers have argued
that metastases develop when disseminated cells reach distant sites with a favorable
microenvironment.49 We, however, found an inverse relationship between the presence of
MED12 mutations and clonally related leiomyomas, suggesting that the genetic background
does influence the ability to form secondary tumors. Compatible with this notion,
leiomyomas of the HMGA2 subtype are significantly larger and show a higher degree of
chromosomal instability.199 Indeed, all of the tumors assessed as clonally related by whole-
genome sequencing corresponded to leiomyomas of the HMGA2 subtype,  and  all  of  the
tumors assessed as clonally related by SNP arrays were negative for MED12 mutations.
However, one set of clonally related leiomyomas consisted of six leiomyomas of the FH
subtype, signifying that the phenomenon is not limited to leiomyomas with HMGA2 defects.
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Although the putative mechanisms by which these tumors spread are largely speculative,
the ability for uterine leiomyomas to spread is not completely surprising considering the
existence of leiomyoma variants displaying quasi-malignant behaviors, including benign
metastasizing leiomyomas, intravenous leiomyomatosis, and disseminated peritoneal
leiomyomatosis.96 Interestingly,  all  of  these  can  harbor HMGA2 rearrangements,189, 190
supporting the notion that leiomyomas of the HMGA2 subtype  are  more  prone  to
dissemination. On the other hand, MED12 mutations  have  also  been  reported  in
disseminated peritoneal leiomyomatosis, including five distinct nodules from the same
patient, each of which displayed a rare and identical MED12 mutation, suggesting a
common clonal origin.308
Another recent study identified MED12 mutations in the myometrium directly adjacent to a
discrete and well-circumscribed leiomyoma. These authors speculated that neoplastic cells
may infiltrate the normal myometrium or that MED12 mutations occur early in the
tumorigenesis, creating a “field effect” in the normal myometrium.318
2.2 Branched tumor evolution
Leiomyomas are composed of smooth muscle cells, vascular smooth muscle cells, stem cell-
like side population cells, and fibroblasts that presumably work together to stimulate cell
proliferation.240 Although phenotypically different, recent evidence has indicated that all of
these cells arise from a single transformed progenitor stem cell.241
By studying the genetic architecture of clonally related leiomyomas, we were able to infer
that some leiomyomas are composed of genetically distinct subpopulations. Indeed, whole-
genome sequencing of four clonally related leiomyomas revealed a pattern of mutations best
explained as a spread from a primary tumor. Furthermore, the mutational pattern within this
primary tumor is compatible with a branching model of tumor evolution (Figure 15).373, 374
Such sequence-level heterogeneity has emerged in several cancer types, but not, to our
knowledge, in any benign tumors before.375
Using  SNP  arrays,  we  were  able  to  confirm  two  additional  cases  of  leiomyomas  with
intratumor genetic heterogeneity. Furthermore, we also detected a mutation in ZNHIT to be
consistently subclonally present in nine different parts of a leiomyoma, supporting the fact
that leiomyomas are composed of a mixture of genetically distinct cell populations. Whether
these genetic subpopulations reflect phenotypically distinct cells that cooperate to stimulate
growth remains to be seen.
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Figure 15. Linear versus branched tumor evolution. Leiomyomas are monoclonal tumors that grow
through clonal expansion. The intratumor genetic heterogeneity observed in leiomyomas suggests a
branching model of tumor growth, in which cells divide into multiple genetically distinct populations.
MED12 mutations and HMGA2 rearrangements are the two most common initiating events in
leiomyomas, since they appear to be clonally present. In contrast, 7q abnormalities and DEPDC5
mutations co-occur with other genetic defects and appear to be secondary events present only in a
subpopulation of cells.
2.3 DEPDC5 as a secondary driver gene
Whole-genome sequencing of four clonally related leiomyomas revealed an identical
deletion on chromosome 22 and a different truncating DEPDC5 mutation in each tumor. In
the context of hereditary cancer syndromes, classical tumor suppressor genes typically
follow a pattern in which the first allele is lost through a germline mutation, whereas the
second is lost through a larger chromosomal deletion.376 While  the  order  of  events  are
largely unknown in sporadic cases, here we show – perhaps unexpectedly – that a shared
clonal deletion provided the first-hit, but an independent truncating mutation provided the
second-hit. Although biallelic loss of DEPDC5 was secondary in relation to the initiating
HMGA2 translocation, DEPDC5 mutations were highly selectively advantageous in this
patient’s tumors. Indeed, we found no other gene to be recurrently mutated among these
four tumors. To confirm DEPDC5 as a recurrently mutated gene, we examined an in-house
whole-genome sequencing dataset of 65 leiomyomas for additional DEPDC5 mutations,
revealing one additional case. This tumor displayed a whole chromosome 22 deletion,
confirming DEPDC5 as a tumor suppressor gene. This makes DEPDC5 the only other gene,
since the discovery of MED12, to be recurrently mutated on a nucleotide level. This case
also provides indisputable evidence for the existence of clonally related leiomyoma nodules.
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Differential expression analysis with leiomyomas harboring a 22q deletion revealed
DEPDC5 as one of the most significantly downregulated genes by deletions affecting
chromosome 22, supporting the view that DEPDC5 is target gene from these large-scale
deletions. However, the majority of these leiomyomas lacked a second-hit in DEPDC5,
suggesting that loss of one allele is sufficient to facilitate tumor growth and lead to selection.
Based on functional evidence, DEPDC5 is  a subunit  of a tumor suppressor complex that
negatively regulates mTORC1,377 supporting a role for mTOR signaling in leiomyomas.
DEPDC5 is a suspected driver gene in glioblastomas and ovarian cancer, since both of these
tumor types occasionally harbor truncating mutations or homozygous deletions affecting
the gene.377 SNPs within the DEPDC5 locus have also been associated with progression to
hepatocellular carcinoma among chronic hepatitis C virus carriers,378 supporting the view
that this gene play a role in tumorigenesis. On the other hand, truncating germline mutations
in DEPDC5 cause hereditary focal epilepsy and brain malformations.379 Although these
germline mutations have not been associated with increased leiomyoma risk, epilepsy is the
most common symptom of tuberous sclerosis – caused by mutations in TSC2 – a gene that,
when mutated in rats, cause uterine leiomyomas and renal cell cancer.242
Although rare in leiomyomas,185 deletions of 22q are one the most common abnormalities
seen in intravenous leiomyomatosis224 and benign metastasizing leiomyomas206, both of
which are characterized by quasi-malignant behavior. Deletions of 22q are also common in
STUMPs223 and leiomyosarcomas380. Furthermore, leiomyosarcomas may display distinct
areas of leiomyoma-like or leiomyosarcoma-like histology, and one study reported that 22q
deletions typically occur only in the leiomyosarcoma-like areas.100 In  short,  the  loss  of
DEPDC5 may increase leiomyomas’ malignant potential.
3. Chromothripsis in leiomyomas
Since our exome-sequencing effort revealed no other recurrently mutated genes besides
MED12, the next step was to explore the genomic landscape of leiomyomas by whole-
genome sequencing. We unexpectedly discovered a subset of leiomyomas to display highly
complex chromosomal rearrangements interconnected by adjacent breakpoints, suggesting
that they had occurred simultaneously. Although a few cytogenetic studies have described
some leiomyomas to harbor complex chromosomal rearrangements,150, 381 the notion that
these have occurred simultaneously cannot not be inferred without high-resolution data
provided by massively parallel sequencing technology. These one-off events in leiomyomas
tend to be more similar to chromothripsis than to chromoplexy or chromoanasynthesis, since
the events we observed frequently harbored alternating copy-number states and lacked
chromosomal amplifications.
Chromothripsis was initially estimated to be a rare phenomenon present only in some 2%
of all cancers.39 Furthermore, chromothripsis has subsequently been associated with TP53
mutations and poor prognosis,382 neither  of  which  is  true  for  leiomyomas.  Leiomyomas
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appear to display “milder” forms of chromothripsis with significantly fewer breakpoints
than the malignant tumors do. Furthermore, a few leiomyomas displayed multiple
independent events of chromothripsis, an observation rarely reported in the malignant cases.
However, the number of breakpoints (or events) should not be the defining feature of
chromothripsis, but rather the underlying mechanism and its associated hallmark features.
Chromothripsis in its most intense form would most likely lead to apoptosis in the presence
of a normally functioning cell-cycle-checkpoint system. Alternatively, these events may
create genetic changes offering a selective advantage. Indeed, we discovered chromothripsis
to be a recurrent generator of genetic changes with a selective value, such as the classical
rearrangement between HMGA2 and RAD51B. It is tempting to speculate that
chromothripsis  is  not  rare  in  leiomyoma  precursor  cells,  since  the  vast  majority  of
chromothripsis events are not expected to generate such specific changes. Our observations
demonstrate, to our knowledge for the first time, that chromothripsis is not limited merely
to malignant tumors nor to neoplasms that frequently harbor TP53 mutations.
4. Chromosomal abnormalities as drivers
As expected based on previous cytogenetic studies,150 whole-genome sequencing revealed
HMGA2 as the most commonly rearranged gene. While most of these rearrangements
targeted 14q24, we identified two leiomyomas to harbor rearrangements that disrupted the
3´UTR sequence for the microRNA repressor let-7b, thus providing an alternative
mechanism for upregulation of HMGA2.  None  of  the HMGA1 rearrangements targeted
14q24. Instead, one of them involved the CARMN locus, located on chromosome 5q32.
CARMN encodes for a long non-coding RNA that is an important regulator of cardiac
smooth muscle cell differentiation and homeostasis.383
4.1 RAD51B as a putative driver gene
The role of RAD51B in leiomyomas has remained a subject of debate. Since RAD51B is the
preferential translocation partner of HMGA2, an effective and tissue-specific regulatory
element may be located within or close to the RAD51B locus. HMGA2 (and HMGA1)
rearrangements occasionally target other regions instead, particularly in other mesenchymal
tumors.150 Interestingly, we found a weaker level of HMGA2 overexpression in leiomyomas
lacking the involvement of RAD51B, supporting the view that this locus contains a
preferable region for HMGA2’s activation. We found two leiomyomas to harbor an HMGA2
rearrangement in which the breakpoints were located downstream of RAD51B, suggesting
that the disruption of RAD51B is not necessarily selectively advantageous. On the other
hand, we identified biallelic loss of RAD51B in a leiomyoma that lacked the involvement of
HMGA2. One study reported an in vitro growth advantage in a leiomyoma subpopulation
harboring biallelic loss of RAD51B compared with a population where only one copy was
disrupted through an HMGA2 rearrangement.384
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RAD51B encodes for a double-strand break repair enzyme, and loss of RAD51B may play a
secondary role in inducing genomic instability. Indeed, haploinsufficiency of RAD51B
results in hypersensitivity to DNA-damaging agents, in a reduction in sister chromatid
exchange, in impaired RAD51 focus formation, and an increase in chromosomal
abnormalities.208 Compatible with these observations, we found a significantly higher
number of breakpoints in leiomyomas that lacked a MED12 mutation. In sum, RAD51B
seems to provide the HMGAx genes with an effective regulatory element and at the same
time provide a tumorigenic “double hit” by disrupting one copy of RAD51B.
We unexpectedly detected RAD51B to be the most uniquely expressed gene in leiomyomas
of the MED12 subtype. Exon-level examination revealed that the upregulation of RAD51B
corresponded to a (long) non-coding transcript of the gene. Interestingly, a previous study
reported a unique alternative last exon of RAD51B to be exclusively expressed in the
uterus,207 suggesting that disruption of this unique isoform could be selectively
advantageous. Since RAD51B is specifically targeted in leiomyomas, and because of the
existence of uterine-specific RAD51B isoforms, this gene may have a unique role in driving
tumors that arise from the uterus. It is therefore tempting to speculate that the overexpression
of this non-coding RAD51B transcript actually contributes to tumorigenesis. Alternatively,
overexpression of RAD51B may just be a passenger consequence, since this non-coding
transcript was also detected in the myometrium – but at lower levels. Functional studies will
provide a better understanding of the role of RAD51B in tumorigenesis.
Of note, the HMGA2 and the RAD51B loci have both been highlighted as frequent
integration hotspots of HPV.385, 386 Since HPV integration can cause genomic instability, it
is tempting to speculate that HPV integration may be involved in forming these
rearrangements. RAD51B is  also  located  within  a  known  fragile  site:  regions  frequently
targeted by viruses.387
4.2 CUX1 as a haploinsufficient tumor suppressor gene
Deletions  affecting  the  q-arm  of  chromosome  7  make  up  the  second  most  common
chromosomal abnormality seen in leiomyomas, and the putative target genes have remained
largely elusive.150 CUX1 has been highlighted as the strongest candidate, since two
leiomyomas recently emerged as harboring inversions disrupting one copy of CUX1.388
With whole-genome sequencing, we discovered that 7q abnormalities are often highly
complex, consisting of inversions, translocations, and deletions at various different sites
along the chromosome arm. Not only did we discover CUX1 as the single most commonly
deleted gene on 7q, but also found that biallelic loss of CUX1 may occur in leiomyomas.
Differential expression analysis revealed CUX1 to be one of the most significantly
downregulated genes by 7q deletions. Loss of one allele appears to be sufficient for
selection, since, of the 14 leiomyomas with a 7q deletion, only one displayed biallelic loss
of CUX1. Compatible with these observations, CUX1 is a haploinsufficient tumor
suppressor gene in acute myeloid leukemia.389 Surprisingly, we and others have been unable
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to identify any nucleotide-level mutations affecting CUX1,390 suggesting that it is easier to
inactivate CUX1 through a variety of large-scale chromosomal abnormalities. CUX1 plays
an important role in the ATM/ATR DNA-damage response pathway,391 suggesting that loss
of this gene may induce genomic instability. In sum, it is safe to assume that loss of CUX1
drives leiomyoma development, although the exact mechanism awaits elucidation.
4.3 IRS4 as a driver of COL4A5-COL4A6 deletions
We discovered a subset of leiomyomas to harbor characteristic deletions that simultaneously
affected COL4A5 and COL4A6, located head-to-head on chromosome Xq22.3. Similar
deletions have previously been discovered in the germline of Alport syndrome patients
displaying diffuse leiomyomatosis (ATS-DL) of the esophageal, tracheobronchial, and
genitourinary tract. Such deletions can also occur as somatic events in esophageal
leiomyomas,392 confirming that they play a role in stimulating smooth muscle overgrowth.
A variety of germline loss-of-function mutations in COL4A2, COL4A3, and COL4A5 causes
Alport syndrome,393 but only a specific type of deletion that affects COL4A5 and COL4A6
leads to diffuse leiomyomatosis as well, suggesting that the minimally deleted region
contains important driver sequences. A recent study described diffuse leiomyomatosis in a
patient harboring a germline deletion that did not span COL4A6,158 suggesting that the
critical sequences are located within COL4A5. Moreover, diffuse leiomyomatosis is not a
symptom if the patient harbors a germline deletion that extends past intron 3 of COL4A6,394
suggesting that other important sequences are located beyond this region. Compatible with
these observations, the somatic deletions we detected did not extend past intron 3 of
COL4A6.
We identified IRS4 – a gene located downstream of COL4A5 – to be the most significantly
upregulated gene in leiomyomas harboring these deletions, suggesting that IRS4 is the actual
driver from these deletions rather than COL4A5 or COL4A6. One logical explanation for
these patterns is that the deleted region contains an insulator that normally blocks the
interaction between the promoter of IRS4 and a distant enhancer located in proximity to
intron 3 of COL4A6 (Figure 16). IRS4 encodes for the insulin receptor substrate 4, which
can stimulate cell proliferation by enhancing the function of IGF-1.395 Interestingly,
subungual exostosis and pediatric T-cell acute lymphoblastic leukemia have been shown to
harbor recurrent translocations that result in IRS4 upregulation.396-398 Furthermore, the
COL12A1 locus is a recurrent translocation partner in subungual exostosis,397 suggesting
that this region also contains an enhancer that can upregulate IRS4.
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Figure 16. The enhancer-insulator model of IRS4 activation in uterine leiomyomas and ATS-DL
patients with a COL4A5-COL4A6 deletion. A deletion that typically affects the 5’ end of both COL4A5
and COL4A6 occurs in a subset of uterine leiomyomas and ATS-DL patients. According to the enhancer-
insulator model, the loss of a putative insulator (I) – located within COL4A5 – results in activation of
IRS4 though a distal enhancer (E) – located beyond intron 3 of COL4A6.
4.4 PLAG1 as a putative driver gene
We identified one leiomyoma of the MED12 subtype as displaying a translocation between
PLAG1 and COL12A1, resulting in high expression of PLAG1. Interestingly, the COL12A1
locus is also targeted by IRS4 translocations in subungual exostosis,396, 397 supporting the
view that the COL12A1 locus contains a selectively advantageous regulatory element. We
also found upregulation of PLAG1 in two quadruple-negative leiomyomas that harbored a
large-scale amplification of the gene. PLAG1 encodes for a zinc finger transcription factor
that is frequently upregulated by translocations in several benign mesenchymal tumors.399
Furthermore, PLAG1 and HMGA2 translocations are mutually exclusive in pleomorphic
adenomas of the salivary gland.400 Interestingly, we detected PLAG1 to be distinctly
upregulated in leiomyomas harboring an HMGA2 or HMGA1 abnormality, suggesting that
these genes are upstream regulators of PLAG1. This hypothesis is supported by the fact that
PLAG1 translocations can also target RAD51B in lipoblastomas.401 Furthermore, HMGA2
and PLAG1 expression levels correlate in thyroid tumors, leiomyomas, and experimental
models.402 Of note, we detected the putative tumors suppressor PLAGL1 to be among the
most uniquely downregulated genes in leiomyomas of the COL4A5-COL4A6 subtype.
PLAGL1 is structurally similar, but functionally different to PLAG1.403
4.5 Other candidate driver genes
The 7q deletions we detected in leiomyomas were often large, complex, and a few did not
span CUX1, suggesting that other genes are simultaneously targeted. According to the
“cancer gene island model”, regions recurrently affected by hemizygous deletions are likely
to harbor multiple target genes that maximize proliferative fitness through cumulative
haploinsufficiencies.404 We identified one sample as displaying a second-hit mutation in
ZNHIT, and two other samples as displaying highly localized rearrangements affecting
CUL1, suggesting that they are also targets of 7q deletions. ZNHIT1 is involved in cyclin
dependent kinase 6 (CDK6)-driven cell-cycle arrest at the G1 phase,405 whereas CUL-1
forms the major structural scaffold part of the SCF-complex and play a role in ubiquitin-
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dependent degradation of numerous cell-cycle regulators including CCND1.406
Interestingly, we identified one leiomyoma as displaying a CCND1 rearrangement, resulting
in the highest expression of the gene among the 38 leiomyomas analyzed. Compatible with
our observations, others have reported a significant upregulation of genes related to cell-
cycle progression in leiomyomas of the HMGA2 subtype, including CCND1, CCND2,
CCND3, and CDK6.203
We also identified another commonly deleted region on 22q that contained the known tumor
suppressor SMARCB1. Furthermore, one leiomyoma harbored an additional chromosomal
rearrangement within this region, resulting in biallelic loss of SMARCB1. SMARCB1 is of
special interest, since this gene was recently associated with an increased risk for
leiomyomas though a germline SMARCB1 mutation.157
Deletions of 1p represent another frequently occurring event in leiomyomas that has been
associated with distinct histopathological features and possible malignant progression.225,
265 Chromosome 1p deletions are common in several cancers and the target genes remain
elusive in these as well. CHD5, CAMTA1, KIF1B, CASZ1, and miR-34a have been
highlighted as the foremost candidates in some cancers,407 and among these, we identified
kinesin family member 1B (KIF1B) as one of the most significantly downregulated gene in
leiomyomas with 1p deletions. However, deletion mapping revealed NPHP4 to be the most
commonly deleted gene on chromosome 1p. NPHP4 has previously been highlighted as a
putative target gene in leiomyomas, owing to recurrent translocation breakpoints located
upstream of the NPHP4 locus.226 We detected  no  significant  dysregulation  of NPHP4 in
leiomyomas with 1p deletions, however.
We also identified one quadruple-negative leiomyoma to harbor a fusion gene involving
IGFBP5 and PDGFRB (Figure 17). Fusions involving the same 3’end of PDGFRB are
frequent in myeloid and lymphoid neoplasms and are associated with hypereosinophilia.408
Such fusions encode for constitutively activated tyrosine kinases; patients with such defects
respond well to low doses of the tyrosine-kinase inhibitor imatinib.408 While identified in
only one quadruple-negative leiomyomas thus far, leiomyomas with such fusions may
represent a rare leiomyomas subtype. Although fusions involving PDGFRB are known to
drive hematopoietic cancers, the disruption of IGFBP5 may further enhance leiomyoma
development.
Figure 17. IGFBP5-PDGFRB fusion protein as a putative driver. We detected a quadruple-negative
leiomyoma to harbor a chromosomal rearrangement resulting in the formation of an in-frame fusion gene
consisting of the first exon of IGFBP5 and the last five exons of PDGFRB. The putative protein product
includes the IGF-binding domain of IGFBP5 and the tyrosine-kinase domain of PDGFRB. This fusion
protein is likely to cause continuous activation of the tyrosine-kinase domain.
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5. Molecular classification of uterine leiomyomas
Uterine  leiomyomas  are  still  widely  regarded  as  a  single  entity,  although  evidence  of
heterogeneity exists at several different levels including symptoms, histopathology, and
therapeutic requirements. Our high-throughput sequencing studies have emphasized
heterogeneity on the genetic level as well, suggesting that molecularly distinct subtypes of
leiomyomas exist (Figure 18). Oncogenic MED12 mutations clearly represent the most
common genetic defect in leiomyoma, with HMGA2 rearrangements as the second most
common. Interestingly, these two defects are mutually exclusive,314 suggesting that they
represent two distinct subtypes of leiomyomas. Biallelic loss of FH is present only in 1% of
sporadic leiomyomas, and although the majority of HLRCC patients’ tumors show loss of
the second FH allele, some may occasionally harbor a MED12 mutation. Interestingly, such
lesions  do  not  show  loss  of  the  second FH allele,409 indicating that FH and MED12
mutations are also mutually exclusive. We have also identified a few leiomyomas with
COL4A5-COL4A6 deletions, all of which have been mutually exclusive with the other three
drivers. More samples are required for validation, however. These four genetic defects
appear to account for over 95% of all leiomyomas, leaving only a fraction of leiomyomas
with no clearly identifiable initiating event (Figure 18).
In contrast to these four mutually exclusive driver genes, deletions of 7q22, 22q, and 1p
frequently co-occur with other genetic changes, suggesting that they are related to tumor
progression rather than tumor initiation. Furthermore, we identified several examples where
these changes were subclonal. Surprisingly, others and we have shown that HMGA1
rearrangements can co-occur with MED12 mutations as a secondary abnormality relative to
the initiating MED12 mutation.310 However, we also identified some quadruple-negative
leiomyomas with an HMGA1 abnormality to display expression patterns that are similar to
those seen in leiomyomas of the HMGA2 subtype, suggesting that HMGA1 rearrangements
may also occur as initiating events.
One interesting candidate driver gene in leiomyomas is KAT6B, which is rearranged in
leiomyomas at approximately 2%.185 This specific translocation may exist as a sole
cytogenetic abnormality, suggesting that it represents another molecularly distinct pathway
to leiomyoma formation. Indeed, a recent study screened for MED12 mutations  in  a
retroperitoneal leiomyoma harboring a KAT6B rearrangement, but found none.220
Interestingly, germline mutations in either KAT6B or MED12 result in Ohdo syndrome,410
suggesting that these two genes are functionally related.
Our gene expression results support the existence of various leiomyoma subtypes, since the
mutation status of MED12, HMGA2, FH, and COL4A5-COL4A6 clearly affected global
gene expression patterns. These distinct patterns suggest that different genetic defects act
through separate pathways. Leiomyomas with HMGA1 or HMGA2 abnormalities displayed
similar global expression signatures, supporting that these structurally and evolutionarily
related transcription factors function similarly in tumorigenesis. In contrast, deletions of
7q22, 22q, and 1p exerted no major influence on the clustering, supporting their role in
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tumor progression. The majority of quadruple-negative leiomyomas clustered into several
unique branches, indicating the presence of a few rare and possibly novel subtypes.
These different mutations are also associated with distinct phenotypes. Indeed, leiomyomas
of the MED12 subtype tends to be smaller,307 and leiomyomas of the HMGA2 subtype tends
to be larger.199 Furthermore, HMGA2 subtype tumors tend to develop as solitary lesions,
whereas MED12 subtype tumors frequently develop as multiple independent lesions.309 We
also found leiomyomas harboring MED12 or FH mutations to be more chromosomally
stable. Unlike cultured leiomyoma cells with MED12 or 7q abnormalities, cells with
HMGA2 rearrangements are able to survive in vitro for numerous passages.371
Some researchers have hypothesized that only a subset of leiomyomas with variant
histology or rare genetic defects have the potential for malignant progression. Indeed,
uterine leiomyomas with bizarre nuclei was recently shown to harbor TP53 and FH
mutations.320 Another recent study proposed that leiomyomas with bizarre nuclei should be
further divided into two distinct subtypes.411 Indeed, one of these subtypes showed a higher
rate of MED12 mutations and immunoreactivity for HMGA2,411 suggesting that the other
subtype corresponds to leiomyomas with FH mutations. Other studies have shown that
leiomyomas with bizarre nuclei and cellular leiomyomas resemble leiomyosarcomas more
than they do leiomyomas, since both of these can harbor TP53 mutations, and both tend to
cluster with leiomyosarcomas in gene expression studies.320 Considering that KAT6B
rearrangements tend to occur in cellular leiomyomas and that they have been described in a
few leiomyosarcomas,219, 222 these defects may increase the malignant potential of
leiomyomas.  Gene  expression  profiling  has  also  shown  that  leiomyomas  with  1p36
deletions tend to cluster with leiomyosarcomas,225 suggesting that 1p36 deletions are related
to malignant progression as well.
Of note, many of the genes involved in leiomyoma formation have been implicated as
drivers of some hematological malignancies. Indeed, chronic lymphocytic leukemia is one
of the few cancer types that harbor MED12 mutations,333 whereas HMGA2, KAT6B and
PDGFRB rearrangements occur in acute myeloid leukemia as well.195-197, 221, 408 In addition,
CUX1 is frequently inactivated in acute myeloid leukemia, where it acts as a
haploinsufficient tumor suppressor gene.389 A  very  recent  study  showed  that  MED12  is
essential to the growth of hematopoietic stem cells in the bone marrow.412 Transgenic mice
overexpressing human HMGA2 under control of the VH promoter/Eμ enhancer develop a
lymphoproliferative disease that resembles human T-cell acute lymphoblastic leukemia.246
Chronic lymphocytic leukemia is also the very first cancer type in which chromothripsis
was discovered.39
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Figure 18. Initiating mutations in leiomyomas. Oncogenic MED12 mutations are clearly the most
common initiating mutation in leiomyomas. Rearrangements resulting in upregulation of HMGA2 are
another common initiating event. Rearrangements of HMGA1 may represent a rare initiating event,
although it can occur as secondary driver as well. Biallelic loss of FH can also initiate tumorigenesis,
and the first-hit can be inherited. Upregulation of IRS4 resulting from deletions affecting the COL4A5
and COL4A6 locus appear to be a rare initiating event. Rearrangements resulting in fusion genes
involving KAT6B are likely to represent another rare initiating event. In only a small fraction of
leiomyomas is the initiating event unknown.
6. Putative biomarkers and dysregulated pathways
Our gene expression analyses revealed several genes to be uniquely expressed in
leiomyomas of different subtypes. The most significant of these represent putative
biomarkers with the potential to classify leiomyomas in future studies. Although succination
of proteins by fumarate has previously been used as a valuable immunohistochemical
biomarker for FH-deficiency,413 we identified AKR1B10 to be uniquely expressed in
leiomyomas of the FH subtype, suggesting that it may serve as an alternative biomarker.
We also detected specific driver mutations to be the main determinants of expression
changes in leiomyomas. In addition to the previously described changes in Wnt/β-catenin
signaling, we identified subtype-specific expression changes in other key tumorigenic
pathways, including prolactin, IGF-1, and NRF2 signaling (Figure 20).
6.1 Activation of Prolactin signaling
We detected a significant activation of prolactin signaling in leiomyomas, particularly in
leiomyomas of the MED12 and HMGA2 subtypes. Indeed, PRL and PRLHR were among
the most upregulated genes in leiomyomas. PRL encodes for the growth hormone prolactin,
and we observed a particularly high expression of PRL in the HMGA2 subgroup.
Interestingly, transgenic mice overexpressing HMGA2 develop pituitary adenomas
secreting prolactin.414 In contrast, leiomyomas of the MED12 subtype displayed a
MED12 HMGA2
FH IRS4 (COL4A5/6)
HMGA1 KAT6B
Unknown initiator
DISCUSSION
87
particularly high PRLHR expression. PRLHR encodes for a prolactin-releasing peptide
receptor that binds to the prolactin-releasing peptide, which then stimulates the release of
prolactin.415 Increased expression of PRLHR recently emerged as stimulating the
proliferation of cultured human leiomyoma cells, and transgenic mice overexpressing
PRLHR develop myometrial hyperplasia with excessive extracellular matrix deposition.252
Prolactin may act as an autocrine or paracrine growth factor in several tumor types,
including leiomyomas.416
6.2 Dysregulation of IGF-1 signaling
In most leiomyoma subtypes, we identified a significant dysregulation of IGF-1 signaling.
Furthermore, statistical analysis revealed IGF2BP2 as the second most uniquely expressed
gene in leiomyomas of the HMGA2 subtype. HMGA2 directly regulates the expression of
IGF2BP2 by binding to an AT-rich regulatory region within its first intron.298 IGF2BP2
encodes for the insulin-like growth factor 2 mRNA binding protein 2 that plays a role in
promoting IGF2 mRNA translation.417 Interestingly, PLAG1 regulates the expression of
IGF2 by binding to its P3 promoter.299-301 We detected upregulation of IGF2 in the majority
of leiomyomas of the HMGA2 subtype; IGF2 encodes for the insulin-like growth factor 2,
which binds to the IGF-1 receptor and thereby promotes growth. HMGA2, PLAG1,
IGF2BP2, and IGF2 are all silenced in adult tissues,298, 418, 419 supporting the view that they
are functionally related.
Statistical analysis revealed ADAM12 to be among the most uniquely upregulated genes in
leiomyomas  of  the MED12 subtype, and pappalysin 2 (PAPPA2)  to  be  among  the  most
uniquely upregulated genes in leiomyomas of the HMGA2 subtypes. Both of these genes
are involved in placental development and encode for proteases of IGFBP-5.420, 421. Insulin-
like growth factor binding proteins (IGFBPs) inhibit the activity of the IGF type 1 receptor
by binding to IGFs. IGFBP-5 inhibits IGF-1-induced proliferation and migration of smooth
muscle cells.422 The role of IGFBP-5 in leiomyomas remains unclear, because IGFBP-5 has
been described to both stimulate as well as inhibit cancer development.423
6.3 Activation of the NRF2 pathway in leiomyomas of the FH subtype
In leiomyomas of the FH subtype, we found the NRF2 pathway to be the most significantly
dysregulated pathway, supporting the theory that high levels of fumarate leads to an
activation of the oncogenic transcription factor NRF2.172 The pentose phosphate pathway
was  the  only  other  significant  pathway,  supporting  that  NRF2  play  a  role  in  redirecting
glucose and glutamine into anabolic pathways.305 Conversely, the HIF-1-α signaling
pathway was not significantly altered, challenging the pseudo-hypoxia hypothesis.166
Furthermore, a few studies have hypothesized that loss of FH could lead to tumorigenesis
though DNA damage caused by an increased production of free radicals.174 However, we
found a low number of chromosomal abnormalities and nucleotide-level mutations in
leiomyomas of the FH subtype.
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Activation of the NRF2 signaling pathway has recently emerged as a common oncogenic
feature of many cancers.424 Indeed, the NRF2 pathway can be activated through gain-of-
function mutations in NFE2L2, or loss-of-function mutations in either cullin 3 (CUL3) or
KEAP1 (Figure 19).425 These mutations result in loss of the interaction between KEAP1 and
NRF2,425 leading to stabilization of NRF2. A recent comprehensive study on the molecular
characteristics of renal cell cancers revealed that renal tumors of papillary type 2 histology
frequently display activation of the NRF2 pathway though mutations in NFE2L2, CUL3,
KEAP1, or FH. Since the hypermethylation phenotype was detected only in the renal tumors
that harbored FH mutations,169 NRF2 activation – rather than hypermethylation – is likely
the primary mechanism by which these gene defects drive tumorigenesis. If NRF2 activation
is indeed the underlying mechanism, it would be reasonable to assume that a subset of
leiomyomas may harbor mutations in other genes of the KEAP1-NRF2-CUL3 apparatus.
Conversely, if hypermethylation is the driving force, a subset of leiomyomas could harbor
mutations in other genes that result in the hypermethylation phenotype, such as in IDHx or
SDHx. Novel therapeutic strategies have recently emerged as targeting the NRF2
pathway,426 suggesting that NRF2 inhibitors could be useful to combat leiomyomas that are
driven by FH mutations.
Figure 19. Different routes to NRF2 activation. NRF2 is, under basal conditions, degraded in the
cytosol by a KEAP1 homodimer that facilitates the ubiquitination and proteasomal degradation of NRF2.
Under high levels of oxidative stress, NRF2 is relocated into the nucleus, where it activates the expression
of genes involved in the antioxidant pathway. The interaction between NRF2 and KEAP1 can be lost
through gain-of-function mutations in NRF2 or through loss-of-function mutations in KEAP1 or CUL3.
Recent studies have proposed that KEAP1 becomes succinated by high levels of fumarate, leading to
loss of this interaction. Abnormally high levels of NRF2 activation are likely to stimulate tumor growth.
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Figure 20. Schematic of highlighted driver genes and pathways in leiomyoma development and
growth. Leiomyomas display subtype-specific differences in key driver pathways including Wnt/β-
catenin, prolactin, IGF-1, and NRF2 signaling. Leiomyomas of the MED12 subtype exhibit high
expression of a non-coding transcript of RAD51B; RAD51B is also the most common translocation
partner of HMGA2 in leiomyomas.
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CONCLUDING REMARKS AND
FUTURE PERSPECTIVES
The findings presented in this thesis work represent an important contribution to our
understanding of uterine leiomyoma etiology. Although these studies have provided
answers to several longstanding questions, they have also raised several new questions: why
are MED12 mutations so common? Is one mutation sufficient to generate a clinically
relevant leiomyoma? What is the mechanism by which leiomyomas spread? Are some rare
leiomyoma subtypes prone to malignant progression? Are ATS-DL patients at increased
risk for uterine leiomyomas as well? Do molecular differences in leiomyomas explain
variations frequently seen in clinical outcomes or responses to treatments?
Our massively parallel sequencing efforts have revealed not only several novel driver genes
in leiomyomas, but also revealed that chromothripsis-like events are not limited to
malignant tumors. Furthermore, these technologies have made it possible to demonstrate
that some separate leiomyomas are indeed of common clonal origin. While the most
important genetic drivers of this disease appear to be discovered, other less common genetic
defects related to tumor initiation or progression remain to be clarified. This may be
particularly true for leiomyoma variants displaying rare histopathology or unusual growth
patterns. Further research into leiomyoma variants displaying some features of malignancy
may also improve our understanding of the early stages of malignant transformation. The
genetic factors that predispose to leiomyomas demand further research as well, because the
currently discovered variants explain only a small fraction of the entire estimated heritability.
Discoveries made through genome-wide methods in these studies have now laid a basis for
the molecular classification of leiomyomas. Further research will determine whether the
candidate biomarkers presented here will provide guidance to researchers and health
professionals. The ability to stratify each lesion into a clinically relevant subclass will pave
the way for improved management through personalized treatments. While these studies
highlight the importance of leiomyoma stratification, they also show that several genes and
pathways are commonly dysregulated in leiomyomas, regardless of subtype. Targeting these
shared abnormalities would be an ideal step in the development of treatments for this
disease. A comprehensive understanding of leiomyoma etiology cannot be reached through
genetics only, however. Leiomyoma research has historically been limited by lack of
suitable cell cultures and animal models. The recent emergence of an animal model
accurately resembling human leiomyomas may finally prove to be an invaluable tool for
investigating targeted therapies and obtaining a comprehensive understanding of this very
common disease.
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